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To date almost all pyrogallol[4]arenes reported in the literature have been prepared 
from alkyl aldehydes. W e were interested in preparing more pyrogallol[4]arenes from 
commercially available benzaldehydes. On synthesising these compounds we 
discovered that they are structurally unique, compared to previously reported 
pyrogallol[4]arenes, as they exist in a rctt chair conformation as determined by X-ray 
crystallography and 1HNMR.
W e also discovered from our synthetic studies that the yields for the 
pyrogallol[4]arenes depend strongly on the electron donating/withdrawing ability o f  
substituents placed in the benzaldehyde, the more electron withdrawing the higher the 
yield. W e also discovered a unique metal salt effect on the condensation o f  pyrogallol 
with 4-fluorobenzaldehyde that doubled the yields o f  the resulting macrocycle. 
Interestingly, this effect is absent with the condensation o f  pyrogallol with alkyl 
aldehydes. The role o f  steric effects, using bulky substituted benzaldehydes was also 
investigated to determine whether the stereochemical outcome for these condensation 
reactions could be controlled.
The further derivatisation o f  the pyrogallol[4]arenes was also investigated. The 
preparation o f  partially and com pletely alkylated derivatives o f  these m acrocycles was 
o f  interest to us. We found that the introduction o f  acetate groups could be readily 
accomplished, however other alkyl groups could not be efficiently introduced into the 
pyrogallol[4]arenes. The partially and com pletely alkylated acetate derivatives o f  
pyrogallol[4]arene were screened for biological activity against HIV-1. It was 
discovered that the partially alkylated derivatives possessed higher selectivity indexes 
than the com pletely alkylated derivatives indicating that biological activity may not 
be dependent on charge.
Abstract:
Chapter 1 
Literature Survey
1.1 Reso reina renes
In 1940, Niederl and V ogel1 studied several condensation products previously  
obtained from the reaction o f  aliphatic aldehydes and resorcinol. From molecular 
weight determinations they concluded that the ratio between aldehyde and resorcinol, 
in the product was 1:1. They proposed a cyclic tetrameric structure (figure 1) 
analogous to cyclic tctrameric structures frequently found in nature, (e.g porphyrins). 
This structure was finally proved in 1968 by Erdtman et al. by a single crystal X-ray 
analysis2.
( 1 )
Figure 1: G eneral Structure o fR esorcin [4]arenes  
A suitable trivial name for these m olecules was never found. Gutsche and Bornher
• 3attempted to classify them as calixarenes by calling them calix[4]resorcinarenes or 
resorcinol-derived calix[4]arenes3,4, but totally different names like Hôgberg 
compounds5, or sim ply octols6,7 also appeared in the literature. In the mid 1990’s the 
name resorcinarenes was suggested8, which is w idely used today.
Resorcinarenes, 1 can be prepared in reasonable to high yields via  a simple, one-step 
procedure using either templates (such as metal tcmplation see Chapter 2) or high  
dilution techniques. M ost cases involve the acid-catalysed condensation reaction 
between resorcinol, 3 and an aliphatic or aromatic aldehyde .5 ,6 ,9 The acid catalysed 
condensation reaction between resorcinol and an aldehyde is generally carried out by  
heating the constituents to reflux in a mixture o f  ethanol and concentrated 
hydrochloric acid for several hours, although for every aldehyde different optimal 
reaction conditions exist . 5,6,9 Usually, the cyclotetramer crystallizes from the reaction 
mixture but, in som e cases, water should be added in order to isolate the product.6,10
PH*? OH
OH I OH
R=Alkyl/Aromatic
(2) (3) (1)
Schcme 1: P reparation  o f  R esorcin[4]arenes
It was also found that resorcinol derivatives carrying electron withdrawing 
substituents like NO 2 or Br6 at the 2-position o f  resorcinol, or in which the hydroxyl 
groups o f  resorcinol are partially alkylated7 do not yield cyclom eric products due to 
the high electron withdrawing nature o f  these groups.
R Group (Scheme 2) Yield (%) Reference
- c h 3 73 7
-(CH 2)4CH3 77 6
-(CH 2)2 C6H 5 69 6
-(CH2)2N a 0 3S 40 1 1
-(CH2)4HO 80 6
-(CH2)5C1 67 6
2-HOC 6H4- 78 1 1
4-BrC6H4- 43 6
4-C 6H 5C6H4- 99 6
4-H 2N C 6H4- N ot reported 1 1
4-AcH N C 6H4- 52 6
4-HOC 6H4- 91 1 1
-(C 6H4)*Fe*(C 6H5) 1 0 1 1
Table 1: Yields o f  se lec ted  resorcinarenes synthesized from  functionalised aliphatic 
or (substituted) benzaldehydes and resorcinols
1.1.1 Structure and Conformations of Resorcinarenes
The non-planarity o f  resorcinarenes means that they can, in principle, exist in many 
different isom eric forms. The stereochemistry is generally defined as a combination o f  
the follow ing two stereochemical elements:
a). The conformation o f  the m acroeyclic ring, which can adopt four symmetrical 
arrangements: Cone (la ), Boat ( lb ) , Chair ( lc ) ,  Saddle (Id). Below are crystal 
structure representations o f  the four conformations.
? I
Y Y
e L , x , 
í í T  
- A u -'<s  
\
( lc )
?
lê
b \  à £  
(Id)
Figure 2: Conformations o f  Resorcin[4] arenes 12
b). The relative configuration o f  the main substituent at the methylene bridges, 
gives the cis (rccc ), cis-cis-trans (reef), cis-trans-trans (roll), trans-cis-trans (rtct).
R
rccc rcct
R
— ^1 trctt
R R
rtct
Figure 3: Configuration of substituent groups on resorcin[4] arenes
Combinations o f  these stereochemical elem ents gives rise to a vast number o f  possible  
stereoisomers. Thus far, the only four that have been found experimentally are the 
rccc  cone, the rctt chair, the rctt saddle and the rctt boat. 1 u3,14.
Typically, resorcinarenes derived from alkyl aldehydes exist in the rccc  cone 
conformation (schem e 2 ), whereas those derived from aromatic aldehydes exist in a 
number o f  different conformations (schem e 3).
H O . ,O H
+
HC1, Ethanol
Aik ^
(3) (4) ( la )
Schem e 2: Condensation o f  resorcinarene with an alkyl aldehyde.
HO OH
HC1, Ethanol
+  Y
Ar
(3) (5) ( la )
Schem e 3: Condensation o f  resorcinarene with an arom atic aldehyde
1.1.2 Therm odynam ic vs K ine tic  fo rm a tion  o f Resorcinarenes
In 1980 , Hôgberg reported that the formation o f  resorcinarenes was a combination o f  
both thermodynamic and kinetic influences on the system. In a reaction o f  resorcinol 
and 4-bromobenzaldehyde, two conformations o f  resorcinarene were formed initially 
(figure 4). The first was the kinetically favoured product, l c  the rc tt-chair 
conformation and the second was the thermodynamically favoured rccc-boat 
conformation15, lb .
F igure 4: ( lc)  rctt chair isomer; ( lb )  rccc boat isom er o f  resorcinarene. 
H ogberg’s study included 'H-NM R, X-ray crystallography, and molecular m odelling  
calculations. He also plotted the yields o f  these two conformations as a function o f  
tim e (figure 5). It is clear from figure 5 that after 2 hours the maximum overall yield 
was reached, resulting in equal amounts o f  both conformations l c  and lb . After a
further 8  hours o f  reaction time, only lb was present. This indicated that formation o f  
isomer lc was reversible under the reaction conditions. This was subsequently 
confirmed by another reaction where isom er lc was treated under the same conditions 
as the condensation. After 5 hours an equal mixture o f  lc and lb was present, 
how ever after a further 5 hours all o f  lc was converted to lb.
Time (hours)
Figure 5: Percentage Yield o f  isom ers l c  and l b  as a  function o f  tim e15.
M olecular m odelling calculations were carried out on the octabutyrate derivatives o f  
lc and lb and they were compared to other theoretical conformations and isomers. 
They were compared to the rccc  boat with R groups in equatorial positions rather than 
axial positions. They were also compared to the rccc  saddle conformation. Molecular 
m odels o f  stereostructures lc and lb  appeared to be relatively free o f  steric 
compression and the phenyl groups are free to rotate. In the case o f  the other 
theoretical stereocentres (such as the rccc  saddle isomer) there was an increased 
intramolecular steric repulsion and interlocking o f  the phenyl groups15.
Anisotropic ring current effects on the proton in the 5 position o f  the resorcinol ring 
were calculated for the theoretical structures (using the Bovey-Johnson equation) and 
then compared to the experimental values for lc and lb ( la  =  0.45ppm and lb  =
0.37ppm). The m odels o f  these stereostructures gave a value o f  0.5ppm for both 
(these values are for the changes in chemical shift and are within acceptable limits). 
However the values for the other two stereocentres were not acceptable, (rccc  boat 
[eq] =  O.lppm; rccc  saddle =  1.9ppm). This result shows that the latter two structures 
are unlikely15
1.1.3 Dcrivatisation of Resorcinarenes
1.1.3.1: Reaction o f  the Hydroxy Groups
The phenolic hydroxy groups o f  resorcinarenes can be com pletely acylated16. Many 
exam ples o f  octaesters (schem e 4 ) 17 o f  rccc, ret I and n e t  regioisomers have been 
reported. The reaction proceeds with both alkyl and aromatic substituents, under basic 
conditions.
(9)
Schem e 4: Acylation o f  resorcinarenes to oetaesters  
The reaction o f  a resorcinarene with an excess o f  diarylchlorophosphate and 
diphenylchlorophosphine, gives octaphosphates1* and octaphosphinites10 respectively. 
This is shown in schem e 5, again basic conditions are used.
Scheme 5: Formation o f octaphosphates and octaphosphinites from resorcinarene
The reaction o f  a resorcinarene with an excess o f  arylsulphonylchlorides gives 
octasulfonates20. Once again this reaction proceeds under basic conditions (schem e 6 ).
O
( 1 )
Schem e 6 : Form ation o f  octasulfonate from  resorcinarene
The reaction o f  a resorcinarene with an excess o f  trimethylchlorosilane gives octa 
silyl derivatives21. This reaction is carried out under basic conditions, (schem e 7).
C H 3
I.
h30 ' ' / Si ' 'C H 3
Cl
(14)
K2 C 0 3 
DM F, 70°C
Schem e 7: O cta sily l derivative form ation  from  resorcinarene
Complete O-alkylations o f  rccc-resorcinarenes result in octaethers (schem e 8 ). The 
attachment o f  eight 3,5-dihydroxy benzyl ether groups to the rccc-resorcinarenes led 
to the first generation dendrimer, 19.
( 1)
Schcme 8: Alkylation of resorcinarene to form anti octaether.
Alkylation o f  a resorcinarene with excess ethylbromoacetate leads to octaesters, 21 
which were then transformed into their corresponding octaacids, 2 2  by hydrolysis, 
(schem e 9)
° % / ° Et
^ ç A - B r
(2 0 )
K2CO3 , Acetone 
60°C
(2 2 )
Scheme 9: Estérification and hydrolysis o f  resorcinarene, to form the octaacid.
-12-
Am inolysis o f  21 with chiral amines and am inoalcohols resulted in chiral octaamide 
derivatives, 2323, as shown in scheme 10.
(21) (23)
Schem e 10: A m inolysis o f  resorcinarene.
Reduction o f  the octaester, 21, with LiAlH 4  gave the octol, 24, which underwent a 
Mitsunobu reaction with phthalimide, 25, DEAD and PPI13 to give an 
octaphthalimide, 26. The hydrazinolysis o f  the phthalimido groups resulted in the 
corresponding octaamine, 27, which was reacted with lactono-lactone to give a water 
soluble resorcinarene-sugar cluster (schem e 11). These sugar clusters are almost 
irreversibly adsorbed on the surface o f  a quartz plate, which acts as a simplified  
m odel o f  a multivalent receptor site24. This property has extensive application in 
biom im etic chemistry in m im icking enzym e interactions on a chemical scale24.
O ^ O E t  E t O ^ O
° -  ^  ' °  UAIH 4
HO. „OH
DMF *  ° T Y °
• r ^ Y + ;
o
0
\lH  
(25) O
R (24)
DEAD
PPh3
NH
NH
(28) O
h 2n  , . n h 2
p  
0  N °
JhL
, 0 '
/ h 2 n n h 2 , 0
(27)
R (26)
R
OH
Laclono-
Laclone
Jtt*
\ OH 
H 0  OH HO7
h o . r ~
Schem e 11: The form ation  o f  a  water-soluble resorcinarene-sugar cluster via octol, 
octaphthalim ide and octaam ine interm ediates, from  the octaester.
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1.1.3.2 Electrophilic Substitutions at the Aromatic Rinas.
The 2-position o f  the resorcinol rings m ay be substituted by mild electrophiles, for 
example by  bromination or by coupling with diazonium salts. More severe reactions 
such as nitration failed probably due to the disruption o f  the resorcinarene skeleton. 
Bromination occurs at room temperature in 80% yield using excess N- 
bromosuccinimide as shown in scheme 1 2 .
(30) (31)
Schem e 12: Brom ination o f  tetram ethyl resorcin[4]arene using excess N-
bromosuccinimide, NBS
Aminomethylation o f  resorcinarenes w ith secondary amines and formaldehyde readily
♦ 2 5  • •give the corresponding tetraamines, via the Mannich reaction (figure 6 ) which exist 
in apolar solvents in a chiral C4 -symmetrical conformation with left or right handed 
orientation o f  the pendant hydrogen bonded amino groups26. In this study there were 
various functional groups including chiral and cation binding functions27 that could be 
easily introduced to the resorcinarene platform.
H
+
O
H
/  \  ' / \  -h 2o
R1 R2 H H
(32) (33)
H. yR1
:N+
H R2
(34)
R1\  / R 2
N
R1
R2
(1) (34) (35)
F igure 6 : Form ation o f  a  tetraamine resorcinarene via the Mannich reaction.
1.1.3.3 Synthesis o f  Chiral Resorcinarenes
In the year 2005 Page et al .28 described the first enantioselective syntheses (schem e 
13) o f  a number o f  enantiomerically pure resoricinarene derivatives. The procedure 
enables ready access to multigram quantities o f  the diastereoisomerically pure 
tetrakis(benzoxazines) (figure 7) in a short route starting from resorcinol and 
dodecanal. Subsequent transformation provides C-4n symmetric resoricinarene 
derivatives as single enantiomers. The residual phenol and secondary amine groups 
allow  for further functionalisation and the possibility o f  accessing a wide range o f  
axially chiral resorcinarene derivatives. Investigations are currently underway to 
assess their application in the areas o f  chiral recognition and asymmetric catalysis.
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(3)
I. C] ,H25CHO, H1
2. P h C H (C H 3)N (C H 2O M e )2
1. nB uL i, M cl
2. HCOOH
1. Pd(OH)2, H4
2. CH20
3. HCOOH
(38) (37 )
Schem e 13: The synthesis o f  chiral resorcinarenes
Alm ost all o f  these m olecules adopt the cone or bowl-shape conformation. The bowl- 
shape o f  these m olecules can be seen from this X-ray structure representation o f  a 
tetrakis(benzoxazine).
(3 9 )
Figure 7: X-Ray structure o f  39
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1.1.4 Applications o f Resorcinarenes
Resorcinarenes are highly soluble in aqueous basic solutions because o f  deprotonation 
o f  the phenolic hydroxyl groups. However, removal o f  the first four protons is much 
easier than the last four. Potentiomeric titrations have shown that the pKa values for 
the first four protons arc lower by two units than the pKa o f  resorcinol, while the last 
four protons cannot even be removed with a strong base like NaOCH 3 . The stability 
o f  the tetraphenolate (figure 8 ) is a result o f  the ideal geometric disposition o f  the O- 
H-O arrangement2 9 ’30 and the possibility o f  delocalisation o f  negative charges. These 
factors combine to yield resorcinarenes as useful tools in cation complexation, with a 
possible application in sensor technology.
Tetraphenolate binds methyl trialkylammonium cations with spectacularly high 
binding constants (K = 3 x l0 4M _1 in 0.5N NaO D ) , 2 7 ,29 ’30 exceeding the corresponding 
constants in biological system s31. The strength o f  binding is only moderately affected 
by changing the ionic strength32 or solvent polarity33, indicating that the interaction is 
based almost exclusively on electrostatic attraction between the positively charged 
R 3 N 'M e and the negatively charged resorcinarene33. In 1993, it was shown that 
neutral resorcinarenes are also able to com plex alkylammonium cations, as was 
proved by a single X-ray crystal structure34.
Figure 8 : Tetraphenolate resorcinarene -  cation receptor 
Resorcinarenes have extensive use as host-guest receptors. One such example is 
illustrated in figure 9, where 6  resorcinarene m olecules encapsulate a quaternary 
ammonium guest. Host structures held together by hydrogen bonds have quite 
significant lifetimes in organic solvents, long enough to directly observe the 
encapsulated guest by NM R  spectroscopy35.
(41)
3 5Figure 9: Ammonium guest encapsulated by six resorcinarene molecules
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1.1.5 C ram ’s Cavitands
Resorcinarenes can be used as the starting material in the synthesis of a class of 
macrocycle know as cavitands, so named by Cram in 1982.36 Cavitands are 
structurally novel and have application in host-guest chemistry.
Scheme 14 outlines the synthesis of a cavitand, which has been synthesised by a 
covalent linkage of neighbouring hydroxyl groups of the corresponding 
resorcin[4]arene. The first reported synthesis outlined a reaction of a resorcinarene 
with excess bromochloromethane in a mixture of DMSO and DMF under basic 
conditions. The cavitand was recovered in 23% yield.
Br
Cl-----^"IH
(42) h
HaC
Cs2C 0 3
DM SO/DM F
CH3
rccc Boat isom er 
(30) (43)
Scheme 14: The synthesis o f the first o f Cram’s cavitand.
Other cavitands contain di alkyl silicon bridges, these have been shown to be able to 
complex with linear guests such as CS2 , propyne (C3H4) and even oxygen (O2 ) . 37 The 
synthesis of this type of cavitand is outlined in scheme 15. The cavitand is 
synthesised, in this particular example, by treatment of a resorcinarene with 
dimethyldichlorosilane in THF/TEA at high dilution yielding the cavitand in 37% 
yield.
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c h 3
rccc Cone isomer 
(30)
Cl/
Cl— Si"ilCH3 
(44) *CH3 
NaOH
DMSO/DMF
Scheme 15: Synthesis o f a dimethylsilicon bridged cavitand.
Cavitands with phosphoryl bridges have also been reported and are a result of the 
reaction of a resorcinarene with dichlorophenylphosphine under basic conditions of 
pyridine in DMF, (scheme 16). This class of cavitand was found to have applications 
in both cation (specifically copper and silver) and anion (specifically chloride and
n o
iodide) binding.
Scheme 16: Synthesis o f a phenyl phosphoryl bridged cavitand.
Carcerands are formed from two cavitands covalenty linked via an oxygen (or 
sulphur) atom in the 2  position of the resorcinol moiety as shown in figure 1 0 .
-21-
(49)
Figure 10: General structure o f a carcerand39.
Carcerands irrevisbly trap guests during their synthesis, which result in “carceplexes”. 
However it is not possible for the guest molecule or ion in a carceplex to escape 
without rupturing covalent bonds in the shell of the host or the guest. The term 
“hemicarcerands” is used to describe cavitand-based hosts that possess holes large 
enough for guest entry or egression to occur. The term for the corresponding host- 
guest complex is a “hemicarceplex”. Guest exchange in hemicarceplexes is in general
1 39quite slow at room temperature .
1.2 P y ro g a llo l[n ]a re n e s
Pyrogallol[4]arenes, 51 are prepared from the condensation of pyrogallol, 50 with 
aldehydes, 1, under acidic conditions. Their synthesis was first reported in the patent
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literature in 199040. The name pyrogallolarene was coined in a similar fashion to a 
resorcinarene, which was derived from rescorcinol41. It’s structural similarity to 
calixarenes (Greek for Chalice “Calix” and Crater “Arene”) also contributed to their 
name. The synthetic route used to prepare a pyrogallolarene is shown in scheme 17 
and as with resorcinarines, many stereoisomers are possible (figure 2 ).
Pyrogallol[4]arene is the only reported product from the condensation of pyrogallol, 2 
and alkyl aldehydes42. Theoretically, trimers, pentamers, hexamers and even higher 
cyclic oligomers are possible, but none have been reported to date.
Scheme 17: Preparation ofpyrogallol[4]arene
1.2.1 Self-Assembly of Pyrogallol|4]arenes
For the past two decades chemists have strived to design discrete spherical molecular 
hosts similar to those found in nature (for example spherical viruses, fullerenes). Such 
frameworks possess cavities capable of entrapping molecular guests and have 
applications in chemistry (for example, catalysis or sensors), biology (drug delivery), 
and materials science (molecular devices). Organic frameworks capable of such 
enclosure of space have been formed by synthesis and by self-assembly. Self­
assembly has proved an attractive means of constructing large, highly organized 
chemical entities.
The acid-catalyzed condensation of pyrogallol and long chain alkyl aldehydes yields 
pyrogallol[4]arenes, which associate in the form of hexameric capsules of 
extraordinary stability due to the presence of 48 intermolecular hydrogen bonds 
seaming the individual pyrogallol[4]arenes together, (scheme 18).
R- C1 1 H23
(52) (52a)
Scheme 18: Assembly o f pyrogallol[4]arenes to hexameric capsules in a variety o f
nonpolar liquid hydrocarbons43.
The use of calix[4]arenes and resorcin[4]arenes for the construction of large 
supramolecular assemblies has long been of interest to many researchers, such as J.L. 
Atwood44. Iwanek, Mattay and co-workers structurally characterized crystals which 
exhibited two different types of assembly via hydrogen bonds: wave-like 2D 
polymeric structures and for C-isobutylpyrogallol[4]arene, a spherical hexameric 
structure (figure l l ) . 45
Unfortunately, it appears that the spherical hexamer was only obtained on one 
occasion.46 The instability of hexamer 53 compared to 
[(C-methylresorcin[4 ]arene)6(H2 0 )g], a very large synthetic molecular capsule, 47 was 
given as the explanation for the failure to obtain crystals of the spherical hexamer 
again. However, in view of the 48 intermolecular hydrogen bonds holding the six 
pyrogallol[4]arenes together, it was believed that the hexamer should be quite stable 
in solvents such as acetonitrile or nitrobenzene, particularly in view of the solution 
stability of [(C-methylresorcin[4 ]arene)6(H2 0 )8] in such solvents.
(53)
Figure 11: Space filling representation o f the C-propylpyrogallol[4] arene hexameric
capsule.
Another interesting property of compound 53 was that the hexamer crystallized in the 
triclinic space group PI bar, although the illustration provided made it clear that such 
a hexamer could support higher symmetry. This low symmetry of such an inherently 
symmetric capsule could prove useful.
In the study of host-guest chemistry of [(C-methylresorcin[4 ]arene)6(H2 0 )8], the high 
symmetry of the large capsule47 has made crystallographic identification of the guests
housed within the capsule impossible. Atwood et al came to the conclusion that a 
lower symmetry capsule should make crystallographic study of the guests therein 
feasible.
(53a)
Figure 12: The oxygen atoms of the capsule in the space-filling metaphor
Figure 12 displays the hydrogen-bonding scheme of 53. The oxygen atoms 
participating in the hydrogen bonding are found in bands, which seam the capsule 
together. The volume available for guests is about 1500A3 48 but thus far, even with 
Plbar space symmetry, the guests on the interior are in each case badly disordered. 
Diffusion NMR was used in this study to identify the guests within their structures.
1.2.2 Host -  Guest Chemistry of Pyrogallol[4]arenes
Selective binding of biorelevant molecules such as amino acids through polar 
interactions in nonpolar organic media is a rapidly growing area of molecular 
recognition.46 Such a polar interaction, however, is far less pronounced in water. In 
fact, amino acid binding in aqueous media has been limited, to aromatic amino acids 
having good hydrophobicity as well as the capability of undergoing n-n stacking or 
charge transfer interaction.49
Kobayashi et al. introduced a highly electron rich aromatic cavity of water soluble 
pyrogallol or resorcinol cyclic tetramer and opened a newer phase of aqueous host- 
guest association involving highly hydrophilic guests such as sugars. It was reported 
that relatively hydrophobic aliphatic as well as aromatic amino acids can be bound to 
the pyrogallol or resorcinol cyclic tetramer (figure 13). The interaction between the 
host as u-base and the guests as either a- or Tt-acid plays an important role. 50 
Results from this research proved that every guest is bound more tightly to the 
pyrogallol host than to the resorcinol host. The former having an additional hydroxy 
group on each of the benzene rings has a more electron-rich and less hydrophobic 
aromatic cavity, as compared with the latter. Thus, the 7i-basicity of the host is an 
important factor.
X
X
X = OH,H 
R = (CH2 )S 0 3Na
(54)
Figure 13: Tetrasulphonated derivative o f resorcin[4] arene or pyrogallol[4]arene,
water soluble amino acid receptor.
This particular result indicates that the present amino acid binding in water, as in the 
case of mono51 and polyol complexation, is not simply due to the so-called
hydrophobic effect but there is substantial stabilization arising from the CH-t: 
interaction52 between the guests as cr-acids and the host as 7T-base.
1.3 T h e  ro le  o f  G p l2 0  in  H IV  in fe c tio n  a n d  G p l2 0  in h ib ito rs
Acquired Immunodeficiency Syndrome (AIDS) is one of the worst pandemics the 
world has ever known. Human Immunodeficiency Virus (HIV) the virus that causcs 
AIDS was first discovered in 1981 in a remote area of central Africa.
HIV works by invading the cells of our immune system and reprogramming them to 
become HIV-producing factories. Slowly, the number of immune cells in the body 
dwindles and AIDS develops.
Figure 14: HIV Cells attaching to a C4 human T-cell54
HIV is a retrovirus, it uses the enzyme Reverse Transcriptase to convert RNA into 
DNA in the host cell.
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HIV infects one particular type of immune system cell, the CD4+T cell; also known 
as a T-helper cell. Once infected, the T-helper cell turns into a HIV-replicating cell. 
HIV slowly reduces the number of T-cells until the infected individual develops 
AIDS. To better understand how HIV infects the body, the basic structure of the virus 
needs to be looked at:
Lipid
M em brane
R N A
R everse  
T ra n sc rip ta se
A n a t o m y  o f  t h e  A I D S  V i r u s
p lT
M atrix
P ro te in s
g p ± 2 0
E nvelope
P ro te in
g p 4 1
Envelope
P ro te in
53Figure 15: Anatomy o f the AIDS virus
• Viral envelope - This is the outer coat of the virus. It is composed of two 
layers of fatty molecules, called lipids. Embedded in the viral envelope are 
proteins from the host cell. There are also about 72 copies of Env protein, 
which protrudes from the envelope surface. Env consists of a cap made of 
three or four molecules called glycoprotein (gp) 1 2 0 , and a stem consisting of 
three to four gp41 molecules.
• p i 7 protein - The HIV matrix protein that lies between the envelope and core.
• Viral core - Inside the envelope is the core, which contains 2,000 copies of 
the viral protein, p24. These proteins surround two single strands of HIV 
RNA, each containing a copy of the virus's nine genes. Three of these genes: 
gag, pol and env - contain information needed to make structural proteins for 
new virions (a HIV virus particle)53.
The entry of HIV into host cells is mediated by the viral envelope glycoproteins (gp), 
which are organised into oligomeric, probably trimeric spikes displayed on the surface 
of the virion. The viral envelope is synthesized as a 160-kilodallon (kD) (gpl60) 
precursor glycoprotein, which is subsequently cleaved into 120-kD (gpl20) and 41- 
kD (gp41) glycoproteins present on the virion particle. These envelope complexes are 
anchored in the viral membrane by the gp41 transmembrane envelope glycoprotein. 
The surface of the spike is composed primarily of the exterior envelope glycoprotein, 
gpl20, associated by non-covalent interactions with each subunit of the trimeric gp41 
glycoprotein complex. Comparison of the gpl20 sequences of different primate 
immunodeficiency viruses identified five variable regions. The first four variable 
regions form surface-exposed loops that contain disulphide bonds at their bases. The 
conserved gpl2 0  regions form discontinuous structures important for the interaction 
with the gp41 ectodomain and with the viral receptors on the target cell. Both 
conserved and variable gp l2 0  regions are extensively glycosylated55.
Entry of primate immunodeficiency viruses into the host cell involves the binding of 
the gpl20 envelope glycoprotein to the CD4 glycoprotein, which serves as the 
primary receptor. The gpl20 glycoprotein binds to the terminal amine of the four 
immunoglobin-like domains of CD4. The gpl20 protein is held on the virion surface 
by a non-covalent interaction with gp4156.
CD4 binding induces conformational changes in the gpl20 glycoprotein, some of 
which involve the exposure and/or formation of a binding site for specific chemokine 
receptors. These chemokine receptors, mainly CCR5 and CXCR4 for HIV-1, serve as 
obligate second receptors for virus entry57.
The gpl20 third variable loop (V3) is the principal determinant of chemokine receptor 
specificity58. However, other more conserved gpl20 structures that are exposed upon 
engagement of CD4 also seem to be involved in chemokine-receptor binding. This 
CD4 induced exposure is indicated by the enhanced binding of several gpl20 
antibodies, which, like V3-loop antibodies, efficiently block the binding of gpl20- 
CD4 complexes to the chemokine receptor58. These are called CD4-induced (CD4i) 
antibodies. CD4 binding may trigger additional conformational changes in the 
envelope glycoproteins.
For example, binding of CD4 to the envelope glycoproteins of some HIV-1 isolates 
induces the release or ‘shedding’, of gpl2 0  from the complex, although the relevance 
of this process to HIV entry is uncertain55.
B
Figure 16: (A) Ribbon diagram o f the minimized mean structure o f HIV gpl20 C5 in 
40% trifluoroethanol and (B) electrostatic map o f the minimized mean structure o f
HIVg p i  20 C5.
Because of the important role of the gpl20 glycoprotein in receptor binding and 
interactions with neutralizing antibodies, information about the gp l2 0  structure is 
important for understanding HIV infection and for the design of therapeutic and 
prophylactic strategies55.
There is profuse evidence to suggest that CD4 binding induces a conformational 
change in gpl2 0 , but much of it derives from intact gp l2 0  with variable loops in place 
of the oligomeric gpl20-gp41 complex.
Analysis of the antigenic structure of gpl20 shows that most of the envelope protein 
surface is hidden from humoral immune responses by glycosylation and oligomeric 
occlusion59.
During virus entry, HIV surface proteins fuse the viral membrane with the target cell 
membrane. The gpl20 protein is a vital participant in the control and initiation of 
fusion. It functions in positioning: locating a cell capable of prolific viral infection, 
anchoring the virus to the cell surface, and orienting the viral spike next to the target 
membrane. It also functions in timing: holding gp41 in a metastable conformation and 
triggering the coordinate release of the three N-terminal fusion peptides of the 
trim eric gp41.
HIV fusion can be inhibited by peptides that mimic the sequences of the N- and C- 
terminal helices by binding to the end N terminal heptad repeat triple helices, or to the 
C terminal regions of Env, thereby preventing six-helix bundle formation60.
1.3.1 V ira l Fusion In h ib ito rs
Binding of drugs can occur at two sites (figure 17). The first is the attachment site on 
the CD4 T-cell and the second is the fusion site on the gpl20. In both cases the 
binding is brought on by electrostatic interactions.
Sit© o f Action of 
A ttachm ent Inhibitors
Membrane
Site o f A ction of 
Fusion Inhibitors
H a irp in  F o rm a tio n  a n d  
M e m b r a n e  F u sio n
CD4 B in d in g
Figure 17: a) CD4 Binding, b) Hairpin Formation and Membrane Fusion6 .
In the first case of inhibition, drugs can block the interaction of CD4 receptors with 
the viral gpl20. In the second case, they inhibit the conformational change (hairpin 
formation) that occurs with gp41 after gpl20 binds to CD4.
It has been recently discovered that a cell surface enzyme called Protein Disulphide 
Isomerase (PDI), plays a vital role in HIV-1 cell entry. PDI attaches to CD4 close to
62which leads to the conformational change in gp l2 0  and gp41 .
the g p l2 0  b ind ing  site, w hich enables PD1 to reduce the disulphide bonds o f  g p l2 0 ,
Figure 18: Molecular Docking Analysis Model ofPDI, CD4 and gp 120 complex62
Figure 18 shows a molecular docking analysis model of PDI, CD4 and gpl20 
complex62. The cysteine residues of gpl20 (yellow), which contain the disulphide 
bonds, are in close proximity to PDI. There is a flexible molecular ‘hinge’ between 
the D2 and D3 regions of CD4, and it is believed that this hinge enables PDI to come 
into contact with gpl20. It is also believed that inhibition of cell surface PDI prevents 
HIV-1 cell entry.
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1.3.2 C u rre n t C om m ercia lly  A va ilab le  Drugs
Current therapies for the treatment of HIV-1 infection employ potent antiretroviral 
drugs that target two distinct retroviral functions: reverse transcription of the viral 
RNA genome and virion maturation. Despite the strength of these regimens, several 
complications exist that limit their efficacy. Current drug regimes are complex, 
involving a large pill burden, and are associated with major toxicity. These factors 
increase the potential for the development of resistance and virologic failure.
These issues highlight the need for the development of novel drugs targeting distinct 
processes in the viral lifecycle63.
Virtually all the compounds that are currently used for the treatment of HIV 
infections, belong to one of the following classes:
1. nucleoside/nucleotide reverse transcriptase inhibitors- NRTIs (AZT, 55,
abacavir, 57 and didanosine, 56.) -  figure 19
2. non-nucleoside/nucleotide reverse transcriptase inhibitors- NNRTIs
(nevirapine, 58 and efavirenz, 59) -  figure 19
3. protease inhibitors - Pis (saquinavir,61, indinavir, 60, and lopinavir,62) -
figure 19
In addition to the reverse transcriptase and protease reaction, various other events in 
the HIV replicative cycle can be considered as potential targets for chemotherapeutic 
intervention. The inhibition of viral entry or indeed binding to the host cells is a 
promising target for the development of new antiviral drugs.
CHj
AZT (55)
Nevirapine (58) Efavirenz (59)
Didanosine (56)
Indinavir (60)
Saquinavir (61)
Figure 19: Commercially available HIV therapeutics
A great variety of polyanionic compounds have been found to be able to interfere with 
virus adsorption to the cell surface: i.e, polysulphates, polysulphonates,
polycarboxylates, polyphosphates, polyphosphonates, polyoxometalates, etc. (Figure 
20, D2S — poly sulphonate). This class of compounds also comprises the cosalane 
analogues (figure 21) containing the polycarboxylate pharmacophore. All these 
compounds exert their anti HIV activity by shielding off the positively charged sites 
in the V3 loop of the viral envelope glycoprotein (gpl20), which is necessary for 
virus attachment to the cell surface heparin sulphate, a binding site, before a more 
specific binding occurs to the CD4 receptor64.
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Figure 20: Dextran-2-sulphate (D2S); n=30 
A  n u m b e r  o f  s tu d ie s  h a v e  s h o w n  th a t s u lp h o n a te d  p o ly s a c c h a r id e s  in c lu d in g  d e x tr a n -  
2 -  s u lp h a te  ( f ig u r e  2 0 )  a n d  h e p a r in  in h ib i t  H I V - 1  in vitro. T h is  is a c h ie v e d  b y
interfering with the interaction between the T-cell determinant CD4 and viral gpl2065.
Figure 21; Cosatane analogue.
Recent advances in the field of viral entry have led to the development of several 
novel antiviral agents that target separate steps in the viral entry process. Since these 
drugs are targeting the parts of the virus life cycle that occur outside the cell, they 
might be better than the traditional drugs which target events that take place inside the 
infected cell. This is because anti HIV drugs which need to be inside the infected cell 
to be active can be efficiently neutralized by some cells, using primitive innate self- 
defence mechanisms such as ‘efflux pumps’, which sense toxins and eject them 
outside of the cell.
D2S has microbiocidal applications (microbiocides kill microbes, such as bacteria, 
fungi or in this case viruses), its use in contraception devices such as condoms, is
vast67.
There is another recent commercially available drug called “Enfuvirtide®” (figure 22). 
The drug mimics gp41 as it consists of 36 amino acid residues. It works by inhibiting 
virus cell fusion through a coil-coil interaction with gp41.
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Figure 22: E n fu v ir tid e- commercially available drug67.
1.3.3 M acrocyclic Therapeutics
The development of a macrocyclic compound with potent and novel antiviral activity 
may provide a significant lead in the formulation of effective microbiocides, either as 
a stand-alone agent or in combination with other synergistic products. The structure of 
a new lead, 65 is shown in Figure 23; it is a macrocycle prepared from a pyrogallol- 
aldehyde condensation and subsequently alkylated and saponified to give the final 
potassium salt product. Work carried out recently by Dr. Nolan’s group at Dublin City 
University has demonstrated that the original synthetic procedures used to prepare the 
target macrocycle (Figure 23) actually give a mixture of partially alkylated products.
R = CH2C02K, H 
(65)
Figure 23: Current leadpyrogall[4]arene.
These mixtures have been biologically evaluated by both in vitro and in vivo 
methods68. In vitro studies have shown promising results with this initial mixture, and 
it is anticipated that with improved appropriate synthesis, this could be greatly 
improved.
W e  b e lie v e  th a t th e s e  m a c r o c y c l ic  d e r iv a t iv e s  a re  e x c e lle n t  c a n d id a te s  as 
m ic r o b io c id e s , a n d  a lth o u g h  th e y  e x is t  as m ix tu re s  th is  m a y  n o t b e  a s ig n if ic a n t  
p r o b le m  fo r  a p p lic a t io n  s in c e  m a n y  o f  th e  m ic r o b io c id e s  p re s e n t ly  in  p h a s e  I I I  c lin ic a l  
tr ia ls  ( P R 0 2 0 0 0 ,  D e x t r a n -2 -s u lp h a te ,  c e l lu lo s e  s u lp h a te )  a re  used as m ix tu r e s 68.
1.4  T h esis  P ro p o sa l
The initial driving force behind our work was the interesting biodata from a 
pyrogallolarene moiety against HIV in clinical trials carried out in Uganda in the early 
nineties by Stephen Harris69.
However many questions arose upon reproduction of this work by, DCU, TopChem 
laboratories® and AIDS Care Pharma here in Ireland.
1) Can the yields of macrocycle be improved?
2) What is the stereochemistry of these macrocycles?
3) Are the lead compounds partially or completely alkylated?
4) What form of these compounds, perform biologically: partial or completely 
alkylated?
5) What are the structural limitations for biological performance -  mechanism of 
action?
6 ) Can effective HPLC methods be developed for the analytical detection of the 
macrocycles?
7) Can an improved lead be developed?
We wished to address all these problems in order to develop a better understanding of 
biological activity and also to optimise the synthetic methods used to prepare these 
compounds. Ultimately, we wished to develop a superior lead structure.
Chapter 2
Synthesis of Aryl and Alkyl 
Pyrogallol [4] arenes
2 .1  In tro d u ctio n :
T h e  c o n d e n s a t io n  o f  b e n z a ld e h y d e , 6 6 ,  w i t h  p y r o g a l lo l ,  5 0 ,  w a s  f ir s t  re p o rte d  in  th e  
p a te n t l i te r a tu r e  b y  H a n is 6 '1 in  th e  e a r ly  1 9 9 0 ’ s. T h is  c o n d e n s a tio n  s a w  e q u a l m o la r  
q u a n t it ie s  o f  a ld e h y d e  a n d  p y r o g a llo l  c o n d e n s e d  u n d e r  a c id  c o n d it io n s  to  fo r m  th e  
te tra p h e n y l p y r o g a l lo l [ 4 ]a r e n e ,  6 7 ,  in  a re p r o d u c ib le  y ie ld .  T h e  a im  o f  th is  re s e a rc h  
w a s  to  in v e s t ig a te  a n d  o p t im is e  th is  c o n d e n s a tio n  re a c t io n .
(66) (50) <67>
S c h e m e  1 9 : Preparation of tetra-4-fluorophenyl pyrogallol[4]arme
W e  a ls o  w e r e  in te re s te d  in  c o m p a r in g  th e  c o n d e n s a tio n  o f  v a r io u s  s u b s titu te d  
a ro m a t ic  a ld e h y d e s  to  th a t o f  th e  a lk y l  a ld e h y d e s . T h e  c o n d e n s a tio n  o f  a c e ta ld e h y d e ,  
6 8 ,  w ith  5 0  w a s  a ls o  in v e s t ig a te d .
OH
OH
(68) (50) (69)
S c h c m c  2 0 :  Preparation o f tetramethylpyrogallol[4]arene.
2 .2  R esu lts  an d  D iscu ssio n :
2.2.1 Tetramerisation of pyrogallol with 4-fluorobenzaldehyde.
The condensation of pyrogallol with 4-fluorobenzaldehyde under acidic conditions in 
ethanol at 78°C gives a reproducible yield of 35%. After only one hour reaction time a 
precipitate begins to form. When the reaction is complete (after five hours) a pink- 
purple product is then filtered and washed. Outlined in scheme 21 is a proposed 
mechanism for the condensation.
Schcme 21: Mechanism o f formation o f pyrogallol[4]arenes
The proposed mechanism involves a series of electrophilic substitutions, to yield a 
linear tetrameric species which cyclises to the thermodynamically stable tetramer. 
The arrangement of the various aromatic rings can vary and gives rise to a number of 
possible different conformations. There is of course the possibility of dimers being
formed, and two dimers coining together in different ways to foim various isomers of 
pyrogallol [4]arene. (See chapter 4).
The 'H-NMR data for this compound shows that the filtered residue is quite pure, 
however the reasonably low yield tells us that the soluble impurities and by-products 
are washed out in the filtrate. It is however unusual to achieve such high purity of a 
single product from a multi-component condensation. Many condensations of 
macrocycles (in particular classical calixarenes) give a complicated mixture of 
products. The proton splitting in the H-NMR (figure 27) is at first confusing. For two 
years, until we managed to obtain a crystal structure we could not unambiguously 
assign the stereoisomer, but on reference to the crystal structure, the splitting is 
explained. We had assumed that we had the rtct cone conformation judging by the 'H- 
NMR. This however was not the case, the crystal structure showed that in fact we had 
the chair rctt conformation
Two singlets at 4.8 ppm and 5.8 ppm each represent two pyrogallol aromatic protons. 
Two of these protons (from the crystal structure) are pointing between the 4- 
fluorophenyl rings of the pyrogallol [4] arene and are therefore shifted upfield by the 
anisotropic effect to 4.8ppm. The other two pyrogallol protons are not as greatly 
affected by these anisotropic effects due to their alignment and therefore appear at 
5.8ppm.
All four protons on the methylene bridges are in the same chemical environment and 
therefore they appear as a singlet at 5.6ppm. The downfield shift is due to the three
aromatic substituents on the bridging carbons. These protons are equivalent to trityl
protons.
The aromatic protons appear as a poorly resolved doublet of doublets at 6.5ppm and 
6 .6 ppm, this is due to the presence of the fluorine atom on the ring. The hydroxyl 
protons appear as three distinct singlets at 7.5ppm, 7.6ppm, and 7.7ppm
chair conformation
Mass spectrometry has also been used to confirm the structure of 65, Electrospray 
Ionization -  Mass Spectrometry (ESI-MS) has shown a single peak for the molecular 
ion M/Z: 951 (M+Na).
These compounds have poor solubility in most solvents. They have a low solubility in 
methanol, but are completely soluble in DMSO. They are not soluble in water, 
chloroform, ethyl acetate or hexane. Crystals of tetra-4-fluorophenyl 
pyrogallol[4]arenc, 65, were grown in DMSO and the X-ray structure is shown in 
figure 21. It would appear that the pyrogallolarene exists solely as a chair rctt isomer. 
The four 4-fluorophenyl rings project out at an angle of 88.5° from the plane of the 
bridging trityl carbons and are separated by 4.29A from each other. The pyrogallol 
rings are at an angle of 87.62° from each other with two pyrogallol units lying in the 
plane. The protons of the pyrogallol subunits are shielded by the ring currents of the 
adjacent pyrogallol ring subunits. The structure obtained is very similar to the 
resorcinarenes prepared from aromatic aldehydes70 except the 'H-NMR spectra differ 
for the proton in the 5-position of the pyrogallol/resorcinol ring in the macrocycle.
Figure 25: X-ray crystal structure o f tetra-4-fluorophenylpyrogallol[4Jarene,65. 
Two different views. (Structure drawn without Hydrogens for simplicity). See
Appendix 1.
y
All crystallography data can be found in Appendix 1. There are a few points to note 
from the crystallography data. The first one is the accuracy of the data. The accuracy 
is denoted by 2 different parameters F2 and R l. F2 is a “goodness of fit” parameter,
and should be as close to 1.000 as possible. Our crystal structure has an F value of 
1.030, which is very good. Secondly the R1 value gives a percentage of electron 
density present that is not accounted for by the crystal structure. Typically values less 
that 0.06 (6 %) are acceptable. Our crystal structure has a R1 value of 0.0401 (4.01%), 
which is also a very good result, and denotes an accurate structure.
2
Figure 26: X-ray crystal structure o f tetra-4-fluorophenylpyrogallol[4]arene,65.
The second point to note is the crystal system. Our crystal adopts a triclinic system. 
There are seven crystal systems in total, they are cubic, tetragonal, orthogonal, 
hexagonal, trigonal, monoclinic and triclinic. Triclinic is the least symmetrical of the 
seven systems. None of the 3 unit cell parameters are equal and none of the sides are 
perpendicular to each other. This crystal system is the most novel of the seven. Figure 
27 displays the crystal packing in a unit cell.
F ig u r e  2 7 :  Crystal packing o f tetra-4-fluorophenyI pyrogallol[4Jarene in a triclinic
unit cell.
The final point to note about the crystal structure is the temperature at which it was 
obtained. As expected, crystal structures are generally resolved at low temperatures. 
This is because at low temperatures there are less vibrations and therefore a clearer 
diffraction pattern. Our crystal structure is no exception, the structure was resolved at 
I00K (-173°C).
2 .2 .2  Y ie ld  O p t im is in g  E x p e r im e n t s
We were further interested in optimising the yields of 65. The first parameter that was 
investigated was the effect o f concentration of pyrogallol on the condensation. For 
this study we varied the concentration of starting materials in the reaction, to 
determine the effect on yield. The concentration of the starting materials was varied
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from 0.250g/ml to 0.083g/ml for a lg  scale reaction. The yields of these reactions are 
shown in Table 2.
Experiment Number Pyrogallol
Concentration
(g/ml)
Volume of 
Solvent (ml)
% Yield
2 .1 .1 - 1 0.250 2 0 %
2 .1 .1 - 2 0.167 4 32%
2.1.1-3 0.14 5 37%
2.1.1-4 0.125 6 34%
2.1.1-5 0 . 1 0 0 8 8 %
2 .1 .1 - 6 0.083 1 0 4%
Table 2: Concentration study and yields
No product was formed in the first reaction (only residual starting material), as the 
concentration was too high, reactions 2.1.1-2, 2.1.1-3 and 2.1.1-4 gave better yields, 
with the yield trailing off, as the concentration decreased. The optimum concentration 
was found to be 0.14g/ml (5mls of solvent) and this was used for future experiments. 
The dilution effect as seen in experiments 2.1.1-5 and 2.1.1- 6  is quite common for 
macrocycle synthesis as dilution encourages oligomer formation.
We suspected that the reactivity of pyrogallol, 50, would increase under base 
conditions due to the hydroxy groups being deprotonated. A series of experiments 
using five different bases were carried out using sodium hydroxide, pyridine, HOBT, 
DBU and triethylamine. On reaction with an aromatic aldehyde under base conditions 
a rapid formation of a green-black solid prevailed.
NMR and particle sizing measurements have shown this solid to be polymeric. There 
was no macrocyclic product formed. A possible explanation for this result involves 
the charge-charge repulsion between pyrogallol moieties, instead of cyclisation 
occurring we believe polymerisation of the pyrogallol occurs as shown in scheme 
22b. It can be clearly seen that there is no “charge-charge repulsion” present in 
scheme 22b and polymerisation is free to occur. All reactions gave a similiar polymer 
product, we are unable to calculate a percentage yield as the molecular weight of the 
polymer (or mixture of polymers) is unknown.
Charge-Charge
Repulsion
A
No Charge-Charge 
Repulsion
No Charge-Charge 
Repulsion
Scheme 22: a) Charge-charge repulsion mechanism o f deprotonatedpyrogallol 
moieties, b) polymerisation mechanism o f deprotonated pyrogallol moieties.
Experiment 2.3.1 was repeated using acetaldehyde in place of 4-fluorobenzaldehyde. 
The results of using an alkyl aldehyde instead of an aromatic aldehyde were 
interesting.
The 'H-NMR initially looked more complicated than that of the tetra-4-fluorophenyl 
pyrogallol[4]arene, 6 8 , with a more complex splitting pattern. However on further 
analysis this was found to be the result of two distinct stereoisomers present. Wc 
developed a simple and efficient procedure to isolate each stereoisomer. As before 
with the tetra-4-fluorophcnyl pyrogallol [4] arene column chromatography cannot be 
used owing to the highly polar nature of these compounds.
We first washed the precipitate with an ethanol/water solution (4:1). The filtrates from 
the washings were set aside. The collected precipitate was then rccrystallised from hot 
ethanol. The collected reaction filtrates were then added to ice, causing a second 
precipitate to form. This precipitate was found to be a tetramer (M/Z: 608) and from 
'H-NMR it was discovered to be a different conformation to that of the precipitate 
isolated from the reaction mixture.
The first isolated product was found to be in the same conformation as that observed 
with the condensation with aromatic aldehydes -  (rctt chair conformation). The latter 
product was seen to have a far simpler *H-NMR and for this reason it is believed to be 
the symmetrical rccc cone conformation. It would appear that the aromatic aldehydes 
give a distinctly different conformation than the alkyl aldehydes. The two products 
are illustrated in figure 28.
2.2.3 Tetram erisation o f Pyrogallo l, 2, w ith  Acetaldehyde, 27.
69a (front view) 69a (side view)
69b (side view)
Figure 28: Conformations o f tetramethylpyrogallol[4Jarene 69a rctt chair 69b rccc
cone
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Figure 29: 1H-NMR (DMSO-dt) o f tetramethyl pyrogallol[4]arene -  rctt chair
conformation, 69a.
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Figure 30: 'H-NMR (DMSO-de) o f tetramethyl pyrogallol[4]arene -  rccc cone
conformation, 69b.
The combined yield for both conformations was 41% (red chair 34% and rccc cone 
was 7%), which is slightly higher but still comparative to that in experiment 2.1.
In both 1 H-NMR spectra above a doublet is observed for the methyl groups of the 
bridging carbons. For the rccc cone conformation they are found at 1,4ppm however 
in the rctt chair conformation they are shifted upfield to 1 . 1  ppm, this is due to the 
methyl group pointing away from the annulus of the pyrogallolarene whereas in the 
case of the rccc cone conformation the methyl groups are in close proximity to the 
annulus and are shifted downfield.
In figure 31 we see a quartet at 4.4ppm, which corresponds to the bridging methylene 
protons. In the case of figure 30, a multiplet is observed for the bridging methylene 
protons, this is because the bridging protons in the rctt chair conformation (although
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similar) are not in the exact same chemical environment. The multiplet is due to two 
overlapping quartets.
In the rccc cone conformation the aromatic protons for the pyrogallol ring are a 
singlet at 6.7ppm. In the case of the rctt chair conformation two distinct chemical 
environments exist for the four aromatic protons, as such there are two distinct 
singlets at 6.4ppm and 5.7ppm, each with an integration of 0.5. Again there is a 
significant shift upfield due to the anistropic effect from the pyrogallol[4]arene 
annulus.
Finally the hydroxy protons of the pyrogallol rings appear as two broad singlets 
between 7 and 8 ppm. A smaller singlet corresponding to the centre hydroxy proton 
appears at 7.4ppm for the rctt chair conformation and at 8.0ppm for the rccc cone 
conformation. The outer two hydroxy protons are in the same chemical environment 
in both conformations and therefore appear as a broad singlet at 7.8ppm (in the rctt 
chair conformation) and 8.2ppm (rccc cone conformation). Here we see that the 
hydroxyl protons of the rccc cone conformation have been shifted downfield and this 
is due to the complex hydrogen bonding network in the upper rim of the 
pyrogallol[4]arene.
Alternative support for this argument comes from the difference in the OH bands in 
the IR spectra of the 2 conformations. The OH band of the rccc cone is far broarder 
than that of the corresponding band of the rctt chair conformation. This is due to the 
increased hydrogen bonding network within the rccc cone conformation.
It was noted in the literature that various macrocycles are produced in higher yield 
when a specific metal chloride is added to the reaction'’1. This is due to a metal 
templation effect. The metal template effect can be used for cyclisation reactions as 
shown in scheme 23.
2.2.4: M e ta l Tem plation Experiments
(71) HO'
(72) X'
Potassium salt
+
O'
'o
K
,0
,0 .
(73)
Scheme 23: Metal templation mechanism o f  crown ethers
Another example of a metal templation reaction is given in scheme 24, where the 
condensation of 2-aminobcnzaldehyde, 74, in the presence of anhydrous /.inc(U) 
chloride gave a tetrameric species, 75.
(74)
Scheme 24: Metal templation assisted synthesis.
We wanted to determine if metal templation could either enhance the yield of the 
tetramer or affect the stereochemical outcome of the reaction. A series of metal 
templation experiments was set up using different metal chlorides. We investigated 
the condensations of both 4-fluorobenzaldehyde, 70, and acetaldehyde, 6 8 , with 
pyrogallol, 50. These reactions involved adding an equivalent of a specific metal 
chloride to the reaction mixture. A total of eleven different salts were investigated. 
The results are shown in table 3.
T etra-4-Fluorophenyl 
pyrogallol[4]arene, 70
Tetramethyl 
pyrogallol [4] arene, 6 8
Expt No. Salt Yield (%) Expt No. Salt Yield (%)
2.31-1 None 35 2.32-1 None 34
2.31-2 NaCl 65 2.32-2 NaCl 30
2.31-3 LiCl 51 2.32-3 LiCl 1 0
2.31-4 KBr 70 2.32-4 KBr 49
2.31-5 CaCl2 39 2.32-5 CaCl2 32
2.31-6 MgCl2 50 2.32-6 MgCl2 2 1
2.31-7 CsCl 61 2.32-7 CsCl 2 0
2.31-8 BaCl2 No product 2.32-8 ZnCl2 No product
2.31-9 ZnCl2 75 2.32-9 CuCl No product
2.31-10 CuCl 33 2.32-10 NiCl2 No product
2.31-11 CuCl2 No product Yield Data refers on y to the chair
2.31-12 NiCl2 81 rctt Chair Tetramer, 5
Table 3: Metal templation experiments and yields
It can easily be seen from this table that certain metal ions enhanced the yield, 
increasing it over two-fold in some cases. For the condensation with 4- 
fluorobenzaldehyde; Sodium, Potassium, Zinc and Nickel ions favour the formation
of the tetramer, whereas for the tetramethylpyrogal 1 o 1 [ 4] arcne, 65, only potassium ion 
gives an enhancement.
It is possible that these enhancements are a result of a chelation effect, since only 
metals, of a specific size / charge ratios enhance the yield. However it is also a 
possibility that tetramerisation is enhanced due to the fact the pyrogallol is slightly 
deactivated by coordination to the metal. Deactivation of the pyrogallol moieties 
would inhibit the formation of polymers or long chain oligomers and perhaps 
encourage the formation of the tetramer. This could also be the reason that the 
addition of some salts to the reaction led to the formation of no product at all. Perhaps 
the pyrogallol was deactivated too much for a reaction to occur. (See chapter 4).
It is unlikely that we are seeing metal templation of the pyrogallol units (as in Figure 
28a), as the rctt isomer is formed. However it could be the case that the intermediates 
are templated (as in figure 28b and 28c). However in the case of figure 28b, where 
two dimers are coming together, this should also lead to a substantial increase in the 
yield of the acetaldehyde condensation, which was not the case, suggesting that the 
process may be stepwise and not involve two dimers coming together.
We believe that the case described is figure 28d makes more sense of the results, that 
is, pyrogallol reactivity is lowered in the presence of a metal salt by chelation. The 
mechanism will be further discussed in chapter 4.
Figure 28a Figure 28b
Figure 28c Figure 28d
Figure 31: 28a metal chelation to four pyrogallol units, 28b metal chelation to two 
approaching dimers, 28c metal chelation to a trimer intermediate and 28d metal 
chelation to an individual pyrogallol unit.
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2.3 Experim enta l:
38mmol (4.74g) of pyrogallol, 50, and 38mmol (4.66g, 4.03ml) of 4- 
fluorobenzaldehyde, 70, were placed into 67.5ml of HCl/ethanol (17.5/50). The 
reaction mixture was refluxed at 78°C -  80°C overnight, and the resulting insoluble 
tetramer was collected by filtration. The collected powder was exhaustively washed 
with a 80:20 mixture of ethanol:water to give 3.0mmol (2.76g, 32% yield) of tetramer
'H-NMR- (400MHz) 5 (DMSO-d6) [ppm]
4.9ppm (2H, s, Ar-H), 5.9ppm (2H, s, Ar-H), 5.7ppm (4H, s, Ar-CH-Ar), 6 .6 ppm 
(8 H, d, J=5.6Hz, Ar-H), 6 .8 ppm (8 H, d, J=8 .8 Hz Ar-H), 7.7 (12H, broad multiplets, 
ArOH).
Mass Spec: M/Z: 951 (M+23)
Microanalysis: C52H36O 12F4 .H2O; Calculated: %C = 65.96; %H = 4.05 
Found: %C = 66.38; %H = 3.85
2.3.1.1: Concentration Study.
2.3.1 P reparation o f te tra -4-fluorophenyl pyroga llo l [4] arene, 65.
The standard conditions as described in 2.3.1 were used with lg  of Pyrogallol, 2, and 
0.85ml of 4-Flourobenzaldehyde, 70.
A series of reactions was set up as outlined in Table 4.
R e a c t io n
N u m b e r
P y r o g a l lo l 4 - F lu o r o
b e n z a ld e h y d e
H C 1
a c id
E t h a n o l %  Y i e l d
2 .1 .1 - 1 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 mls 2 mls n.p
2 .1 .1 - 2 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 mls 4mls 32%
2.1.1-3 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 ml 5ml 37%
2.1.1-4 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 mls 6 mls 34%
2.1.1-5 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 mls 8 mls 8 %
2 .1 .1 - 6 l.Og
(8 mmol)
0.85ml
(8 mmol)
2 mls lOmls 4%
T a b l e  4 :  Concentration Studies
All Products were confirmed to be 65 by ’H-NMR.
2.3.1.2: Tetramerisation under basic conditions
4mmol (0.5g) of pyrogallol, 50, was treated with 4mmol (0.46g, 0.42ml) of 4- 
fluorobenzaldehyde in ethanol (50ml), under basic conditions (table 5). The reaction 
mixture was refluxed at 78°C -  80°C overnight, and the resulting (insoluble) tetramer 
was collected by filtration. The collected product was exhaustively washed with a 
80:20 mixture of ethanol:water.
Pyrogallol 4-Fluoro
benzaldehyde
Ethanol Reagent Reagent
Amount
% Yield
4mm ol 
(0.50g)
4mmol
(0.42ml)
5ml Hydrochloric 
Acid (37%)*
6 m mol 
(0.6ml)
37%
4mmol
(0.50g)
4mmol (0.42ml) 5ml Sodium
Hydroxide
6mmol
(0.24g)
n.p
4mmol
(0.50g)
4mmol (0.42ml) 5ml Pyridine 6m mol 
(0.48ml)
n.p
4mmol
(0.50g)
4mmol (0.42ml) 5ml DBU 6mmol
(0.87ml)
n.p
4mmol
(0.50g)
4mmol (0.42ml) 5ml HOBT 6mmol
(0.82g)
n.p
4mmol
(0.50g)
4mmol (0.42ml) 5ml Triethylamine 6mmol
(0.83ml)
n.p
Table 5: Condensation under basic conditions
*Control Reaction
* The product isolated from the control reaction was confirmed to be Tetramer 65 by 
'H-NMR.
2.3.2 Preparation of tetramethyl pyrogallol[4]arene, 69.
15.9mmol (2.00g) of pyrogallol, 50, and 15.9mmol (0.70g, 0.90ml) of acetaldehyde, 
68, were placed into 27ml of ethanol :HC1 (20:7) The reaction mixture was heated to 
78°C -  80°C overnight, and the resulting insoluble tetramcr was collected by 
filtration. The collected precipitate was washed with a 80:20 mixture of ethanol:water 
to give 1.25mmol (0.77g, 34%yield) of tetramer 69a.
'H-NMR- (400MHz) 8  (DMSO-4) [ppm]
l.ISppm (12H, d, J= 7.2Hz CH-CHj), 4.45ppm (4H, Muitiplet, J=7.2Hz, Ar-CH- 
CH3), 5.7ppm (2H, s, ArH), 6.4ppm (2H, s, ArH), 7.4ppm (4H, Broad Singlet, 
ArOH). 7.8ppm (8 H, Broad Singlet, ArOH).
Mass Spec: M/Z: 631 (M+23)
Microanalysis: C32H32O 12; Calculated: %C = 63.13; %H = 5.30 
Found: %C = 63.03; %H = 5.36
2.3.2.1 Isolation of 69b:
The fíltrate was poured onto ice to give a second precipitate. This precipitate was 
collected by suction filtration and was washed with cold water to give 0.26mmol 
(0,15, 7% yield) of tetramer 69b.
'H-NMR- (400MHz) 5 (DMSO-d6) [ppm]
1.48ppm (12H, d, J=7.2Hz CH-CH3 ), 4.45ppm (4H, Quartet, J=7.2Hz, A 1 -CH-CH3 ), 
6.7ppm (411 s, ArH), 8.0ppm (4H Broad Singlet, ArOH). 8.2ppm (8 H Broad Singlet, 
ArOlI).
Mass Spec: M/Z: 631 (M+23)
Microanalysis: C32H32O 12; Calculated: %C = 63.13; %H = 5.30 
Found: %C = 63.19; %H = 5.28
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The reaction procedure used was the same as that used in the preparation of tetra-4- 
fluorophenyl pyrogallol[4]arene, 65, in 2.3.1 above. (All reactions carried out for 
36hrs) All reaction mixtures consisted of 8.0mmol (l.Og) of pyrogallol, 8.0mmol 
(0.99g, 0.86ml) of 4-fluorobenzaldehyde, 70, 3.5mls of concentrated hydrochloric 
acid in 10ml of ethanol, with the exception that a metal salt chloride was added to the 
reaction mixture (see table 6).
2.3.3.1 M eta l-tem pla tion  experiments: te tra-4-fluorophenylpyroga llo l[4 ]arene
EXPT NO. SALT QUANTITY OF SALT % YIELD
2.31-1 None N/A 35
2.31-2 NaCl 8mmol (0.47g) 65
2.31-3 LiCl 8mmol (0.34g) 51
2.31-4 KBr 8mmol (0.95g) 70
2.31-5 CaCl2 8mmol (0.89g) 39
2.31-6 MgCl2 8mmol (0.76g) 50
2.31-7 CsCl 8mmol (1.35g) 61
2.31-8 BaCl2 8mmol (1.66g) n.p
2.31-9 ZnCl2 8mmol (1.09g) 75
2.31-10 CuCl 8mmol (0.79g) 33
2.31-11 CuCl2 8mmol (1.08g) n.p
2.31-12 NiCl2* 8mmol (1.90g) 81
Table 6: Metal templation experiments for tetra-4-fluorophenyl pyrogallol[4] arene. 
*NiCl2.6H20  was used.
2 .3 .3 .2  M e t a l - t e m p l a t i o n  e x p e r im e n t s :  t e t r a m e t h y p y r o g a l l o l [ 4 ] a r e n e .
The reaction procedure used was the same as that used in the preparation of 69, in
2 .3 .2  above. (All reactions were earned out for 36hrs) All reaction mixtures consisted 
of 8.0mmol (l.Og) ofpyrogallol, 8.0mmol (0.35g, 0.45ml) of acetaldehyde, 3.5mls of 
concentrated hydrochloric acid in 10ml of ethanol, with the exception that a metal salt 
chloride was added (see table 7).
E X P T  N O . S A L T Q U A N T I T Y  O F  S A L T % Y I E L D
2.32-1 None N/A 34
2.32-2 NaCl 8mmol (0.47g) 30
2.32-3 LiCl 8mmol (0.34g) 10
2.32-4 KBr 8mmol (0.95g) 49
2.32-5 CaCl2 8mmol (0.89g) 32
2.32-6 MgCl2 8mmol (0.76g) 21
2.32-7 CsCl 8mmol (1.35g) 20
2.32-8 ZnCl2 8mmol (1.09g) n.p
2.32-9 CuCl 8mmol (0.79g) n.p
2.32-10 NiCl2* 8mmol (1.90g) n P
T a b l e  7: Metal templation experiments for tetramethyl pyrogallol [4] arene. 
*NiCl2.6H20  was used.
Chapter 3 
Synthesis of PyrogaIIol[4]arenes II
3.1 E le c tr o n ic  E ffec ts:
We were interested in determining the effect substituents in the benzaldehyde would 
have on both yield and stereochemical outcomes of the condensation reaction. 2- 
fluorobenzaldehyde, 7 9 ,  3-fluorobenzaldehyde, 7 8 ,  3,4-difluorobenzaldehyde, 8 1 ,  3,5- 
difluorobenzaldehyde, 8 0  and pentafluorobenzaldehyde, 8 4 ,  were used to investigate 
the effect of the position of the fluorine on the ring. 4-chlorobenzaldehyde, 7 6  and 4- 
bromobenzaldehyde, 7 7  were used to complete the halo-benzaldehyde series. These 
were also compared to non-halogen systems using benzaldehyde, 6 7 ,  4- 
ethoxybenzaldehyde, 8 5 ,  4-nitrobenzaldehyde, 9 0  4-hydroxybenzaldehyde, 8 8 ,  and p- 
tolualdehyde, 8 2 ,  which were subsequently compared to the trifluoro-p-to I ualdehyde, 
8 3 .  (figure 32). All condensations were carried out in ethanol under acidic conditions 
(hydrochloric acid) for 5 hours.
F CH3
F igure 32: Condensation products (67, 76-95).
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The y ield  results are tabulated in  Table 8.
T etram er
No.
A ldehyde U sed % Y ield  -  
rccc  Cone
%  Y ield  -  
rc tt C hair
7 6 4-Chlorobenzaldehyde - 18
7 7 4-Bromobenzaldehyde - 7
6 7 Benzaldehyde - 15
7 8 3 -Fluorobenzaldehyde - 31
7 9 2-Fluorobenzaldehyde - 46
8 0 3,5 -Difluorobenzaldehy de - 12
8 1 3,4-Difluorobenzaldehyde - 16
8 2 p-Tolualdehyde - 45
8 3 Trifluorotolualdehyde - 26
8 4 Pentafluorobenzaldehyde - 4
8 5 4-Ethoxybenzaldehyde - 56
8 6 2-Bromobenzaldehyde - 54
8 7 3,5 -Dibromobenzaldehyde - 47
8 8 4-Hydroxybenzaldehyde - 58
8 9 2-Chlorofuraldehyde N o P roduct N o p roduct
9 0 4-Nitrobenzaldehyde - 8
9 1 Bromal N o P roduct N o  P roduct
9 2 Decanal 55 -
9 3 Formaldehyde N o P roduct N o  P roduct
9 4 Cyclohexanecarboxaldehyde - 28
9 5 4-t- Butylbenzaldehyde 2 7 66
6 5 4-F luorobenzal dehyde* - 32
6 9 Acetaldehyde* 7 34
Table 8: Yield Results
* Experim ental results for these condensations are in  C hapter 2.
We will first discuss the results for 7 6 ,  7 7 ,  7 8 ,  8 2 ,  8 3 ,  8 5 ,  8 8 ,  9 0  and 6 5 ,  all o f these 
tetramers are prepared from benzaldehydes possessing different substituents in the 
para and m eta positions. A general trend can be observed: the stronger the electron 
withdrawing group in the benzaldehyde the lower the yield. This means that a positive 
inductive electronic effect (electron donating group) enhances the yield. W e plotted 
yield against Hammett a  values to determine i f  a linear relationship exists. The results 
are shown in figure 33, a linear relationship does indeed exist with an R value o f  0.93.
C p d .  N o . R - G r o u p %  Y i e l d <t  V a l u e 72
5 0 4 -N 0 2 8 0.78
3 6 4-C1 18 0.23
3 7 4-Br 25 0.23
4 3 4 -CF3 26 0.54
3 8 3-F 31 0.34
3 0 4-F 32 0.06
4 2 4 -CH3 45 -0.17
4 5 4 -OCH2CH3 56 -0.56
4 8 4-OH 58 -0.37
T a b l e  9 :  Trend of yield with a  values.
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This trend is obvious with the nitro groups being the strongest electron-withdrawing 
and as a result gave the lowest yield, only 8%, whereas aldehydes with strong electron 
donating groups, 4-ethoxybenzaldehyde and 4-hydroxybenzaldehyde, gave yields of 
56-58%. It should be noted that all products gave the rctt chair stereoisomer based on 
the 'H-NMR
3.2 S te r ic  F a c to rs :
We also wanted to consider steric effects on the outcome of these condensations, and 
we selected tetramers, 84, 86, 87, 92, 94, 95 and 69 (table 8), for this investigation.
For all the aromatic aldehyde derived tetramers prepared to this point the rctt chair 
conformer is the sole product. However, on using acelaldehyde (with an alkyl R group 
rather than aromatic) two conformations, the rccc cone conformation and rctt chair 
were isolated with the rctt chair being the major product.
A comparison was made using the longer chain alkyl aldehyde n-decanal. The 
resulting macrocycle, 92, gave the rccc cone conformation as the sole product.
On its own the result for the decanal condensation is not surprising, as condensation
-j'i t t 
of resorcinol with alkyl aldehydes gives the same result . What is surprising is the
formation of the rctt chair conformation on condensation with acetaldehyde. This
conformation has been reported for resorcin[4]arenes70 but only on condensation with
aromatic aldehydes (4-hydroxbenzaldehyde) and even then it was a minor product.
The extra hydroxyl group on the benzene ring in pyrogallol (when compared to 
resorcinol) obviously adds to the reactivity of the phenyl ring to the extent that this 
conformation is thermodynamically favoured.
We then decided to condense cyclohexanecarboxaldehyde, 95. We were interested in 
cyclohexane because like phenyl systems, it is a non aromatic six membered ring. 
Interestingly the cone conformation did not form but the rctt chair conformation 
formed in a reasonably low yield («25%) and also in low purity. Once again 
purification has proven difficult owing to the polar nature of these compounds. We 
believe that this result demonstrates that it is the six-membered ring (i.e. size) that 
dictates the stereochemical outcome of this reaction.
From here we attempted condensations with aromatic aldehydes that contained bulky 
groups on the phenyl ring, to give tetramers 84, 86 and 87. Condensation with 2- 
bromobenzaldehyde, gave 86 in high yield in the rctt chair conformation. This can be 
explained in terms of electronic factors, but it is quite surprising with regard to steric 
considerations, since one would have thought that a bromine group in the ortho­
position would cause too much steric hindrance and condensation would not occur.
Based on the X-ray crystal structure of tetra-4-fluorophenyl pyrogallol[4]arene the 
three dimensional structure of tetramers 86 and 87 are shown in figure 34. For 
tetramer 86 we would assume the phenyl groups to be arranged so that the bromines 
are not in close proximity in order to relieve steric strain (as shown). As a result free 
rotation of the groups, should be inhibited, which should result in a poor yield. In the 
case of 87 the phenyl rings are completely locked in space, as a result of the size
(atomic radius Br = 1.2A, compared with F = 0.7A) of the pendant groups. The 
phenyl groups are not free to rotate therefore the reduction in yield of 87 in 
comparison to 86 is not surprising.
Figure 34: a) Tetramer 46, tetra-2-bromophenylpyrogallol[4]arene. b) Tetramer 47, 
tetra-3,5-dibromophenyl pyrogallol[4]arene. Both rctt chair stereoisomers.
In the case of tetramer 84, a low yield was obtained, we believe that the inductive 
effect on the ring was too great, (with five fluorine groups) and polymerisation 
occurred. This effect will be discussed in more detail later.
Following this we tried a condensation reaction with tetra-4-f-butylbenzaldehyde. We 
believed, based on the X-ray structure of 65, that there would be far too much steric 
hindrance between the t-butyl groups on the neighbouring phenyl rings and either 
tetramerisation would be inhibited or the rccc cone conformation (or even the rctc 
cone conformation) would be the preferential conformation. This was not the case. An 
extraordinary high yield was recorded for this condensation. For the tetra-4-/- 
butylphenyl pyrogallol[4]arene, the rccc cone conformation was formed in 27% yield
(total yield for both conformations was 93%). This result was unexpected, it seems 
that the optimum isomer would be a rtct chair isomer, but this did not form at all. 
Electronically the /-Butyl group has a highly positive inductive effect on the ring and 
therefore would aid the condensation. However on looking at the crystal structure of 
the rctt chair conformation this would mean that two /-butyl groups are sterically 
close together in the product. This result tells us that although the tetramerisation is 
influenced by steric factors, electronic factors seem to play a more prominent role in 
the tetramerisation.
Figure 35: 3-D Schematic o f rctt chair stereoisomer o f tetra-4-t-hutylphenyl
pyrogallol[4]arene, 95
3.3 C o n d e n sa tio n  w ith  N o n -b en zy l S ystem s :
Bromal (CBr^CHO) was condensed with pyrogallol, however instead of a tetramer 
being formed, a polymerisation reaction took place. We believe that this was due to 
the strong negative inductive effects of the three bromine atoms.
A furan ring was used in the place of benzene by using 2-chlorofuraldehyde. This 
heterocycle, although aromatic like benzene, has different electronic properties. 5- 
membered heteroaromatics have an increased reactivity when compared to benzene, 
as they are more 7T-electron rich (6 7 1-electrons for 5 atoms)74. However according to 
this argument, the yield of the tetramer should have been enhanced. Perhaps the 
system is too reactive as polymerisation occurred once again.
Formaldehyde (HCHO) was condensed with the hope of investigating which 
conformation would be formed. However, again due to the enhanced reactivity 
(compared with acetaldehyde CH3CHO), polymerisation occurred.
3.4 G a llic  A cid  C o n d e n sa tio n s :
After the library of pyrogallol[4]arenes was constructed, a series of condensations 
with gallic acid, in place of pyrogallol, was carried out with 4-fluorobenzaldehyde and 
acetaldehyde (scheme 24). A white insoluble solid was formed and due to its high 
insolubility it is believe to be a 3-D networked polymeric product. Microanalysis 
confirms that it is not the desired tetramer, as the carbon to hydrogen ratios are not the 
same as the theoretical values. It is believed that the formation of a 3-D network 
would be aided by the presence of the carboxylic acid group in the 5 position of 
pyrogallol.
(2)
COOH
(96)
COOH R
(97a,b)
R(97a) = R (97b )= CH
Scheme 25: Condensation o f gallic acid with 4-fluorobenzaldehyde and
acetaldehyde.
3 .5  E x p er im en ta l:
3.1 Preparation of tetra-4-chloropheny!pyrogalIol[4]arene, 76.
3.9mmol (0.49g) of pyrogallol, 50, was treated with 3.9mmol (0.55g) of 4- 
chlorobenzaldehyde in a HCl:ethanol (1.7ml:5ml) solution. The reaction mixture was 
refluxed at 78°C -  80°C overnight, and the resulting insoluble tetramer was collected 
by filtration. The precipitate was washed exhaustively with a 80:20 mixture of 
ethanol :water to give 0.17mmol (017g, 18% yield) of tetramer 76.
‘H-NMR- (400MHz) (DMSO-d6) 8  [ppm]
4.9ppm (2H, s, Ar-H), 5.9ppm (2H, s, Ar-H), 5.6ppm (4H, s, Ar-CH-Ar), 6 .6 ppm 
(8 H, d, J=7.2Hz Ar-H), 7.0ppm (8 H, d, J=7.2Hz Ar-H), 7.7 (12H, broad multiplets, 
ArOH).
Mass Spec: m/z: 1018 (M+23)
Microanalysis: C52H36O 12CI4 H2O; Calculated: %C = 61.67; %H = 3.78 
Found: %C = 61.67; %H = 3.64
3.2 Preparation of tetra-4-bromophenylpyrogalIol[4]arene, 77.
The procedure described in 3.1 was followed using 7.53mmol (0.96g) of pyrogallol, 
50, 7.53mmol (1.39g) of 4-bromobenzaldehyde, to give 0.15mmol (0.18g, 7% yield) 
of tetramer 77.
'H-NMR- (400MHz) (DMSO-d6) 8  [ppm]
5.1ppm (2H, s, Ar-H), 5.9ppm (2H, s, Ar-H), 5.6ppm (4H, s, Ar-CH-Ar), 6 .6 ppm 
(8 H, d, J=8.0Hz Ar-H), 7.1ppm (8 H, d, J=8.0Hz Ar-H), 7.7 (12H, broad multiplets, 
ArOH).
Mass Spec: m/z: 1195 (M+23)
Microanalysis: C52H3 6 0 i2Br4 H2O; Calculated: %C = 52.46; %H = 3.22 
Found: %C = 52.28; %H = 3.00
3.3 Preparation of tetraphenylpyrogallol[4] arene, 67.
The procedure described in 3.1 was followed using 3.9mmol (0.49g) of pyrogallol, 
50, and 3.9mmol (0.4lg) of benzaldehyde, to give 0.15mmol (0.13g, 15%yield) of 
tetramer 67 was collected.
1 H-NMR- (400MHz) (DMSO-d6) 8  [ppm]
5.2ppm (2H, s, Ar-H), 5.8ppm (2H, s, Ar-H), 5.7ppm (4H, s, Ar-CH-Ar), 6 .6 ppm 
(8 H, d, J=7.6Hz Ar-H), 6 .8 ppm (8 H, d, J= 7.6Hz Ar-H and 4H, multiplet, Ar-H 
overlapping), 7.6 (12H, broad multiplets, ArOH).
Mass Spec: m/z: 880 (M+23)
Microanalysis: C52H40O 1 2 H2 O; Calculated: %C = 71.39; %H = 4.84 
Found: %C = 71.50; %H = 4.66
3.4 P repara tion o f te tra-3-fluorophenylpyroga llo l[4 ]arene, 78.
The procedure described in 3.1 was followed using 8.0mmol (l.Og) of Pyrogallol, 50, 
and 8.0mmol (0.99g, 0.85ml) of 3-fluorobenzaldehyde, to give 0.62mmol (0.57g, 
31 %yield) of tetramer 78.
!H-NMR- (400MHz) (DMSO-de) 5 [ppm]
5.0ppm (2H, s, Ar-H), 6.0ppm (2H, s, Ar-H), 5.7ppm (4H, s, Ar-CH-Ar), 6.4ppm 
(4H, d, J=6.4Hz Ar-H), 6.45ppm (4H, d, J=6.4Hz Ar-H) 6.65ppm (4H, multiplet, Ar- 
H) 6.95ppm (4H, multiplet, J=6 .8 Hz Ar-H), 7.8 (12H, broad multiplet, ArOH).
Mass Spec: m/z: 951 (M+23)
Microanalysis: C52H36O12F4 H2O; Calculated: %C = 65.96; %H = 4.05 
Found: %C = 66.36; %H = 3.93
3.5 Preparation of tetra-2-fluorophenylpyrogallol[4]arene, 79.
The procedure described in 3.1 was followed using 8.0mmol (l.Og) of Pyrogallol, 50, 
and 8.0mmol (0.99g, 0.85ml) of 2-fluorobenzaldehyde, to give 0.92mmol (0.85g, 46% 
yield) of tetramer 79 was collected.
'H-NMR- (400MHz) (DMSO-d6) 8  [ppm]
5.05ppm (2H, s, Ar-H), 6.0ppm (2H, s, Ar-H), 5.9ppm (4H, s, Ar-CH-Ar), 6.45ppm 
(4H, multiplet, Ar-H), 6.75ppm (8 H, multiplet, Ar-H), 6.9ppm (4H, multiplet, Ar-H), 
7.65-7.9 (12H, singlets, ArOH).
Mass Spec: m/z: 951 (M+23)
Microanalysis: C52H36O 12F4 H2 O; Calculated: %C = 65.96; %H = 4.05 
Found: %C = 66.30; %H = 3.89
3.6 Preparation of tetra-3,5-fluorophenylpyrogaIlol[4]arene, 80.
The procedure described in 3.1 was followed using 8.0mmol (l.Og) of Pyrogallol and 
8.0mmol (1.14g, 0.87ml) of 3,5-difluorobenzaldehyde, to give 0.24mmol (0.24g, 12% 
yield) of tetramer 80.
'H-NMR- (400MHz) (DMSO-d6) S [ppm]
4.85ppm (2H, s, Ar-H), 5.9ppm (2H, s, Ar-H), 5.75ppm (4H, s, Ar-CH-Ar), 6.25ppm 
(8 H, multiplet, Ar-H), 6.70ppm (4H, multiplet, Ar-H), 7.9ppm (12H, broad multiplet, 
ArOH).
Mass Spec: m/z: 1023 (M+23)
Microanalysis: C52H320i2Fg'H20; Calculated: %C = 61.42; %H = 3.17 
Found: %C = 61.62; %H = 3.31
3.7 Preparation of tetra-3,4-difluorophenylpyrogalIol[4]arene, 81.
The procedure described in 3.1 was followed using 12.0mmol ( 1.5g) of Pyrogallol, 
50, and 12.0mmol (1.71g, 1.33ml) of 3,4-difluorobenzaldehyde, to give 0.47mmol 
(0.47g, 16% yield) of tetramer 81.
!H-NMR- (400MHz) (DMSO-d6) 8  [ppm]
4.70ppm (2H, s, Ar-H), 5.85ppm (2H, s, Ar-H), 5.65ppm (4H, s, Ar-CH-Ar),
6.40ppm (4H, multiplet, Ar-H), 6.50ppm (4H, multiplet, Ar-H), 6.95ppm (4M,
multiplet, Ar-H), 7.7-8.0 (12H, singlets, ArOH).
Mass Spec: m/z: 1023 (M+23)
Microanalysis: C52H32O1 2F8 II2O; Calculated: %C = 61.42; %H = 3.17 
Found: %C = 61.73; %H = 3.47
3.8 Preparation of tetra-^-methylphenylpyrogaIlol[4]arene, 82.
The procedure described in 3.1 was followed using 8.0mmol (l.Og) of pyrogallol, 50, 
and S.OmmoI (0.96g, 0.94ml) of/Molualdehyde, to give 0.43mmol (0.83g, 45% yield) 
of tetramer 82.
'H-NMR- (400MHz) (DMSO-d6) S [ppm]
5.1 Opptn (2H, s, Ar-H), 5.85ppm (2H, s, Ar-H), 5.60ppm (411, s, Ar-CH-Ar),
6.53ppm (8 H, d, J=7.6Hz Ar-H), 6.67ppm (8 H, multiplet, Ar-H), 7.5 (12H, broad
multiplet, ArOH).
Mass Spec: m/z: 935 (M+23)
Microanalysis: C55H4 8O 1 2 H2O; Calculated: %C = 71.88; %H = 5.48 
Found: %C = 72.32; %H = 5.21
-81-
3.9 Preparation of tetra-4-trifluoromethylphenyIpyrogallol[4]arene, 83.
The procedure described in 3.1 w as fo llow ed  using 8.0mmol (l.O g) o f  pyrogallol, 50, 
and 8.0mmol (1.39g, 1.09ml) o f  ¿»-trifluorotolualdehyde, to givel.24 m m o l (0.59g, 
26%  yield) o f  tetramer 83.
'H -N M R - (400MHz) (D M SO -d6) 8 [ppm]
5.05ppm (2H, s, Ar-H ), 5.95ppm  (2H, s, A r-H ), 5.75ppm  (4H, s, A r-C H -A r), 
6.85ppm (8H, d, J=7.6Hz Ar-H ), 7.35ppm  (8H, d, J=7.6Hz A r-H ), 7.9 (12H , broad 
multiplet, A rO H ).
M ass Spec: m/z: 1128 (M+23)
M icroanalysis: C 56H36O 12F 12H2O; Calculated: % C  = 58.65; % H  = 3.34 
Found: % C  = 58.56; % H  = 3.23
3.10 Preparation of tetra-(pentafluoro)-phenylpyrogallol[4]arene, 84.
The procedure described in 3.1 w as follow ed  using 8.0mmol (l.O g) o f  pyrogallol, 50, 
and 8 -Om m ol (1.57g , 0.99ml) o f  pentafluorobenzaldehyde, to give 0.08mmol (0.1 Og, 
4% yield) o f  tetramer 84.
‘H -N M R- (400MHz) (D M SO -de) 8 [ppm]
5.15ppm  (2H, s, Ar-H ), 5.80ppm (2H, s, A r-H ), 5.45ppm (4H, s, A r-C H -A r), 7.3-7.9 
(12H , broad multiplet, A rO H ).
M ass Spec: m/z: 1249 (M+23)
M icroanalysis: C 52H20O 12F20H2O; Calculated: % C  = 50.58; % H  = 1.80 
Found: % C  = 50.37; % H  = 1.65
3.11 Preparation of tetra-4-ethoxyphenylpyrogallol[4]arene, 85.
The procedure described in 3.1 w as fo llow ed  using 15.9m m ol (2.0g) o f  pyrogallol, 
50, and 15.9m m ol (2.39g, 3.0ml) o f  4-ethoxybenzaldehyde. A fter washing, the 
product w as still found to be quite impure and recrystalisation from  an 80:20 mixture 
o f  Ethanol: W ater w as carried out. 2.22m m ol (2.29g, 56%  yield) o f  tetramer 85.
!H -N M R- (400MHz) (DM SO-dô) S [ppm]
1.1 ppm (12H , broad singlet, A r-0 -C H 2C H 3), 3.7ppm (8H, broad singlet, Ar-O - 
C H 2C H 3), 5.05ppm (2H, s, A r-H ), 5.75ppm  (2H, s, Ar-H ), 5.35ppm  (4H, s, A r-C H - 
A r), 6.35ppm (16H , broad singlet, A r-H ), 7.2-7.9 (12H , broad multiplet, A rO H ).
M ass Spec: m/z: 1056 (M+23)
3.12 Preparation of tetra-2-bromophenylpyrogallol[4]arene, 86.
The procedure described in 3.1 w as fo llow ed  using 16.0mmol (2.0g) o f  pyrogallol, 
50, w as treated w ith 16.0mm ol (2.92g, 1.84ml) o f  2-bromobenzaldehyde, to 
give2.16m m ol (2.53g, 54%  yield) o f  tetramer 8 6 .
'H -N M R - (400MHz) (D M SO -dé) 8 [ppm]
5.05ppm (2H, s, A r-H ), 6.0ppm (2H, s, A r-H ), 5.9ppm (4H, s, A r-C H -A r), 6.45ppm 
(4H, d, J=7.2H z A r-H ), 6.75ppm  (8H, d, J=7.2H z Ar-H ), 6.9ppm (4H, Multiplet, Ar-
H ), 7.65-7.9ppm  (12H , singlets, A rO H ).
M ass Spec: m/z: 1195 (M+23)
M icroanalysis: C52H360 i2B r4'H20; Calculated: % C  = 52.46; % H  = 3.22 
Found: % C  = 52.02; % H  = 2.94
3.13 Preparation of tetra-3,5-dibromophenyIpyrogaIIol[4]arene, 87.
The procedure described in 3.1 w as follow ed  using 16.0mmol (2.0g) o f  pyrogallol, 
50, and 16.0mmo1 (4.20g) o f  3,5-dibrom obenzaldehyde, to givel.8 9 m m ol (2.80g, 
47% yield) o f  tetramer 87.
'H -N M R - (400MHz) (DM SO-dó) S [ppm]
4.85ppm (2H, s, A r-H ), 6.05ppm (2H, s, A r-H ), 5.80ppm (4H, s, A r-C H -A r), 6 .8ppm 
(8H, s, A r-H ), 7.35ppm  (4H, s, A r-C H -A r), 7.8ppm (4H, s, A rO H ), 8.1ppm  (8H, s, 
A rO H )
M ass Spec: m/z: 15 11  (M+23)
M icroanalysis: C52H320i2Brg; Calculated: % C  = 41.97; % H  = 2 .17  
Found: % C  = 41.88; % H  = 2.14
3.14 Preparation of tetra-4-hydroxyphenylpyrogallol[4]arene, 88.
The procedure described in 3.1 w as follow ed  using 16.0mmol (2.0g) o f  pyrogallol, 
50, and 16.0ramol (1.94g) o f  4-hydroxybenzaldehyde, to give2.29m m ol (2.10g, 
58% yield) o f  tetramer 8 8 .
'H -N M R - (400MHz) (D M SO -d6) S [ppm]
M ass Spec: m/z: 944 (M+23)
5.52ppm  (2H , s, A r-H ), 5.95ppm  (2H , s, A r-H ), 5.58ppm  (4H , s, A r-C H -A r),
6 .35ppm  ( 8H , d, J=9.2H z A r-H ), 6 .45ppm  (8H, d, J=9.2H z A r-H ), 7 .3-7 .9ppm  (12H ,
broad m ultiplet, A rO H ), 8.7ppm  (4H , broad singlet, A rO H )
M icroanalysis: C 52H40O 16H2O; Calculated: %C =  66.52; %H =  4.51
Found: %C =  65.91; %H =  4 .3 2
3.15 Attempted preparation of tetra-5-ehIorofuranpyrogallol[4]arene, 89.
8.0mmol (l.O g) o f  pyrogallol, 50, w as treated w ith 8.0mmol (1.04g) o f  5-chloro-2- 
furaldehyde under concentrated acid conditions (HC1, 2ml) in ethanol (5ml). The 
reaction mixture w as refluxed at 78°C -  80°C overnight, and the resulting (insoluble) 
black solid w as collected b y  filtration. The collected precipitate was washed 
exhaustively w ith a 80:20 mixture o f  ethanol:water. A fter w ashing the product w as 
still found to be quite impure and recrystallisation from  an 80:20 mixture o f  
ethanol:water w as carried out. On analysis this product w as found not to be tetramer 
89, but a m ixture o f  oligom ers and polym ers.
3.16 Preparation of tetra-4-nitrophenylpyrogallol[4]arene, 90.
The procedure described in 3.1 w as follow ed using 16.0mm ol (2.0g) o f  pyrogallol, 
50, and 16.0m m ol (4.20g) o f  4-nitrobenzaldehyde, to give 0.32mmol (0.33g, 8% yield) 
o f  tetramer 90 w as collected.
'H -N M R - (400MHz) (D M SO-dg) 5 [ppm]
4.6ppm (2H, s, A r-H ), 5.9ppm  (2H, s, A r-H ), 5.75ppm  (4H, s, A r-C H -A r), 6.85ppm 
(8H, d, J=7.6H z A r-H ), 7.75ppm  (8H, d, J=7.6Hz A r-H ), 7.9-8.lppm  (12H , broad 
multiplet, A rO H ).
M ass Spec: m/z: 1060 (M +23)
3.17 Attempted preparation of tetra-(tribromo)-methylpyrogallol[4]arene, 91.
15.9m m ol (2.0g) o f  pyrogallol, 50, w as treated w ith 15.9m m ol (4.47g, 1.68ml) o f  
bromal under concentrated acid conditions (HC1, 3.7m l) in ethanol (10m l). The 
reaction mixture was refluxed at 78°C -  80°C overnight, and the resulting (insoluble) 
black solid w as collected by filtration. The collected precipitate w as washed 
exhaustively w ith a 80:20 m ixture o f  ethanol:water. A fter washing the product w as 
still found to be quite impure and recrystalisation from an 80:20 mixture o f  
ethanol: water w as carried out. On analysis this product w as found not to be tetramer 
91, but a mixture o f  oligom ers and polymers.
3.18 Preparation of tetradecylpyrogallol[4]arene, 92.
The procedure described in  3.1 w as follow ed using 15.9m m ol (2.0g) o f  pyrogallol, 
50, and 15.9m m ol (2.48g, 3.0ml) o f  n-decanal. 2.20mm ol (2.32g, 55% yield) o f  
tetramer 92 w as collected.
'H -N M R - (400MHz) (D M SO -d6) 5 [ppm]
1.25ppm  (19H , broad singlet, -C H 2-C H 3), 4.15ppm  (4H, quartet, A r-CH -CF^), 
6.80ppm (4H, multiplet, A r-H ), 8.15 (4H, s, A rO H ) 8.65 (8H, s, A rO H ).
M ass Spec: m/z: 1080 (M +23)
M icroanalysis: C 64H96O 12H 2O; Calculated: % C  = 71.48; % H  = 9.18 
Found: % C  = 71.5 7; % H  = 9.00
M icroanalysis: C 52H 36O20N 4 H 20; Calculated: %C =  65 .96; %H =  5.31
Found: %C =  60 .07; %H =  3 .29; % N= 5.10
3.19 Attempted preparation of pyrogallol[4]arene, 93.
The procedure described in 3.1 w as fo llow ed  using 16.0m m ol (2.0g) o f  pyrogallol, 
50, and 16.0mmol (4.20g) o f  3,5-dibrom obenzaldehyde. The reaction mixture was 
refluxed at 78°C -  80°C overnight, and the resulting (insoluble) black solid was 
collected b y  filtration. The collected precipitate w as washed exhaustively w ith  a 80:20 
m ixture o f  ethanol: water. A fter w ashing the product w as still found to be quite impure 
and recrystallisation from  an 80:20 mixture o f  ethanol:water w as carried out. On 
analysis this product w as found not to be tetramer 93, but a mixture o f  oligom ers and 
polym ers.
3.20 Preparation of tetra-4-cyclohexylpyrogallol[4]arene, 94.
The procedure described in 3.1 w as follow ed using 6.36m m ol (0.80g) o f  pyrogallol, 
50, and 6.36mm ol (0.77m l) o f  cyclohexane carboxaldehyde, to give 0.44mmol (0.39g, 
28%  yield) o f  tetramer 94.
M ass Spec: m/z: 903 (M +23)
M icroanalysis: C 52H 64O 12H2O; Calculated: % C  = 69.47; % H  = 7.40 
Found: % C  = 70.67; % H  = 7.20
3.21 Preparation of tetra-4-M>utylphenylpyrogallol[4]arene, 95.
The procedure described in 3.1 w as follow ed  using 15.9m m ol (2.0g) o f  pyrogallol, 
50, and 15.9m m ol (2.58g, 2.66ml) o f  4-/-butylbenzaldehyde, to give2.63m m ol (2.84g, 
6 6 %  yield) o f  tetramer 95 (rctt Chair).
'H -N M R - (400MHz) (D M SO -d 6) 6  [ppm]
1.05 ppm (36H , broad singlet, C (C H 3)3), 5.6ppm (4H, s, A r-C H -A r), 5.8ppm (2H, s, 
Ar-H ), 6 .1ppm  (2H, s, A r-H ), 6 .6ppm (8H, d, j=8.0H z Ar-H ), 6.9ppm (8H, d, 
J=8.0Hz A r-H ), 7.5ppm  (8H, d, J= 11.2H z A rO H ), 7.6ppm  (2H, s, A rO H ), 7.9ppm 
(2H, s, A rO H ).
M ass Spec: m/z: 1104 (M +23)
M icroanalysis: C 68H 72O 12 H2O; Calculated: % C  = 74.29; % H  = 6.78 
Found: % C  = 74.59; % H  = 6.64
Com bined washings and filtrates w ere then treated w ith ice and 1.08mmol (1.16g, 
27%  yield) o f  tetramer 95a (rccc cone) w as collected.
'H -N M R - (400MHz) (D M SO -d 6) Ô [ppm]
1.29 ppm (36H , broad singlet, C (C H 3)3), 5.7ppm  (4H, s, A r-C H -A r), 6.4ppm (4H, s, 
Ar-H ), 6 .8ppm (8H, d, J=8.4Hz A r-H ), 7.1ppm  (8H, d, J=8.4Hz Ar-H ), 7.6ppm (8H, 
s, A rO H ), 7.8ppm (4H, s, A rO H ).
M ass Spec: m/z: 1104 (M +23)
M icroanalysis: C 68H72O 12; Calculated: % C  = 74.29; % H  = 6.78 
Found: % C  = 74.49; % H  = 6.72
3.22 Condensation of Gallic Acid, 58 with 4-fluorobenzaldchyde.
58.8mraol (lO.Og) o f  gallic acid, 58, and 58mmol (7.1 lg , 6.15m l) o f  4- 
fluorobenzaldehyde were placed into 81m l o f  HCl/ethanol (21/60). The reaction 
mixture w as refluxed at 78°C -  80°C overnight. The reaction yielded trace amount o f  
an insoluble white solid, which could not be characterised.
3.23 Condensation of Gallic Acid, 58 with acetaldehyde.
58.8mmol (10 .Og) o f  gallic acid, 58, and 58.8inmol (2.60g, 3.30ml) o f  acetaldehyde 
were placed into 81m l o f  HCl/ethanol (21/60). The reaction m ixture w as refluxed at 
78°C — 80°C overnight. The reaction yielded 0.3g o f  an insoluble white solid, which 
could not be characterised.
C h a p t e r  4  
C o n d e n s a t i o n  M e c h a n i s m
The optim isation w ork carried out in the previous chapters raises som e interesting 
questions concerning the m echanism o f  reaction and the conformational outcome:
1) W e have observed a strong electronic effect w ith respect to the various 
substitutents o f  the benzaldehydes used.
2) The benzaldehydes yield  different stereoisomers relative to the alkyl 
aldehydes. Furthermore, within the alkyl aldehyde series it w ould appear that 
acetaldehyde is unique in that it yields two different stereoisomers.
3) A  ‘metal effect’ is observed in the reactions with 4-fluorobenzaldehyde.
4) Steric repulsion can be used with benzaldehydes to give a change in 
stereochem ical outcom e o f  the m acrocycles.
The electronic effects indicate that the less reactive the aldehyde the higher the yield 
o f  product, indicating that com peting reactions such as polym erisation are lowered.
The stereochem ical outcom e for these reactions seems to be independent o f  electronic 
factors for the benzaldehyde series, all derivatives (barring the t-butyl derivatives) 
yielded the rctt chair conformations. W e believe that the driving force for the 
stereochem ical outcom e for these reactions result from steric effects. This is perhaps 
best demonstrated from the result o f  the condensation o f  cyclohexanecarboxaldehyde 
w hich yielded the rctt stereoisomer. A lthough it is an alkyl aldehyde, it ’ s size and 
shape sterically m im ics the size and shape o f  a phenyl ring, and this dictates the 
stercochem ical outcome.
Outlined in scheme 25 is a proposed m echanism for the condensation o f  pyrogallol, 
50, with substituted aldehydes. A  few  things should be pointed out concerning the 
intermediates foim ed, first o f  all intermediate A , 98, is chiral and should be produced 
as a racemate under the conditions used. Intermediates C , 100, and D, 101, are 
diastereomers. From sim ple m olecular m odelling (stick and ball m odels) w e have 
found that only certain diastereomers w ill yield  a m acrocycle and these are identified 
in schem e 25. The m acrocycles yielded from these intermediates are the rctt chair 
stereoisomers. The reason for this is that the other diastereomers are sterically 
repulsed upon approach to each other.
H ow ever, it should be noted that carbocation intermediates m ay be generated during 
the reaction (scheme 25) i f  this is the case then the enantiomeric effect o f  intermediate 
A , 98, m ay be eliminated since racémisation w ill occur upon formation o f  the 
carbocation.
To explain the observed metal effect on yield w e must look at a series o f  possible 
explanations. The first involves a metal templation effect, as mentioned in Chapter 2; 
this is observed w ith other m acrocycle systems. Outlined in figure 36 are a series o f  
possible templation interactions that can occur between metal salt and the hydroxy 
groups o f  pyrogallol. Each situation shown should lead to the rccc cone stereoisomer, 
how ever for the benzylaldehydes w e still observe the rctt stereoisomer, and 
interestingly the acetaldehyde condensation does not show a change in stereoisomer 
ratio. W e believe, based on these results that w e can eliminate this particular 
tem plation effect as an explanation for yield enhancement.
(50) (98) (99)
rccc Cone 
(51a)
HO
OH
H O - .
7JT
1 . 0 H
« / j l  OH 
R ___/
OH
/ — u R R J = (
HO * 0 OH
JL
HO T  OH
OH
reti Chair
(51b)
Schemc 26: Condensation mechanism.
A  second templation could also occur between tw o dimeric intermediates B , 100, as 
outlined in figure 36. H ow ever, i f  this w as to occur then w e should see an observable 
increase in yield  o f  not on ly the benzaldehyde products but also o f  the acetaldehyde 
condensation reaction. Since an increase is not observed in the latter case w e believe 
that this alternative tem plation is occurring.
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W e believe that cyclotetram erisation is enhanced in the presence o f  metal salts as a 
consequence o f  chelation between pyrogallol, 50, and the metal salt as shown in 
figure 36. I f  such chelation occurs, then pyrogallol should be slightly deactivated 
toward electrophilic attack, since electron density within the pyrogallol ring w ould be 
low ered as a result o f  chelation. The substituent studies o f  the benzaldehydes also 
support this idea, that is, the less reactive substrates generate the highest yields. W e 
believe that deactivation o f  the pyrogallol moieties w ould inhibit the formation o f  
polym ers or long chain oligom ers (com peting reactions) and perhaps encourage the 
formation o f  the tetramer. This could also be the reason that the addition o f  some salts 
to the reaction led to the formation o f  no product at all. Perhaps the coordination o f  
pyrogallol caused a strong deactivation preventing reaction from  occurring.
X '  HO \ 
x 'H O ^ A j y O H
H<i o H  O ò H  HoT o h
H O - j V  H C k X ^ O H  I  
Figure 36a
I
Figure 36b
Figure 36c
, - M +
O ' 1
HO'
h o ^ a ^ òh
Figure 36d
Figure 36: 36a metal chelation to four pyrogallol units, 36b metal chelation to two 
approaching dimers, 36c metal chelation to a trimer intermediate and 36d metal 
chelation to an individual pyrogallol unit.
Chapter 5 
Derivatisation of Pyrogallol[4] arenes
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5.1 Results and Discussion
5.1.1 Alkylation 1: Toward a completely alkylated pyrogallol[4]arene:
The first attempt at alkylating pyrogallol[4]arenes, 51, was reported in the patent 
literature by Harris in 1995M. Although Harris claimed to have produced the fully 
alkylated species, w e believe he m ay not have had. On analysis, and duplication o f  his 
synthetic methods, w e found that a mixture o f  partially alkylated products was 
formed. T o  this end w e endeavoured to solve this problem and develop methods to 
prepare fully alkylated pyrogallol[4]arenes.
W e started our investigation with a variety o f  rcll chair pyrogallol[4]arenes, described 
in the previous chapter. The first alkylation reaction w e considered involved using 
ethylbrom oacctate, in acetone under basic conditions at 60°C (scheme 27).
OH
B r ^ Y
(20) O
OEt
(65,67,69, 
76-83, 85-87)
Dry Acetone 60°C
k 2c o 3
104 R| " C l, 105 r 2
<TO
I01
106 r 3 X X . 107 R» X x Br
108 r 5 d 109 Ré b T1
110 Ry o r F 1 1 1 Rs
F
112 r 9 X C 113 R io ' C . „ ,
114 R ii X x CFs 115 R 12 o m « i
116 R 13 o r Br 117 Rl4 'TQrBr
Br
Scheme 27: Alkylation o f pyrgallol[4Jarene to corresponding dodeca acetate ester.
I f  left to react for one or two days, w e  found that only partially alkylated products 
w ere prepared. W e found that this reaction had to be driven to completion. To achieve 
this goal extra equivalents o f  ethylbrom oacetate and potassium carbonate were added 
each day over a five-day period. A fter the 5 days, all solvents w ere rem oved and the 
crude ester w as precipitated with dilute acid, after filtration the crude ester was 
recrystallised from hot methanol. The main impurities w ere found to be bromine salt 
by-products. W e attempted to purify these reaction m ixtures b y  silica gel column 
chrom atography how ever; w e found this to be ‘ im possible’ since w e would only 
obtain less than 5%  o f  the compound loaded onto the column. W e believe this is due
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to  th e  h ig h ly  p o la r  n a tu re  o f  th e  c o m p o u n d s . W e  e v e n  fo u n d  th a t  so lv e n ts  su c h  as 
m e th a n o l w o u ld  n o t  im p ro v e  th e  r e c o v e ry  o f  th e s e  c o m p o u n d s  (w h e n  u s in g  e th y l 
a c te ta te , o r  c h lo ro fo rm  o n ly  tr a c e  a m o u n ts  o f  c o m p o u n d  c o u ld  b e  e lu te d  f ro m  th e  
c o lu m n ) . T h e re fo re  p u r if ic a t io n  h a d  to  b e  c a r r ie d  o u t b y  re p e a te d  re c ry s ta ll is a tio n s . 
U n fo r tu n a te ly  e v e n  w ith  r e p e a te d  re c ry s ta l l is a t io n , a b s o lu te  p u r i ty  (d e te rm in e d  b y  1H - 
N M R  a n d  m ic ro a n a ly s is )  w a s  n o t  a c h ie v e d  a n d  th e re fo re  c o m p le te  c h a ra c te r is a tio n  
w a s  n o t  p o s s ib le  a t th is  s ta g e , a lth o u g h  a ll p ro d u c ts  w e re  id e n tif ie d  b y  m a ss  
s p e c tro m e try  c o n f irm in g  th e  p re s e n c e  o f  a  s in g le  d o d e c a  s u b s t i tu te d  p ro d u c t.
T h e  y ie ld s  fo r  th e  a lk y la t io n  re a c t io n s  a re  o u tl in e d  in  ta b le  10. T h e s e  re s u lts  a re  q u ite  
in te re s t in g , th e  e s te rs  p re p a re d  f ro m  te tra m e rs  p o s s e s s in g  su b s ti tu e n ts  o r th o  to  th e  
b r id g in g  c a rb o n  110 a n d  116, ( f ig u re  3 7 )  g iv e  r is e  to  lo w e r  y ie ld s  o n  a lk y la tio n . O n  
e x a m in in g  o u r  c ry s ta l  s tru c tu re  (C h a p te r  2 )  w e  c a n  se e  w h y  th is  w o u ld  b e  so . In  
te tra m e rs  w ith  p h e n y l r in g s  th a t  c o n ta in  o r i/z o -su b s titu e n ts , a lk y la tio n  to  th e  
n e ig h b o u r in g  p y ro g a llo l  h y d ro x y  g ro u p  w o u ld  b e  in h ib ite d  fo r  s te r ic  re a so n s . T h is  is  
m o re  so  th e  c a se  fo r  la rg e r  s u b s titu e n ts , th a n  s m a lle r  su b s ti tu e n ts  as se e n  o n  
c o m p a r is o n  o f  116 (6 %  y ie ld )  to  110 (2 4 %  y ie ld ) . A ll  o th e r  e s te rs  g iv e  re s p e c ta b le  
y ie ld s  e x c e p t fo r  117 w h ic h  p o s s e s s e s  tw o  b ro m in e  g ro u p s  m e ta  to  th e  b r id g in g  
c a rb o n s . A g a in  w e  b e l ie v e  s iz e  o f  th e  s u b s titu e n ts  m a y  b e  p la y in g  an  im p o r ta n t  ro le  
s in c e  1 1 1  g iv e s  a  re s p e c ta b le  y ie ld .
% Yield Results
Number of R-Group Dodeea-acetate Ester
1 . 4 - f lu o ro p h e n y l 3 5 %
2 . m e th y l 8 0 %
3. 4 -c h lo ro p h e n y l 8 8 %
4. 4 -b ro m o p h e n y l 7 2 %
5. p h e n y l 2 9 %
6 . 3 - f lu o ro p h e n y l 8 1 %
7. 2 - f lu o ro p h e n y l 2 4 %
8 . 3 ,5 -d if lu o ro p h e n y l 5 7 %
9. 3 ,4 -d if lu o ro p h e n y l 2 8 %
10. 4 -m e th y lp h e n y l 6 2 %
11 ,( tr if lu o ro ) -4 -m e th y lp h e n y l 5 7 %
12. 4 -e th o x y p h e n y l 5 4 %
13. 2 -b ro m o p h e n y l 6%
14. 3 ,5 -d ib ro m o p h e n y l 17%
Table 10: Y ie ld  r e s u lts  f r o m  e s te r i f ic a tio n  rea c tio n .
W e  a lso  a t te m p te d  to  c o m p le te ly  a lk y la te  th e  c o n e  r c c c  is o m e r  o f  th e  
p y ro g a llo l[4 ]a re n e  p re p a re d  f ro m  a c e ta ld e h y d e , 69. W e  fo u n d  th a t  e v e n  u n d e r  fo rc e d  
r e a c tio n  c o n d it io n s  a n d  e x te n d e d  re a c t io n  t im e s  th a t  o n ly  a  m ix tu re  o f  p a r t ia l ly  
a lk y la te d  p ro d u c ts  c o u ld  b e  p re p a re d . W e  b e l ie v e  th a t  th is  is  la rg e ly  d u e  to  tw o  
e ffe c ts : 1) s te r ic  h in d ra n c e  in  th e  u p p e r  r im  o f  th e  p y ro g a llo l[4 ]a re n e  a n d  2 )  th e  u p p e r  
r im  o f  a  c o n e  r c c c  p y ro g a l lo l[4 ]a re n e  a lso  p o s s e s s e s  a  la rg e  a n d  v e ry  s tro n g  h y d ro g e n  
b o n d in g  n e tw o rk  b e tw e e n  th e  tw e lv e  h y d ro x y  g ro u p s  (T h e  d if f ic u lty  in  d e p ro to n a tin g
r e s o rc in a re n e s  is  d is c u s s e d  in  c h a p te r  1). In  o r d e r  to  a lk y la te  th e  u p p e r  r im , w e  m u s t  
o v e rc o m e  th is  h ig h ly  s ta b le  h y d ro g e n  b o n d in g  n e tw o rk . T h is  s a m e  d if f ic u l ty  a lso
75o c c u rs  w ith  c a l ix [4 ]a re n e s  in  th e  a lk y la tio n  o f  th e  lo w e r  r im  h y d ro x y  g ro u p s  .
T h e  re c ry s ta l l is e d  c h a ir  rctt d o d e c a -a c e ta te  e s te r  d e r iv a tiv e s  w e re  th e n  h y d ro ly s e d  
in to  th e  c o r re s p o n d in g  d o d e c a  a c e ta te  p o ta s s iu m  sa lts , (s c h e m e  2 8 ). T h is  re a c t io n  w a s  
fo u n d  to  b e  s tr a ig h tfo rw a rd  a n d  u s u a lly  r e a c h e d  c o m p le tio n  in  tw o  h o u rs .
EtO„ n KO
° O K
(104-117) (118-131)
Scheme 28: Base catalysed hydrolysis of dodeca-acetate pyrogallol[4]arene to the 
corresponding dodeca-potassium acetate salt.
Y ie ld  v a lu e s  fo r  th is  re a c tio n  a re  sh o w n  in  ta b le  11 a n d  a re  g e n e ra l ly  q u ite  h ig h . T h e  
d o d e c a -a c e ta te  s a l t  is  w a te r -so lu b le .
W e  fo u n d  th a t  th e  m o s t  e f f ic ie n t w a y  to  p u r i f y  th e  re s u lt in g  sa lts  is  b y  a  s im p le  
r e p re c ip i ta t io n , f ro m  h y d ro c h lo r ic  a c id , to  fo rm  th e  c o r re s p o n d in g  d o d e c a -a c e ta te  
a c id , ( s c h e m e  2 9 )  w h ic h  is  in s o lu b le  in  w a te r . T h e  sa lt is  r e g e n e ra te d  in  h ig h  p u r i ty  b y  
a  fu r th e r  p re c ip i ta t io n  o f  th e  a c id  b y  t r e a tm e n t w ith  p o ta s s iu m  h y d ro x id e  in  e th a n o l 
( th e  s a lt  is  in s o lu b le  in  e th a n o l) .
HC1, 20°C
KOH, Methanol
20°C
(118-131)
Scheme 29: Acid catalysed precipitation of dodeca-acetate acid from corresponding 
dodeca-potassium acetate salt, and the reformation of the dodeca salt by base
catalysed precipitation.
Number of R-Group Dodeca-acetate 
Potassium Salt
Dodeca-acetate Acid
1. 4 - f lu o ro p h e n y l 95 72
2 . m e th y l 95 80
3. 4 -c h lo ro p h e n y l 77 93
4. 4 -b ro m o p h e n y l 79 85
5. p h e n y l 91 63
6 . 3 -f lu o ro p h e n y l 73 95
7. 2 - f lu o ro p h e n y l 80 84
8 . 3 ,5 -d if lu o ro p h e n y l 76 95
9. 3 ,4 -d if lu o ro p h e n y l 76 95
10. 4 -m e th y lp h e n y l 75 96
11 .( tr if lu o ro ) -4 -m e th y lp h e n y l 7 4 83
12. 4 -e th o x y p h e n y l 63 81
13. 2 -b ro m o p h e n y l 9 4 93
14. 3 ,5 -d ib ro m o p h e n y l 95 80
Table 11: Yield Results for all salt and acid formation reactions.
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110. Ester: R ’ =  C H 2C O O E t 116. Ester: R' = C H 2C O O E t
124. Salt: R ' = CH 2C O O K  130. Salt: R' = C H 2C O O K
138. A cid: R' = C H 2C O O H  144. Acid: R’ = C H 2CO O H
F igu re  37: Alkylatedpyrogallol[4]arenes with ortho-substituted aryl groups.
The dodeca-acetate acids (scheme 28) are formed in high purity and are fully 
characterised b y  'H  N M R  (figure 38), m icroanalysis and ESI mass spectrometry. W e 
also grew crystals o f  the dodeca ester derivatives for X -ray crystallography, but they 
were o f  insufficient size for X -ray diffraction studies to be carried out.
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F ig u r e  3 8 : 1H -N M R  (D M S O  - d 6)  -  T e tr a -4 - fIu o r o p h e n y l p y r o g a llo l[ 4 ] a r e n e  d o d e c a -
a c e ta te  a c id  d e r iv a tiv e .
(1 3 2 )
F ig u r e  3 9 : T e tr a -4 - f lu o r o p h e n y lp y r o g a llo l[ 4 J a r e n e  d o d e c a -a c e ta te  a c id  d e r iv a tiv e , 
132. (E q u iv a le n t  p r o to n s  la b e l le d  f o r  1 H -N M R  in te rp re ta tio n )
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The 'H -N M R  o f  tetra-4-fTuorophenyl pyrogallol[4]arene dodeca-acetate acid 
derivative, 132, is shown in figure 38. There are six different acetate protons (Ha, H a , 
Hb , H b , H c and H c ). Ha and Hc appear as 2 distinct doublets at 4.12ppm  and 4.25ppm. 
These tw o protons are pointing aw ay from the centre o f  the ring and therefore appear 
more upfield than the other acetate protons. H b and H b each appear as singlets w hich 
are overlapping w ith a doublet derived from either H a or Hc . This multiplet appears at 
4.5ppm. Ha and Hc appear as 2 doublets, one o f  w hich is overlapping with the two 
singlets from Hb and Hb at 4.5ppm and the other singlet appears at 4.8ppm. The 
protons on the m ethylene bridges o f  the pyrogallol[4]arene (Hd) are seen as a singlet 
at 6.2ppm. The aromatic pyrogallol protons (He) are split into two distinct singlets 
ow ing to the rctt-chair isom er (chapter 2). These are observed at 5.4ppm and 5.9ppm 
respectively. The doublet o f  doublets (Hf) is poorly resolved due to the presence o f  a 
fluorine atom on the ring and is seen at 6 .6ppm and 6.9ppm. The carboxylic acid 
protons are not observed ow ing to some D 20  in D M S O -d 6.
5.1.2 Alkylation 2: Toward a Single Partially Alkylated Pyrogallol[4]arene
A s mentioned previously, partially alkylated derivatives have shown biological 
activity, however, it is not possible to purify these com plicated reaction mixtures into 
their single components thus identification as to w hich alkylated species possesses the 
‘ best’ biological activity is not possible.
W ith this in mind w e cam e up w ith an alternative synthetic strategy to prepare a pure 
tetra-substitued p yrogallo l[4]arene as outlined in schem e 30. W e first attempted to 
stoichiom etrically alkylate one o f  the three hydroxyl groups o f  pyrogallol, then this
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derivative w ould then be condensed w ith an aldehyde to yield the target tetramer. 
(schem e 30)
T he hydrogen on the central hydroxy group (Carbon 2) o f  pyrogallol is the most 
acidic hydroxyl proton and therefore should be displaced more readily than the other 
two. W e had hoped that w e could stoichiom etrically control the alkylation to give the 
m onoalkylated pyrogallol.
The first step in this reaction was successful, after intense purification, v ia  column 
chromatography and recrystallisation, the desired product w as isolated and 
characterised. 146 w as then condensed w ith 4-fluorobenzaldehyde, 70, how ever only 
a black precipitate w as recovered, no target tetramer, 147, w as found.
It has been seen w ith calix[4]arenes75’76, that w hen a calix[4]arene with acetate groups 
on it, undergoes a reaction in harsh acidic conditions, the acetate groups can be 
cleaved o f f  o f  the calix[4]arene. W e believe this to be the case here also. Under 
hydrochloric acid conditions the acetate group is being cleaved as shown in scheme 
30. This synthetic plan w as abandoned.
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Attempt 1 EtO,
OH
H O . _ .  ^OH
1. EtBrOAc (Icq) 
K2C 03 
Dry Acetone O
(50)
HO OH
(146)
Attempt 2
OH
HO OH
2. EtBrOAc (leq)
tc2co3
Dry DMF
(50)
Attem pted Condensation
(146)
EtO. O
O
HO OH
H . ^ ,0  HC1
+  Y EtOH, 80°C
(146)
R
(2 ) (147)
Scheme 30: Attempt at partial alkylation.
Etr>
OH
HO.
H v  ^ 0  HCI
“I" \ ElOH, 80°
R
t C
H O
(146) (2) (50)
Scheme 31 : Acid Catalysed cleavage and regeneration of starting material.
5,1.3 Alkylation 3: Toward Partially Alkylated Pyrogallol[4]arenes using 
Stoichiometric Control.
A s mentioned previously the hydroxy group on the two position o f  the pyrogallol is 
more acidic, and would undergo alkylation more readily than the other two. This is 
still the case in the pyrogallol[4]arene tetramer. In order to synthesise partially 
alkylated derivatives, w e attempted a series o f  stoichiom etrically-controlled 
alkylations as shown in schem e 32.
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Tetra-substituted enriched 
(148-150)
B r ^ Y
O Et
. 0  (20) 
4e q
Dry Acetone 
K;CO, 
60°C
OH
O f ^ O E l  
O (20)
10 cq
Dry Acetone 
K,COj 
6ÔT
OR'
Deca-substituted enriched 
(157-15 9 )
OEt
O (20)
6 c q  v ’
Dry Accione 
KjCO, 
60°C
OEt
Dry Acetone 
KjCO j 
6f)°C
OR'
Hexa substituted enriched 
(15 1-15 3 )
OR'
Octa-substituted enriched 
(154-156)
S ch em e 32: P a r t i a l  a l k y l a t i o n  a t t e m p t  2 .
W e realised that this procedure w ould not yield  a single pure compound, how ever w e 
endeavoured to m ake an enriched sample o f  a particular partially substituted 
derivative. For exam ple reaction 2 (using six equivalents) w ould yield  a mixture o f  
predom inately hexa-alkylated pyrogallol[4]arene (along with som e tetra-alkylated to 
octa-alkylated).
The first two attempts o f  this reaction, using 4 and 6 equivalents o f  
ethylbromoacetate, yielded no product, and the third attempt (8 equivalents) gave a 
low  yield, <5% . U sing 10 equivalents o f  ethylbromoacetate gave a mixture o f  
partially and com pletely alkylated pyrogallol[4]arenes, in substantial yield. It would 
appear that the alkylation reaction has a minimum stoichiometric threshold, anything 
under 10  equivalents yields little or no alkylation product.
The partially alkylated esters w ere converted to the corresponding potassium salts and 
acids as outlined in schemes 28 and 29. 'H -N M R  and ESI m ass spectrometry were 
used to characterise the acid derivatives, the 'H -N M R  spectra w ere poorly resolved 
ow ing to a m ixture o f  compounds. M ass Spectra gave a bell curve o f  m olecular ion 
peaks centralising about 200-300 a.m .u.’ s below  the mass o f  the com pletely alkylated 
products.
These partially alkylated salt derivatives w ere also evaluated as G p l2 0  inhibitors 
(chapter 7).
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5.1.4 Alkylation 4: Alkylations using Various other Alkylating Agents
A s  part o f  our S A R  study, w e w ere interested in observing:
1) The effect o f  a longer carbon chain carboxy substituent on biological activity
2) The effect o f  a neutral substituent
3) The effect o f  replacing the carboxylate w ith a sulfonate group.
W e decided to prepare a series o f  new  alkylated derivatives o f  the tetra-4-
fluorophenyl pyrogallol[4]arene, 65.
Ethylbromopropionate:
For the first case w e  decided to introduce ethlybromopropionate since it contains an 
extra m ethylene spacer (schem e 33).
Scheme 33: Alkylation of pyrgallol[4]arene using ethylbromopropionate.
W e em ployed the same reaction conditions developed for the preparation o f  the 
acetate derivatives. This reaction resulted in a fine yellow  powder, and on 
recrystallisation from hot methanol very  little product was present. The impurities 
rem oved w ere found to be a m ixture o f  water-soluble inorganic brom ine salts. It was 
not possible to characterise or continue the reaction as the amount o f  product obtained 
w as so little and it w as also very impure. It is thought that this system would be too
.0
(51) (167) R
sterically hindered for alkylation to occur, but more than likely  it is because 
ethylbromopropionate is a poorer electrophile than ethylbromoacetate, and therefore 
less reactive.
1 -Bromopropanc:
The next alkylating agent that w as used w as 1 -bromopropane, this attempt proceeded 
as in scheme 34, again using the tetra-4-fluorophenyl pyrogallol[4]arene, 65, and also 
the tetramethyl pyrogallol[4]arene, 69.
OH
Br'
(168)
k 2c o 3
Dry Acetone 60°C
(51)
R im - R 170
(169, 170)
-CH,
S chem e 34: Alkylation o f pyrogallol[4]arene using 1 -bromopropane.
O nce again this reaction w as unsuccessful, as only inorganic bromine salts were 
produced. This reaction is reported in the literature for calix[4]arenes77,78. In the first 
reference B udka et al. uses propyl iodide w ith caesium  carbonate in acetone (41% ). 
H ow ever he reports that this reaction on ly  gives an alkylated product o f  the 1 ,3- 
alternate conform ation o f  the calixarene. In the other reference D udic et al. reports the 
alkylation in 76%  yield  (conform ation not specified) using propyl iodide and sodium 
hydride in anhydrous D M F. These are very  severe conditions, and there are only four
alkylation sites. In the case o f  pyrogallol[4]arenes there are 12 alkylation sites. It is 
clear from this that propyliodide is too w eak an electrophile for this alkylation.
2-Chloroethvl Sulphonate Sodium  Salt:
The final alkylating agent used was 2-chloroethyl sulphonate sodium salt, again using 
the tetra-4-fluorophenyl pyrogallol[4]arene, 65, via  scheme 35. W e were interested in 
pursuing this class o f  compound for biological reasons. It is know n that polyanions 
can act as G P120 inhibitors66, furthermore the charge on sulphonates are independent 
o f  pH unlike carboxylates. To this end w e endeavoured to form a range o f  
dodecasulphonate derivatives.
(171) 
-----------------------»
k 2c o 3
Dry Acetone, 60°C
(65) (172)
Schcme 35: Alkylation of pyrogallol[4]arene using 2-chloroethylsulphonate sodium
salt.
O n c e  a g a in  th is  r e a c t io n  w a s  u n s u c c e s s fu l ,  th e  y e l lo w -o ra n g e  p ro d u c t  th a t  w as
p ro d u c e d  w a s  fo u n d  to  b e  in o rg a n ic  h a lo g e n  sa lts . A g a in  th is  is  d u e  to  th e  e le c tro p h ile
b e in g  to o  w e a k  to  u n d e rg o  a lk y la tio n .
5.2 Experimental:
5.1.1 General procedure: alkylation of tetra-4-fluorophenyl pyrogallol[4]arene, 
30, with ethylbromoacetate
4.32m m ol (4.00g) o f  tetramer 65, (schem e 26) w ere reacted w ith 69.12m m ol (11.54 g, 
7.66m l) o f  ethylbromoacetate and potassium carbonate (108m m ol, 14.90g) in 240ml 
o f  dry acetone. The reaction was carried out at 60°C for 5 days. The reaction was 
driven to com pletion b y  the addition o f  0.2  equivalents o f  ethylbromoacetate and 
potassium carbonate each day. On cooling to room  temperature all volatiles were 
rem oved under reduced pressure. The residue w as treated w ith 5ml o f  dilute HC1 and 
then filtered to yield  a fine yellow  powder. The crude ester was purified by  
recrystallisation from hot methanol, to g ive  1.51m m ol (2.96g, 35%  yield), o f  dodeca- 
ethylacetate pyrogallol[4]arene tetramer 104
5.1.2 Base hydrolysis of dodeca-acetate ester 104
O.lOmmol (0.19g) o f  dodeca-acetate ester 104 was treated with 5.0mmol (0.28g) o f  
potassium hydroxide under reflux in ethanol at 80°C for overnight. On filtration 
O.lOmmol (0.19g 95%  yield) o f  dodeca-acetate potassium salt 118 was recovered.
5.1.3 Acid hydrolysis of dodeca-acetate potassium salt 118
0.09mmo1 (0 .19g) o f  the dodeca-acetate potassium salt 118 was dissolved in distilled 
water. Concentrated hydrochloric acid w as added drop-wise, until a white precipitate
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formed. The reaction m ixture w as allow ed to stand overnight whereupon the dodeca- 
acetate acid, 132, w as isolated by centrifugation and washed with distilled water, to 
g ive  0.07mmol (0.1 lg ,  72 %  yield) o f  dodeca-acetate acid 132.
‘H -N M R- (400MHz) (D M SO -d 6) 8 [ppm]
4.1 ppm (4H, d, J=7.2H z, A r-0 -C H 2-C 0 0 H), 4.3 ppm (4H, d, J=7.2Hz, AX-O-CH2- 
CO O H ), 4.5 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.8 ppm (4H, d, J=7.2Hz, Ar- 
O -C H 2-CO O H ), 5.4ppm (2H, s, Ar-H ), 5.9ppm (2H, s, Ar-H ), 6.2ppm (4H, s, Ar- 
C H -A r), 6.7ppm (8H, broad singlet, Ar-H ), 6.9ppm (8H, multiplet, Ar-H ).
M ass Spec: m/z: 1647 (M +Na), 1663 (M +K)
5.2.1 Alkylation of tetramethyl pyrogallol[4]arene, 69, (rctt -  Chair) with 
ethylbromoacetate
The general procedure as described in 5 .1.1  was follow ed using 0.82mmol (0.50g) o f  
tetramer 69, (schem e 26), 13.16m m ol (2.20g, 1.46m l) o f  ethylbromoacetate, and 
20.6mmol (2.84g) o f  potassium  carbonate, in 30ml o f  dry acetone, to give 0.66mmol 
(0.6g, 80% yield) o f  dodeca-ethylacetate pyrogallol[4]arene tetramer 105.
5.2.2 Base hydrolysis of dodeca-acetate ester 105
The procedure as described in 5.1.2 was followed using 0.33mmol (0.3g) o f dodeca-
acetate ester 105 and 9.9mmol (0.56g) o f potassium hydroxide, to give 0.31mmol
(0.32g 95% yield) o f dodeca-acetate potassium salt 119.
5.2.3 Acid hydrolysis of dodeca-acetate potassium salt 119
The general procedure as described in 5.1.3 w as follow ed using 0.26mmol (0 .15g) o f  
dodeca-acetate potassium salt 119, to g ive  0.21m m ol (0.12g, 80% yield) o f  dodeca- 
acetate acid 133.
‘H -N M R- (400MHz) (DM SO-de) 5 [ppm]
1.3 ppm (12H , s, -C H 3), 4.3 ppm (4H, s, A r-C H -C H 3), 4.5 ppm (8H, d, J=8.4Hz, Ar- 
O -C H 2-C O O H ), 4.7 ppm (16H , multiplet, A r-O -C ïT j-C O O H ), 5.5ppm (2H, s, Ar-H ), 
6.9ppm (2H, s, Ar-H ),
M ass Spec: m/z: 1327 (M +Na), 1343 (M +K)
5.3.1 Alkylation of tetra-4-chlorophenyl pyrogallol[4]arene, 76, with ethylbromo 
acetate
The general procedure as described in 5 .1.1  w as follow ed using 0.30mmol (0.30g) o f  
tetramer 76, (schem e 26) , 4.83mmol (0.80g, 0.53ml) o f  ethylbromoacetate, and 
7.55m m ol (1.04g) o f  potassium carbonate, in 5ml o f  dry acetone, to g ive  0.26mmol 
(0.54g, 8 8%  yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 106.
5.3.2 Base hydrolysis of dodeca-acetate ester 106
The procedure as described in 5.1.2  w as follow ed using 0.15m m ol (0.30g) o f  dodeca- 
acctate ester 106 and 3.03mmol (0 .17g) o f  potassium hydroxide. 0.12m m ol (0.25g 
77%  yield) o f  dodeca-acetate potassium salt 120.
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The general procedure as described in 5.1.3 w as follow ed using 0.14m m ol (0.30g) o f  
dodeca-acetate potassium salt 120, to give 0.13m m ol (0.22g, 93%  yield) o f  dodeca- 
acetate acid 134.
'H -N M R- (400MHz) (D M SO - d6) ô [ppm]
4.0 ppm (8H, d, J=8.4Hz, A r-0 -C H 2-C 0 0 H), 4.4 ppm (12H , multiplet, A r-0 -C H 2- 
CO O H ), 4.7 ppm (4H, d, J=8.4Hz, A r-0 -C H 2-C 0 0 H ), 5.3ppm (2H, s, A r-H ), 5.8ppm 
(2H, s, A r-H ), 6.0ppm (4H, s, A r-C H -A r), 6 .6ppm (8H, broad singlet, Ar-H ), 7.0ppm 
(8H, d, J=9.2Hz, Ar-H ).
M ass Spec: m/z: 1729 (M +Na)
5.4.1 Alkylation of tetra-4-bromophenyl pyrogallol[4]arene, 77, with ethylbromo 
acetate
The procedure as described in 5 .1.1  w as follow ed  using 0.26mmol (0.30g) o f  tetramer
77, (schem e 26) , 4.10m m ol (0.68g, 0.45ml) o f  ethylbromoacetate, and 6.40mmol 
(0.88g) o f  potassium  carbonate, in 5ml o f  dry acetone, to give 0.18m m ol (0.40g, 72%  
yield) o f  dodeca-cthylacetate pyrogallol[4]arene, tetrarner 107.
5.4.2 Base hydrolysis of dodeca-acetate ester 107
The general procedure as described in 5.1.2  was follow ed using 0.14m m ol (0.30g) o f  
dodeca-acetate ester 107 and 3.03mmol (0 .17g) o f  potassium hydroxide, to give 
O .llm m o l (0.24g 79%  yield) o f  dodeca-acetate potassium salt 121.
5.3.3 Acid hydrolysis of dodeca-acetate potassium salt 120
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The procedure as described in 5.1.3 was follow ed using 0.13m m ol (0.30g) o f  dodeca- 
acetate potassium salt 121, to give 0.11 m m ol (0.2 lg ,  85%  yield) o f  dodeca-acetate 
acid 135.
‘H -N M R- (400MHz) (D M SO -d 6) § [ppm]
4.1 ppm  (8H, overlapping doublets, J=7.2Hz, A r-0 -C H 2-C 0 0 H), 4.4 ppm (12H , 
multiplet, A r-0 -C H 2-C 0 0 H ), 4.7 ppm (4H, d, J=7.6Hz, A r-0 -C H 2-C 0 0 H ), 5.5ppm 
(2H, s, Ar-H ), 5.9ppm (2H, s, A r-H ), 6.1 ppm (4H, s, A r-C H -A r), 6 .6ppm (8H, broad 
singlet, Ar-H ), 7.2ppm (8H, d, J=8.4Hz, Ar-H ).
M ass Spec: m/z: 1887 (M + N a)
5.5.1 Alkylation of tetraphenyl pyrogallol[4]arene, 67, with ethylbromoacetate
The general procedure as described in 5 .1.1  w as follow ed using 0.70mmol (0.60g) o f  
tetramer 67, (scheme 26) , l l . lm m o l (1.84g, 1.22m l) o f  ethylbromoacetate, and 
17.35m m ol (2.40g) o f  potassium  carbonate, in 25m l o f  dry acetone, to give 0.20mmol 
(0.38g, 29%  yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 108.
5.5.2 Base hydrolysis of dodeca-acetate ester 108
5.4.3 Acid hydrolysis of dodeca-acetate potassium salt 121
T he procedure as described in 5 .1 .2  w as fo llow ed  u sing  0 .159m m ol (0 .30g) o f
dodeca-acetate ester 108 and 2 .39m m ol (0 .1 3g) o f  potassium  hydroxide, to g iv e
0 .14m m ol (0 .29g , 91%  yield ) o f  dodeca-acetate potassium  salt 122.
The procedure as described in 5.1.3 w as follow ed using 0.06mmol (0.12g) o f  dodeca- 
acetate potassium salt 122, to give 0.038mmol (0.07g, 63%  yield) o f  dodeca-acetate 
acid 136.
M ass Spec: m/z: 1575 (M + N a)
5.6.1 Alkylation of tetra-3-fluorophenyl pyrogalloI[4]arene, 78, with ethylbromo 
acetate
The procedure as described in 5.1.1 w as follow ed using 0.32mmol (0.30g) o f  tetramer
78, (scheme 26) . 5.12m m ol (0.86g, 0.57m l) o f  ethylbromoacetate, and 8.0mmol 
( l . lg )  o f  potassium carbonate, in 5m l o f  dry acetone, to give 0.26mmol (0.51g, 8 1%  
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 109.
5.6.2 Base hydrolysis of dodeca-acetate ester 109
The procedure as described in 5.1.2  w as follow ed using 0.15m m ol (0.30g) o f  dodeca- 
acetate ester 109 and 3.03mmol (0.17g) o f  potassium  hydroxide, to give O .llm m ol 
(0.28g 73 %  yield) o f  dodeca-acetate potassium salt 123.
5.6.3 Acid hydrolysis of dodeca-acetate potassium salt 123
5.5.3 Acid hydrolysis o f dodeca-acetate potassium salt 122
The procedure as described in 5.1.3 was followed using 0.06mmol (0.12g) o f dodeca-
acetate potassium salt 123, to give 0.06mmol (0.1 Og, 95% yield) o f dodeca-acetate
acid 137.
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4.0 ppm (8H, overlapping doublets, J=7.6H z, A r-0 -C H 2-C 0 0 H ), 4.5 ppm (12H , 
m ultiplet, A r-0 -C H 2-C 0 0 H ), 4.8 ppm (4H, d, J=8.4Hz, A r-0 -C H 2-C 0 0 H ), 5.4ppm 
(2H, s, Ar-H ), 5.9ppm (2H, s, Ar-H ), 6.1ppm  (4H, s, A r-C H -A r), 6.5ppm (8H, broad 
singlet, Ar-H ), 6.9ppm (4H, triplet, J=6 .8H z, A r-H ), 7.1ppm  (4H, quartet, J=6.4Hz, 
Ar-H ).
M ass Spec: m/z: 1647 (M + Na)
5.7.1 Alkylation of tetra-2-fluorophenyl pyrogallol[4|arene, 79, with ethylbromo 
acetate
The procedure as described in 5.1.1 w as follow ed using 0.32mmol (0.30g) o f  tetramer
79, (schem e 26) , 5.12m m ol (0.86g, 0.57m l) o f  ethylbromoacetate, and 8.0mmol 
( l . lg )  o f  potassium carbonate, in 5ml o f  dry acetone, to g ive  0.08mmol (0 .15g, 24%  
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 110.
5.7.2 Base hydrolysis of dodeca-acetate ester 110
The procedure as described in 5.1.2  w as follow ed using 0.04mmol (0.08g) o f  dodeca- 
acetate ester 110 and 1.07m m ol (0.06g) o f  potassium  hydroxide, to g ive  0.03mmol 
(0.06g 80% yield) o f  dodeca-acetate potassium salt 124.
5.7.3 Acid hydrolysis of dodeca-acetate potassium salt 124
‘H -N M R - (400M H z) (D M SO - d6) S [ppm]
The procedure as described in 5.1.3 w as fo llow ed  using 0 .025m m ol (0 .050g) o f
dodeca-acetate potassium  salt 124, to g iv e  0.021 m m ol (0 .034g , 84%  yield ) o f  dodeca-
acetate acid 138.
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3.8 ppm (4H, d, J=6 .8H z, A r-0 -C H 2-C 0 0 H ), 4.2 ppm (4H, d, J=6 .8Hz, A r-0 -C H 2- 
C O O H ), 4.5 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.7 ppm (4H, d, J=6 .8H z, Ar- 
O -C H 2-CO O H ), 5.5ppm (2H, s, A r-H ), 6.2ppm (2H, s, A r-H ), 6.4ppm (4H, s, Ar- 
C H -A r), 6.9ppm (8H, broad multiplet, A r-H ), 7.1ppm  (8H, broad singlet, Ar-H ).
M ass Spec: m/z: 1663 (M +K)
5.8.1 Alkylation of tctra-3,5-difluorophenyl pyrogallol[4]arene, 80, with 
ethylbromoacetate
T he procedure as described in 5.1.1 w as follow ed using 0.30mmol (0.30g) o f  tetramer
80, (schcm e 26) , 4.80mmol (0.80g, 0.53ml) o f  ethylbromoacetate, and 7.5mmol 
(1.04g) o f  potassium carbonate, in 5ml o f  dry acetone, to give 0.17m m ol (0.35g, 57%  
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 111.
5.8.2 Base dydrolysis of dodeca-acetate ester 111
The procedure as described in 5.1.2  w as follow ed using O.lOmmol (0.20g) o f  dodeca- 
acetate ester 111 and 2.15m m ol (0.12g) o f  potassium hydroxide, to give 0.076mmol 
(0 .16g 76%  yield) o f  dodeca-acetate potassium salt 125.
5.8.3 Acid hydrolysis of dodeca-acetate potassium salt 125
'H -N M R - (400M H z) (D M SO - d6) ô [ppm]
The procedure as described in 5 .1 .3  w as fo llow ed  u sin g  0 .056m m ol (0 .1 2g) o f
dodeca-acetate potassium  salt 125, to g iv e  0 .053m m ol (0 .09g , 95%  yield ) o f  dodeca-
acetate acid 139.
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4.0 ppm (4H, d, J=8.0Hz, A r-0 -C H 2-C 0 0 H), 4.1 ppm (4H, d, J=8.0Hz, A r-0 -C H 2- 
C O O H ), 4.4 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.7 ppm (4H, d, J=8.4Hz, Ar- 
O -C H 2-CO O H ), 5.2ppm (2H, s, A r-H ), 5.8ppm (2H, s, Ar-H ), 6.1ppm  (4H, s, Ar- 
C H -A r), 6.2ppm (8H, broad singlet, A r-H ), 6 .8ppm (4H, triplet, J=6 .8Hz, Ar-H ).
M ass Spec: m/z: 1735 (M +K )
5.9.1 Alkylation of tetra-3,4-difluorophenyl pyrogallol[4]arene, 81, with 
ethylbromoacetate
The procedure as described in 5.1.1 w as follow ed using 0.30mmol (0.30g) o f  tetramer
81, (schem e 26) , 4.80mmol (0.80g, 0.53ml) o f  ethylbromoacetate, and 7.5m m ol 
(1.04g) o f  potassium carbonate, in 5m l o f  dry acetone, to give 0.083mmol (0.17g, 
28%  yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 112.
5.9.2 Base hydrolysis of dodeca-acetate ester 112
The procedure as described in 5.1.2  w as follow ed using 0.05mmol (0.10g) o f  dodeca- 
acetate ester 112 and 1.21m m ol (0.07g) o f  potassium hydroxide, to give 0.038mmol 
(0.08g 76%  yield) o f  dodeca-acetate potassium salt 126.
5.9.3 Acid hydrolysis of dodeca-acetate potassium salt 126
The procedure as described in 5.1.3 was follow ed using 0.028mmol (0.06g) o f  
dodeca-acetate potassium  salt 126, to give 0.027mmol (0.045g, 95%  yield) o f  dodeca- 
acetate acid 104.
'H -N M R - (400M H z) (D M SO - d6) ô [ppm]
4.1 ppm (8H, overlapping doublets, J=8.0Hz, A r-0 -C H 2-C 0 0 H), 4.3 ppm (4H, s, Ar- 
0 -C H 2-C 0 0 H ), 4.4ppm (8H, multiplet, A r-0 -C H 2-C 0 0 H), 4.7 ppm (4H, d, 
J=8.4Hz, A r-0 -C H 2-C 0 0 H ), 5.1ppm  (2H, s, A r-H ), 5.7ppm (2H, s, A r-H ), 6.1ppm 
(4H, s, A r-C H -A r), 6.3ppm (4H, broad singlet, A r-H ), 6 .6ppm (4H, broad singlet, Ar- 
H), 7.0ppm (4H, quartet, J=6.4Hz, Ar-H ).
M ass Spec: m/z: 1719  (M+ Na)
5.10.1 Alkylation of tetra-4-methylphenyl pyrogallol[4]arene, 82, with 
ethylbromoacetate
The procedure as described in 5.1.1 w as follow ed using 0.33mmol (0.30g) o f  tetramer
82, (schem e 26) , 5.28mm ol (0.88g, 0.59ml) o f  ethylbromoacetate, and 8.25mmol 
(1.14 g) o f  potassium carbonate, in 5ml o f  dry acetone, to give 0.21m m ol (0.40g, 62% 
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 113.
5.10.2 Base hydrolysis of dodeca-acetate ester 113
The procedure as described in 5.1.2  w as follow ed using 0.16mm ol (0.30g) o f  dodeca- 
acetate ester 113 and 3.03mmol (0.17g) o f  potassium hydroxide, to give 0.12mmol 
(0.24g 75 %  yield) o f  dodeca-acetate potassium  salt 127.
5.10.3 Acid hydrolysis of dodeca-acetate potassium salt 127
The procedure as described in 5.1.3 w as follow ed using 0.06mmol (0.12g) o f  dodeca- 
acetate potassium  salt 127, to give 0.055m mol (0.09g, 96% yield) o f  dodeca-acetate 
acid 141.
lH -N M R - (400M H z) (D M SO - d6) 8 [ppm]
-1 2 2 -
2.1 ppm (12H , s, Ar-CH a), 3.9 ppm (8H, overlapping doublets, J=7.2Hz, A r-0 -C H 2- 
C O O H ), 4.4 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.6 ppm (4H, d, J=7.2Hz, Ar- 
O -C H 2-C O O H ), 5.6ppm (2H, s, Ar-H ), 5.8ppm (2H, s, Ar-H ), 5.9ppm (4H, s, Ar- 
C H -A r), 6.5ppm (8H, broad singlet, Ar-H ), 6 .8ppm (8H, d, J=6.4Hz, Ar-H ).
M ass Spec: m/z: 1631 (M+ Na)
5.11.1 Alkylation of tetra-(trifluoro)-4-mcthylphenyl pyrogallol[4]arene, 83, with 
ethylbromoacetate
The procedure as described in 5 .1.1  w as fo llow ed  using 0.27m mol (0.30g) o f  tetramer
83, (schem e 26) , 4.32mmol (0.72g, 0.48ml) o f  ethylbromoacetate, and 6.75m m ol 
(0.93g) o f  potassium  carbonate, in 5ml o f  dry acetone, to give 0.15m m ol (0.33g, 57%  
yield) o f  dodeca-ethylacetate pyrogallol[4] arene, tetramer 114.
5.11.2 Base hydrolysis of dodeca-acetate ester 114
The procedure as described in 5.1.2  w as follow ed using 0.16m m ol (0.30g) o f  dodeca- 
acetate ester 114 and 3.03mmol (0.17g) o f  potassium hydroxide, to g ive  0.12mmol 
(0.27g 74 %  yield) o f  dodeca-acetate potassium salt 128.
5.11.3 Acid hydrolysis of dodeca-acetate potassium salt 128
'H -N M R - (400M H z) (D M SO - d6) 8 [ppm]
The procedure as described in 5.1.3 w as fo llow ed  using 0 .053m m ol (0 .12g) o f
dodeca-acetate potassium  salt 128, to g iv e  0 .044m m ol (0 .08g , 83% yield ) o f  dodeca-
acetate acid 142.
4.0 ppm (4H, d, J=7.6Hz, A r-0 -C H 2-C 0 0 H ), 4.2 ppm (4H, d, J=7.6Hz, A r-0 -C H 2- 
CO O H ), 4.4 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.8 ppm (4H, d, J=7.6Hz, Ar- 
0 -C H 2-C 0 0 H ), 5.5ppm  (2H, s, Ar-H ), 5.9ppm (2H, s, A r-H ), 6.2ppm (4H, s, Ar- 
C H -A r), 6.9ppm (8H, broad singlet, A r-H ), 7.4ppm  (8H, d, J=6.4Hz, Ar-H ).
M ass Spec: m/z: 1847 (M + N a)
5.12.1 Alkylation of tetra-4-ethoxyphenyl pyrogallol[4]arcne, 85, with 
ethylbromo acetate
The procedure as described in 5 .1.1  w as follow ed using 0.29mmol (0.30g) o f  tetramer
85, (scheme 26) , 4.65m m ol (0.77g, 0.51m l) o f  ethylbromoacetate, and 7.27m m ol 
(l.OOg) o f  potassium carbonate, in 5ml o f  dry acetone, to give 0.16m m ol (0.36g, 54% 
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 115.
5.12.2 Base hydrolysis of dodeca-acetate ester 115
The procedure as described in 5.1.2  w as follow ed using 0.15m m ol (0.30g) o f  dodeca- 
acetate ester 115 and 3.03mmol (0 .17g) o f  potassium hydroxide, to give 0.095mmol 
(0.23g, 63%  yield) o f  dodeca-acetate potassium  salt 129.
5.12.3 Acid hydrolysis of dodeca-acetate potassium salt 129
‘H -N M R - (4 0 0 M H /) (D M SO - d6) ô [ppm]
The procedure as described in  5.1.3 w as fo llow ed  u sing  0 .05m m ol (0 .1 2g) o f  dodeca-
acetate potassium  salt 129, to g iv e  0 .041m m ol (0 .8g , 81% y ie ld ) o f  dodeca-acetate
acid 143.
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1.3ppm  (12H , triplet, J=6.4ppm, -O C H 2C H 3), 3.9ppm (16H  overlapping multiplets- 
8H multiplet, -O C H 2C H 3, 8H, multiplet, A r-0 -C H 2-C 0 0 H ), 4.5ppm  (12H , multiplet, 
A r-0 -C H 2-C 0 0 H ), 4.7 ppm (4H, d, J=7.6Hz, A r-0 -C H 2-C 0 0 H ), 5.8ppm (2H, s, A r­
i l ) ,  5.9ppm (2H, s, Ar-H ), ó.Oppm (4H, s, A r-C H -A r), 6 .6ppm (16H , broad multiplet, 
Ar-H ).
M ass Spec: m/z: 1751 (M + N a)
5.13.1 Alkylation of tetra-2-bromophenyl pyrogallol[4]arene, 86, with 
ethylbromoacetate
T he procedure as described in 5.1.1 w as follow ed using 1.71m m ol (2.00g) o f  tetramer
8 6 , (scheme 26) , 27.36m m ol (4.57g, 3.03ml) o f  ethylbromoacetate, and 42.75mmol 
(5.90g) o f  potassium carbonate, in 60ml o f  dry acetone, to give O.lOmmol (0.22g, 6 %  
yield) o f  dodeca-ethylacetate pyrogallol[4]arene, tetramer 116.
5.13.2 Base hydrolysis of dodeca-acetate ester 116
T he procedure as described in 5.1.2  w as follow ed using 0.078mmol (0 .18g) o f  
dodeca-acetate ester 116 and 1.51m m ol (0.09g) o f  potassium hydroxide, to give 
0.073mmol (0 .17 g  94%  yield) o f  dodeca-acetate potassium salt 130.
5.13.3 Acid hydrolysis of dodeca-acetate potassium salt 130
'H -N M R - (400M H z) (D M SO - d6) Ô [ppm]
T he procedure as described in 5.1.3 w as fo llow ed  using 0 .052m m ol (0 .12g) o f
dodeca-acetate potassium  salt 130, to g iv e  0 .048m m ol (0 .09g , 93%  yield ) o f  dodeca-
acetate acid 144.
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4.1 ppm (8H, overlapping doublets, J=7.2Hz, A r-0 -C H 2-C 0 0 H), 4.5 ppm (16H, 
multiplet, A 1--O-CH2-C O O H ), 5.0ppm (2H, s, A r-H ), 5.8ppm (2H, s, Ar-H ), 6.1ppm  
(4H, s, A r-C H -A r), 6.3ppm (4H, broad doublet, J=6.4Hz, Ar-H ), 6.9ppm (8H, 
multiplet, Ar-H ), 7.3ppm (4H, d, J=7.2Hz, Ar-H ). 12.9ppm (12H , broad singlet, - 
O C H 2C O O H )
M ass Spec: m/z: 1887 (M + N a)
5.14.1 Alkylation of tetra-3,5-dibromophenyl pyrogallol[4]arene, 87, with 
ethylbromoacetate
The procedure as described in 5.1.1 w as follow ed using 0.68mmol (l.OOg) o f  tetramer
87, (schem e 26) , 10.81m m ol ( 1.81 g, 1.20ml) o f  ethylbromoacetate, and 16.89mmol 
(2.33g) o f  potassium carbonate, in 30ml o f  dry acetone, to give 0.116m m ol (0.29g, 
17%  yield) o f  dodeca-ethylacetate pyrogallol[4] arene, tetramer 117.
5.14.2 Base hydrolysis of dodeca-acetate ester 117
The procedure as described in 5.1.2  w as follow ed using O.lOmmol (0.25g) o f  dodeca- 
acetate ester 117 and 2.00mmol (0.1 lg )  o f  potassium  hydroxide, to give 0.095mmol 
(0.25g 95%  yield) o f  dodeca-acetate potassium salt 131.
5.14.3 Acid hydrolysis of dodeca-acetate potassium salt 131
'H -N M R - (400M H z) (D M SO - d6) ô [ppm]
The procedure as described in  5.1.3 w as fo llow ed  u sing  0 .046m m ol (0 .12g) o f
dodeca-acetate potassium  salt 131, to g iv e  0 .037m m ol (0 .08g , 80%  yield ) o f  dodeca-
acetate acid 145.
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4.0 ppm  (4H, d, J=8 .8H z, A r-0 -C H 2-C 0 0 H), 4.2 ppm (4H, d, J=8.4Hz, A r-0 -C H 2- 
C O O H ), 4.5 ppm (12H , multiplet, A r-0 -C H 2-C 0 0 H ), 4.9 ppm (4H, d, J=8 .8Hz, Ar- 
O -C H 2-CO O H ), 5.3ppm (2H, s, Ar-H ), 5.9ppm (2H, s, A r-H ), 6.2ppm (4H, s, Ar- 
C H -A r), 7.5ppm  (12H , broad singlet, Ar-H ).
Mass Spec: m/z: 2203 (M + N a)
5.15.1 Partial alkylation of tetra-4-fluorophenyl pyrogallol[4]arene, 65, with 
ethylbromoacetate
The procedure as described in 5 .1.1  w as follow ed using 0.43mmol (0.40g) o f  tetramer 
65, (schem e 26) , 4.30m m ol (0.72g, 0.48ml) o f  ethylbromoacetate, and 6.90mmol 
(0.95g) o f  potassium carbonate, in 7m l o f  dry acetone, to give 0 .12g o f  n-ethylacetate 
pyrogallol[4]arene, tetramer 157. Y ie ld  values are not possible to calculate, as exact 
m olecular masses are unknown.
5.15.2 Base hydrolysis of n-acetate ester 157
The procedure as described in 5.1.2  w as follow ed using 0.1 Og o f  dodeca-acetate ester
157 and 1.25m m ol (0.07g) o f  potassium hydroxide, to give 0.09g o f  dodeca-acetate 
potassium salt 160. Y ie ld  values are not possible to calculate, as exact m olecular 
masses are unknown.
5.15.3 Acid hydrolysis of n-acetate potassium salt 160
The procedure as described in 5.1.3 w as follow ed using 0.06g o f  dodeca-acetate 
potassium salt 160, to give 0.06g o f  dodeca-acetate acid 163. Y ie ld  values are not 
possible to calculate, as exact m olecular masses are unknown.
'H -N M R - (400M H z) (D M SO - d6) Ô [ppm]
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3.9 ppm (6H, broad multiplet, A r-0 -C H 2-C 0 0 H), 4.3 ppm (6H, broad multiplet, Ar- 
0 -C H 2-C 0 0 H ), 4.6 ppm (2H, broad multiplet, A r-0 -C H 2-C 0 0 H), 5.2ppm (2H, 
multiplet, Ar-H ), 5.7ppm  (2H, multiplet, Ar-H ), 5.9ppm (4H, multiplet, A r-C H -A r), 
6 .6ppm  (8H, broad singlet, Ar-H ), 6.7ppm  (8H, broad multiplet, Ar-H ).
M ass Spec: m/z: B ell curve o f  peak observed between 1400 and 1700
* 'H -N M R  Splitting is poor ow ing to there being a m ixture o f  similar compounds
present.
5.16.1 Partial alkylation of tetra-4-chlorophenyl pyrogallol[4]arene, 76, with 
ethylbromoacetate
The procedure as described in 5 .1.1  w as follow ed using 0.40mmol (0.40g) o f  tetramer
76, (schem e 26) , 4.00mmol (0.67g, 0.44ml) o f  ethylbromoacetate, and 6.40mmol 
(0.88g) o f  potassium carbonate, in 7m l o f  dry acetone, to give 0.29g o f  n-ethylacetate 
pyrogallol[4]arene, tetramer 158. Y ie ld  values are not possible to calculate, as exact 
m olecular masses are unknown.
5.16.2 Base hydrolysis of n-acetate ester 158
The procedure as described in 5.1.2  w as follow ed using 0.20g o f  dodeca-acetate ester
158 and 2.50mmol (0.14g) o f  potassium hydroxide, to g ive  0.19g o f  dodeca-acetate 
potassium salt 161. Y ie ld  values are not possible to calculate, as exact m olecular 
m asses are unknown.
1 H -N M R - (400M H z) (D M SO - d6) § [ppm]*
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The procedure as described in 5.1.3 was follow ed using 0.10g o f  dodeca-acetate 
potassium salt 161, to give 0.09g o f  dodeca-acetate acid 164. Y ie ld  values are not 
possible to calculate, as exact m olecular masses are unknown.
‘H -N M R - (400MHz) (D M SO - d6) ô [ppm]*
4.4ppm (16H , broad multiplet, A 1-O -C H 2-C O O H ), 4.6ppm (4H, broad multiplet, Ar- 
O -C H 2-C O O H ), 5.4ppm (2H, s, Ar-H ), 5.8ppm (2H, s, Ar-H ), 6.1 ppm (4H, broad 
singlet, A r-C H -A r), 6.7ppm  (8H, broad singlet, Ar-H ), 7.1 ppm (8H, broad doublet, 
Ar-H ).
M ass Spec: m/z: B ell curve o f  peak observed betw een 1550 and 1800
* 1 H -N M R  Splitting is poor ow ing to there being a mixture o f  similar compounds
present.
5.17.1 Partial alkylation of tetra-4-bromophenyl pyrogallol[4]arene, 77, with 
ethylbromoacetate
The procedure as described in 5.1.1 w as follow ed using 0.34mmol (0.40g) o f  tetramer
77, (schem e 26) , 3.40mm ol (0.57g, 0.38ml) o f  ethylbromoacetate, and 5.50mmol 
(0.75g) o f  potassium carbonate, in 7m l o f  dry acetone, to give 0 .16g o f  n-ethylacetate 
pyrogallol[4]arene, tetramer 159. Y ie ld  values are not possible to calculate, as exact 
m olecular masses are unknown.
5.16.3 Acid hydrolysis of n-acetate potassium salt 161
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5.17.2 Base hydrolysis of n-acetate ester 159
The procedure as described in 5.1.2 w as follow ed using 0.1 Og o f  dodeca-acetate ester
159 and 1.25m m ol (0.07g) o f  potassium hydroxide, to g ive  0.08g o f  dodeca-acetate 
potassium salt 162. Y ie ld  values are not possible to calculate, as exact m olecular 
masses are unknown.
5.17.3 Acid hydrolysis of n-acetate potassium salt 162
T he procedure as described in 5.1.3 w as follow ed using 0.05g o f  dodeca-acetate 
potassium salt 162, to g ive  0.05g o f  dodeca-acetate acid 165. Y ield  values are not 
possible to calculate, as exact m olecular masses are unknown.
'H -N M R - (400MHz) (D M SO - d6) S [ppm]*
4.4ppm (12H , broad multiplet, A r-0 -C H 2-C 0 0 H ), 4.7ppm  (4H, broad multiplet, Ar- 
0 -C H 2-C 0 0 H ), 5.5ppm  (2H, multiplet, Ar-H ), 5.9ppm (2H, multiplet, Ar-H ), 
6.0ppm (4H, broad singlet, A r-C H -A r), 6 .6ppm (8H, broad singlet, A r-H ), 7.2ppm 
(8H, broad singlet, Ar-H ).
M ass Spec: m/z: Broad bell curve o f  peak observed between 1300 and 2000
* 'H -N M R  Splitting is poor ow ing to there being a m ixture o f  similar compounds 
present.
5.18.1 Alkylation of tetra-4-fluorophenyl pyrogallol[4]arene, 65, with ethylbromo 
propionate
T he procedure as described in 5.1.1 w as follow ed using 1.08mmol (1.00g) o f  tetramer 
65, (schem e 26), 16.23m m ol (2.94g, 2.08ml) o f  ethylbromopropionate, and 
22.68m mol (3 .13g) o f  potassium carbonate, in 30ml o f  dry acetone. A fter
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recrystallisation <0.01m m ol o f  tetramer 167 was retrieved and the hydrolysis 
reactions w ere not carried out.
5.19.1 Alkylation of tctra-4-fluorophenyI pyrogallol[4]arene, 65, with 1- 
bromopropane.
0.22mmol (0.20g) o f  tetramer 65, (scheme 26) w as reacted w ith 3.45mmol (0.42g, 
0.31m l) o f  1-bromopropane under base conditions o f  potassium  carbonate (5.39m mol, 
0.74g) in 12ml o f  dry acetone. The reaction w as carried out at 60°C for 2 days. On 
cooling to room  temperature all volatiles w ere rem oved under reduced pressure. The 
residue w as treated with 5ml o f  dilute HC1 and then filtered to yield  0.25g o f  a sticky 
yello w  paste. Based on the 1 H -N M R  spectrum o f  this paste, it w as assumed to be 
residual inorganic brom ine salts.
5.20.1 Alkylation of tetramethyl pyroga!lol[4]arene, 69, with 1-bromopropane.
The reaction as in 5.19 .1 w as follow ed using 0.33mmol (0.20g) o f  tetramer 69, 
(scheme 26), 5.26mmol (0.65g, 0.42ml) o f  1-bromopropane and 8.22mmol ( 1 .1 3g) o f  
potassium carbonate in 12m l o f  dry acetone. A gain  the reaction yielded 0.29g o f  a 
sticky yellow  paste. Based on the 'H -N M R  spectrum o f  this paste, it was assumed to 
be residual inorganic brom ine salts.
5.21.1 Alkylation of tetra-4-fluorophenyl pyrogallol[4]arene, 65, with 2-chloro 
ethyl sulphonate sodium salt.
0 .54m m ol (0 .50g) o f  tetram er 65, (schem e 26) w as reacted w ith  8 .64m m ol (1 .59g ) o f
2-chloro ethyl sulphonate sod ium  salt under base conditions o f  potassium  carbonate
(13 .50m m ol, 1.86g) in 30m l o f  dry acetone. The reaction w as carried out at 60°C for 6
days. The reaction was driven to completion by the addition of 0.2 equivalents of 2- 
chloro ethyl sulphonate sodium salt and potassium carbonate each day. On cooling to 
room temperature all volatiles were removed under reduced pressure. The residue was 
treated with 15ml of dilute HC1 and then filtered to yield a yellow-orange product. 
This product was then recrystallised from hot methanol, however no product was 
recovered from the recrystallisation. On evaporation of the methanol, the yellow- 
orange product was recovered, and again NMR implied that the product was residual 
inorganic salt.
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P o l y m e r  S y n t h e s i s
A n  attempt was made to prepare on a large scale tetramer 65. The reaction w as carried 
out on a lOOg scale. W e noticed im m ediately that an exotherm occurred upon addition 
o f  all reagents at room temperature. W e brought the exotherm under control by 
cooling the reaction mixture in an icebath. Once the temperature normalised the 
reaction mixture w as brought back to 80°C and allow ed to stir for five  hours.
The product o f  this reaction w as purified using the same procedures described for the 
tetramer how ever the product remained highly discoloured and the yield o f  product 
was calculated at 40% (based on tetramer formation). W e proceeded to brominate 
(scheme 36) this recovered product using bromine in glacial acetic acid at room 
temperature. Upon addition o f  bromine the reaction mixture turned from red to a dark 
purple. It should be noted that w e had previously attempted bromination o f  the 
tetramer isolated (see scheme 37) from small scale reactions, and w e observed that 
bromination did not occur. H ow ever, in this case a reaction did occur. The product 
w as w orked up by sim ple w ashing w ith water. W e proceeded to alkylate using 
ethylbrom oacetate, this reaction w as carried out for 24 hours and the isolated product 
w as im m ediately saponified w ith sodium hydroxide.
The crude product w as purified using acid/base precipitations, how ever w e also 
noticed that a percentage o f  this product (in the acid form) w as insoluble in methanol. 
A fter a series o f  precipitations from methanol w e isolated an orange red product. 
M ass specrometery by  both ESI and M A L D I techniques did not give any identifiable 
peaks. H ow ever, the 'H  N M R  o f  this product clearly demonstrates that this product is 
not a m acrocycle, but a polym er by-product. Based on integrations w e believe that 
this polym er is 50% alkylated.
C O N F ID E N T IA L
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These results demonstrate that polym erisation is indeed in com petition with 
cyclisation. But o f  perhaps greater significance is that the isolated product from  this 
w ork is at least one order o f  magnitude higher in bioactivity relative to the best 
alkylated m acrocycles
OH
H O - ^ L / O H
u  +
(50)
H+, EtOH
OH
k 2c o 3
Dry Acetone
n
Bromine
Glacial Acetic Acid
(174)
Scheme 36: Formation o f  bioactive polymer.
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Br2
Glacial Acetic Acid
Scheme 37: Bromination step
Experimental
6.1: Large scale condensation of pyrogallol, 50, with 4-fluorobenzaIdehyde, 70.
100 g scale: It was observed that this reaction is very exothermic upon addition o f  all 
reagents and that it is independent o f  the order o f  addition o f  reagents. A  viscous 
solution w as generated after 1 hour o f  reaction time and this did m ake stirring o f  the 
m ixture som ewhat problem atic. The reaction mixture w as worked up using the 
described method, and the isolated red product w as washed w ith ethanol/water 4:1. It 
w as found that further w ashing with ethanol rem oved most o f  the red colour to give a 
som ewhat colourless product. 20 grams o f  product, 173 were isolated.
6.2: Bromination of product 173 to form 174.
The same procedure involved suspending 14.4 grams o f  the polym er in 150 m L o f  
glacial acetic acid. To this solution w as added dropwise bromine and the reaction 
mixture w as allow ed to stir at room  temperature. Upon addition o f  bromine the 
reaction m ixture turned from  light red to purple. A fter 48 hours the reaction mixture
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w as w orked up by  filtering through a glass frit. The collected product, 174  w as then 
washed w ith  water until the filtrate w as colourless and w as then dried at room 
temperature for three days.
6.3: Alkylation of 174 with ethylbromoacetate to give 175.
The same procedure as described above (alkylation) w as em ployed on a  8-gram scale 
o f  174  starting material.
6.4: Base H ydrolysis o f  175  to give 176.
Same procedure used above was em ployed on 8 gram s o f  175  that w as prepared 
above. The product w as further purified by dissolving the product in water and 
precipitating the product with methanol. The precipitate w as then collected by 
centrifugation and washed with methanol. This procedure wras carried out again until 
a nonsticky light red powder was obtained.
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Chapter 7 
Analytical and Biological Investigations
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7.1 Introduction:
It has been reported that polyanionic species can act as gp l20  inhibitors66. W e believe 
this is also the case for the alkylated pyrogallol[4]arenes w hich possess negative 
charges. E L IS A  (Enzym e-Linked Immunosorbent A ssay) studies indicate that 
pyrogallolarenes inhibit the binding o f  gp l2 0  to C D 4 cells, by binding to the cellular 
receptor on the virus binding site as w ell as binding to the fusion site on g p l2 0 . 
Pyrogallolarenes w ere also found to be specific and they do not inhibit reverse 
transcriptase, proteases or clotting proteins.
7.2 Results and Discussion:
The screening assay w as carried out by Dr Shattock’ s group at St. G eorge’ s Hospital 
in London and is based on the im m obilization o f  infectious virions to 96 w ell plates. 
Three separate conditions w ere used, as shown in figure 40.
a), V irus is pretreated with titrated compound (detecting direct antiviral activity)
b), Target C ells are pretreated with titrated com pound (detecting direct antiviral 
activity)
c), Titrated compound, virus and target cell are all incubated together.
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F ig u re  40: Screening Method
Figure 41 shows the various pyrogallolarenes that were used in biological testing and 
table 12  outlines the assay results (also see appendix 2 ).
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OR OR OR
ROs .OR ROs .O R  ROs .OR
R = C H 2C O O K ^ s\
v
(118 ) F
OR
ROv
R= C H ^ C O O K ^ ^  R= C H 2C O O K ^ \ ^
(120) Cl 
OR
.OR RO.
( 1 2 1 )
OR
.O R ROs
Br
.OR
R =  H, CH 2C O O K ^ k  R= H, CH 2C O O K  R= H, CH 2C O O K ^ k
(160) F (16 1)  Cl <l6 2 > Br
OR OR
RO. .OR ROv .OR
R= C H 2C O O K  CH3 R =  H, C H 2C O O K ^ L
(119 ) (176a,b) F
F ig u re  41: P y r o g a l l o l a r e n . e s  t h a t  w e r e  s e n t  f o r  G P 1 2 0  i n h i b i t i o n  a c t i v i t y
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Com pound
Number
Description EC-50 TC-50 Selectivity
Index
176a Polym er 0.015 350 23333
176b Polym er 0 .0 12 350 29166
118 Tetra-4-fluorophenyl pyrogallol 
[4]arene dodeca acetate salt.
8.683 2812 334.33
121 Tetra-4-bromophenyl pyrogallol 
[4]arene dodeca acetate salt.
0.494 195.6 400.89
120 Tetra-4-chlorophenyl pyrogallol 
[4]arene dodeca acetate salt.
2.65 868.19 335.54
160 Tetra-4-fluorophenyl pyrogallol 
[4]arene partially alkylated acetate 
salt.
12 .0 1 1131.09 88.49
162 Tetra-4-bromophenyl pyrogallol 
[4]arene partially alkylated acetate 
salt.
2.64 1375.65 526.72
161 Tetra-4-chlorophenyl pyrogallol 
[4]arene partially alkylated acetate 
salt.
0.247 1015 4158.4
119 Tetramethyl pyrogallol [4] arene 
dodeca acetate salt (rctt chair).
0.228 1172.5 5203.4
Table 12: GP120 inhibition results.
EC-50 =molar concentration of an agonist, which produces 50% of the maximum 
possible response for that agonist.
TC-50 = molar concentration of an agonist, which kills 50% of uninfected cells
There are some definitive trends in the biological activity o f  the m acrocycles tested. 
The first interesting trend to be observed is to do with charge. It is suggested by the 
mechanism o f  action that charge (i.e. the numbers o f  anionic groups) is related to 
bioactivity. H owever, it is seen that partially alkylated pyrogallol[4]arenes, 161, have 
a far higher (by a factor o f  1 2 ) selectivity index then that o f  the com pletely alkylated 
counterpart, 120. This discrepancy w ould suggest that perhaps activity is independent
-1 4 2 -
o f  charge. This result has also been reported recently in the case o f  sulphonated 
naphthyl porphyrins79. In this study a number o f  porphyrins with varying degrees o f  
alkylation were tested for their biological activity against H IV -1. It w as found that the 
partially sulphonated porphyrins had a greater activity than the com pletely alkylated 
adducts.
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W hy are the partially alkylated derivatives more active than the com pletely alkylated 
derivatives? It w ould appear as mentioned in Chapter 1 that charge m ay not be the 
sole factor for biological activity. B y  the nature o f  these compounds being partially 
alkylated, they therefore possess ‘redox active’ phenol groups. Phenol groups can
• • SO
undergo redox chemistry as outlined in scheme 38 .
OH
Catechol, (178)
A g 20
S n C l,
o-benzoquinone, (179)
Schem e 38: Redox Chemistry o f Phenols
W e believe that it m ay be possible that the remaining phenol/quinone groups in our 
m acrocyles could be interfering w ith  PDI, a redox active enzym e. I f  this is indeed 
occurring then the required conform ational change o f  gp -1 2 0  m ay be inhibited and it 
is this that is preventing viral entry.
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We also discovered a new lead structure from this work, which is a polymer 
derivative (176a and 176b). It was found by 'H-NM R that this polymer is 50% 
alkylated .65 The polymer is far larger than the macrocycles, it also contains possibly 
hundreds o f  phenols along with acetate groups. Furthermore we believe that this 
polym er is partially oxidised since it was treated with bromine prior to alkylation. The 
polym er prepared in this work possesses ten times the biological activity o f the 
partially alkylated macrocycle species. We believe that two possible explanations 
could be given to explain these results. The first is that negatively charged polymeric 
species have shown superior activity w ith other systems63, but this does not eliminate 
the possibility that interference with PDI may also be occurring.
To determine if  size is an issue with all compounds tested we decided to investigate 
possible promiscuous effects. Promiscuous drugs, (i.e. those that have promiscuous 
effects) as opposed to selective drugs, can be ju s t as potent. The promiscuity relates to 
the ability o f  a drug to form larger complexes or clusters in solution. The formation o f 
these clusters is typically caused by hydrogen bonding or electrostatic interactions. In 
these cases it is the complex or cluster that is biologically active and not the individual 
drug molecule. The size o f these aggregates/particles in aqueous solution would have 
an effect on the biological activity. It has been reported that pyrogallol[4]arenes form 
highly symmetrical spherical clusters in solution43,44, (although there was no particle 
size data to back up this proposal). To that end, we decided to carry out a PCS 
(Photon Correlation Spectroscopy) analysis on these compounds.
“PCS measures Brownian m otion and relates it to the size to particles” . Brownian 
m otion is the random movement o f particles due to the bombardment by solvent (or
C O N F ID EN TIA L
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gas) molecules that surround them. PCS can only measure particles with sizes below 1 
micron, or more correctly particles w ith sufficiently low  density, as above this size 
particles are generally affected by processes such as gravity -  causing sedimentation -
_ Q1
thus eliminating Brownian motion and therefore can not be measured by PCS .
PCS measures light intensities that change in time relative to the sizes o f particles 
(small particles move quickly and therefore light intensity changes quickly at the 
detector, whereas large particles move slowly and hence light intensity changes at the 
detector are slow) being “viewed” by the detector.
PCS uses a correlation function to aid in deciphering the particle size. Large particles
have a slow changing correlation function whereas small particles have a fast
changing correlation function. This correlation function is then fitted to a straight line,
the slope o f  which is related to the Z-average particle size, or the intensity o f the
averaged particle diameter. This is known as the cumulant analysis and it gives a
* * 8 1single mean value for particle size .
The results o f  the PCS analysis are outlined in table 13. Five different compounds 
were analysed for their particle/cluster size in an aqueous matrix. ‘Z-A ve’ is the 
average size o f the various different sized clusters in solution. Poly-dispersal Index, 
(PDI) is a measure o f  how  many different sized clusters are present. For m ono­
dispersed system (i.e. only one size o f  cluster) the PDI should be lower than 0.3.
CO N F ID EN TIA L
-145-
C O N F ID EN TIA L
Record N um ber Sample Name
Z-Ave.
(nm) PDI
Peak 1 Area 
Intensity
Peak 2 Area 
Intensity
72 4-Fluoro Salt 393.7 0.564 64 35
74 4-Chloro Salt 411.9 0.528 74 25
116 4-Chloro partial Salt 486.3 0.535 62 37
73 Methyl salt -  scl 103.4 0.31 98 1
73
(Different Batch) Methyl salt -  pg l 103.3 0.193 100 0
125b Polymer 74.61 0.513 100 0
Table 13: PCS Data
For macrocycles 118 and 120, which showed poor biological activity, the PCS data 
gives a high PDI value, indicating a num ber o f  different sized clusters present in 
solution. The average sizes o f  these clusters are quite high, 394nm and 412nm 
respectively
For macrocycle 119, two separate batches o f this compound were analysed and gave 
similar results. Both have acceptable PDI values and both only have one size cluster. 
The size o f  the cluster is far lower than the 118 and 120, at 103nm. This compound 
also has good biological activity.
The polym er sample 176a, has the highest biological activity o f  all samples tested. 
The average size o f  the polym er cluster is also the lowest o f  all the samples, at 74nm. 
This suggests that the size o f the cluster and not the actual molecule plays an 
important role in the biological activity.
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The partially alkylated derivative o f  the tetra-4-chlorophenyl pyrogallol[4]arene, 161, 
is the exception to the trend. Despite the good biological activity, its PCS data makes 
it comparable to 118 and 120 w hich both displayed poor biological activity. The 
average size o f  the cluster is 486nm and the PDI is 0.535. This indicates that there are 
a few  different cluster sizes in the aqueous matrix. This is probably owing to the fact 
that there exists a mixture o f partially alkylated compounds in the sample. Perhaps 
there is one cluster comparable in size to those other biologically active compounds 
and that is why the EC50 for this com pound is so high, at 5.4pg/ml. The only solution 
here would be to try and separate the different molecules in the sample. This has been 
attempted in the past and to no avail.
7.21 Stereoisomers:
It would have been o f great interest to observe the difference (if  any) in the biological 
activity o f  two different stereoisomers o f the same pyrogallol[4]arene. As mentioned 
in Chapter 2, we successfully isolated both the chair rctt and the cone rccc isomers o f 
tetramethylpyrogallol[4]arene. W e had hoped to convert these into the respective 
water-soluble dodeca acetate salts and compare their biological activities. However as 
discussed in Chapter 5, it was not possible to alkylate the cone rccc isomer, therefore 
such a  comparison was not possible to carry out.
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In com bination studies the lead compound mixtures have shown potent synergy with 
non-nucleotide reverse transcriptase inhibitor (NNRTI) TM C-120 (Tibotec PLC lead 
compound Average o f Combination Indices calculated at EC50, EC75 and EC90 from 
three separate experiments was 0.454 suggesting good synergy with both 
com pounds61.
7.2.2. Drug Delivery Vehicles: Synergy Studies.
T M C -12 0
Figure 42: Structure o f  TMC-120.
The question is why do the macrocycles show a synergy with these N NRTI’s? The 
m echanism  o f action o f  all compounds reported in  this thesis involves the inhibition 
o f viral replication at the early stages in the viral life-cycle. (either binding with the 
V3 loop o f  gp-120 or inhibition o f  PDI or both). However the enhancement o f 
preformance o f  an NNRTI would not be expected, but if  we look at the solubility 
properties o f  the NNRTI that acts synergistically w ith our leads we will note that all 
molecules are hydrophobic with poor w ater solubility. W e believe that our 
m acrocycles are solubilising these compounds, in essence they are behaving as drug 
delivery vehicles.
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Shown in figure 43 is a proposed mechanism as to how  hydrophobic NNRTI may 
bind with our macrocycles. Each macrocycle possesses a ‘hydrophobic clip’, we 
believe that sections o f  the NNRTI can fit into or weakly associate via 71-71 stacking 
with these clips, as a result an inclusion complex is formed and it takes on the 
solubility properties o f the macrocycle, the whole complex is thus water soluble. Due 
to tim e constraints a complete physical analysis o f  this phenom ena could not be 
determined and included in this work. I would propose a series o f physical studies 
including differential scanning calorimetry, phase solubility testing, hydrophobic dye 
extractions and aqueous !H NM R titrations to prove this effect as a mechanism of 
action.
The biological results o f  this synergistic effect are quite exciting, these macrocycles 
can be readily used in  the formulation o f N N R TI’s, not only do they possess a 
biological activity but they also can act as a drug delivery vehicles making them a
Hydrophobic clip
Figure 43: Hydrophobic clip
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very valuable compounds. Furthermore these compounds are quite inexpensive to 
make, thus they can compete with other delivery vehicles.
7.3. HPLC Method Development
As mentioned above, we desired to isolate each component in the tested mixtures. We 
already attempted selective synthesis o f  these m ixtures, unfortunately this endeavour 
failed. W e turned our attention to developing an HPLC method that could separate 
these mixtures, such a method would not only be o f  value for separation and isolation 
but is also required if  we w ish to obtain quantitative data o f  in vivo bioavailability and 
performance.
An HPLC method had been previously developed by an industrial partner TopChem 
laboratories®, the method is outlined below in table 14:
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TopChem Laboratories® Analytical Method
Colum n W avelength M obile Phase F low  Rate Sam ple
Concentration
R un
Time
C18 2 1 0 nm 0.05M  KH2P 0 4  
(pH3)
0.5ml/min 26mg/ml 60mins
Table 14: TopChem Laboratories® Analytical Method 
There are many problem s w ith the shown method:
1) The sample concentrations are ‘ridiculous’-this concentration is far too high 
for it to be used practically for in vivo analysis. (Typical sample concentrations 
should range from O.Olmg/ml to lm g/m l)
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2) Separation o f  various substituted derivatives could not be achieved, 
furthermore this method was not very efficient in separating the unsubstituted 
pryrogallolarene from  the ester and acid derivatives.
3) The run time is very long, which is not ideal for multiple injections.
We chose to redevelop this method in the hope to solve the above two problems.
In developing this method we needed to take the following into consideration:
1) Column selection.
2) M obile phase.
3) Sample concentration and diluent.
4) Flow rates.
In terms o f column selection we chose a Zorbax C l 8 column to start with, and the 
compounds used for analysis were the tetram er derivatives prepared from pyrogallol 
and acetaldehyde. In terms o f  mobile phase we had some limitations; we could not use 
a mobile phase w ith a pH  below 4. This lim itation came from instrument 
considerations here at DCU. Sample concentrations that we started with were quite 
high at 13mg/ml and we selected a detection wavelength at 210nm (optimum 
absorption).
The first method attempted is shown in table 15 and is referred to as method A. We 
initially decided to add an organic element to the mobile phase to increase the solvent 
strength and we also increased the pH o f the mobile phase from 3 to 7. W e believed 
that at pH 7 the acids would be deprotonated and would therefore have a faster 
retention time than either the ester or unsubstituted macrocycle.
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On introducing methanol into the mobile phase, the retention time o f the various 
compounds decreased significantly, so much so, that all derivatives o f the 
pyrogallol[4]arenes were eluted in the first 4 minutes. It was also found that the 
sample peaks were quite intense on the chromatogram, as a result we decided to lower 
the sample concentration to 1 .35m g/m l.
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Analytical Method Development- Method A
C olum n Wave­
length
M obile Phase Flow
Rate
Sam ple
Concentration
R un
Time
C18 2 1 0 nm 85:15 0.05M 
K2P 0 4:M e0H  (pH7)
0.5ml/
min
1.35mg/ml 60mins
Table 15: Analytical Method Development -  Method A 
On repeated injections using this method, we noticed something peculiar. The 
intensity o f  the peaks increased with each injection. We believe this to be due to a 
“column saturation effect”. W e believe that our analyte is absorbing onto the polar 
sites on the column and after multiple runs all the polar sites on the column are 
‘elim inated’. This conclusion makes sense since our analytes are polar in nature and 
are capable o f  binding tightly to any available silyloxy/silylhydroxy sites which are 
remaining on the surface. W hat we have discovered also explains the required high 
sample concentrations o f the TopChem® m ethod since most o f the injccted sample has 
been eliminated by absorption, therefore, only traces o f the original sample after 
injection are eluting from the column. To ensure complete column saturation multiple 
injections at high concentration were carried out overnight.
Confident that column saturation was complete we began lower the sample 
concentration. The next concentration prepared was at 0.5 mg/ml, again we observed
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a capped peak (off scale), the sample was further diluted to 0.25mg/ml again peak 
capping was observed, we continued to dilute the acid sample until we reached an 
optimum concentration o f  0.0625mg/ml, (figure 44) in effect we have decreased the 
concentration by a factor o f  416 from the original industrial method.
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Data File:
Sample ID: Operator (fry): Injection Date: Injection Method: Run Time (min): Workstation: Instrument (Inj):
c:\siHr\data\ac-l-72a002_TUn 1 “ 210.00 mn RESULTS SC-1-72A O v O lo2 ‘S. mqDemonstrator 09/03/2004 10:32:47 c:\star\Btudent\edS new mth-mth 20-000
Varían Diode Array
Operator (Calc): Calc Dele:Times Calculated: Calculation Method: Instrument (Calc): Run Mode:Peak Measurement: Calculation Type: Calibration Level;
Demonstrator 09/03/2004 10:52:55 1c:\star\stiident\edS newmth.mthVarían Diode ArrayAnalysisPeak AreaPercentN/AVerification Tolerance; N/A
PeakNo Peak Name Result 0 RetTime(min)
TimeOfTset(mil)
Area(COWltl) RelRetTime
Sep.Code Width Status 1/2 Cotíes (aec)
Croup
99-6713 3.843 0.000 114626752 0.00 BB 16 8 0
2 0.022S 10.880 0.000 25861 0.00 BB 25.0 03 0,2567 14,464 0.000 295196 0.00 BB 29.8 04 0.0292 16.069 0.000 33570 0.00 BB 35.5 05 0.0203 19.240 0.000 23379 0.00 BB 0.0 0Tétala 100.0000 0.000 115004752
Figure 44: HPLC o f the salt at concentration 0.0625mg/ml.
After solving the concentration problem we carried out single injections o f the 
tetramer, ester, acid and salt using method A and the results are shown in table 16.
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Compound Retention time (minutes)
Salt 3.824
Pyrogallol acetaldehyde tetram er 4.784
Ester 3.981 and 4.456
Acid 3.843
Table 16: Retention Times under Method A 
All compounds were then  m ixed together at 0.125 mg/mL and injected, however only 
two resolved peaks w ere observed in the chromatogram at 3.835 and 4.784 minutes,
indicating overlap o f  peaks (figure 45).
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byectioa Mdbod: 
Rim Time (min): 
WorkMoiion: 
Instrument (Xnj):
OW /Ï004 11:45:0»
c:\minr\* tuden t\c*16 i»v
20-000
Vnrian Dlod» Array
I
Operator (Calc): 
ColcDtlo:
Times Calculated: 
Cslaulaticm Mstfaod: 
Instrument (Calc): 
Run Mode: ri!*k MWBBHUont: 
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Calibration LmvI: 
Verification Tolennra
09/03/2004 12:05:16 I
c:\ftai\stodenAed5 aew rnth rath
Vurùm Diode Array
Analysis
Peak Aren
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N/A
N/A
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M  P > L -C Z -  I "SL
I»« Ha.» •iS.O
31-7*17 
*45.4379 
0,0307 
0.0197 
0,0434 
O 0999 
0 0061 
0.2744 
1.1719 
0.0153 
0.0085
0.0427
3.835 
4 784 
6.179 
7.029 
7.523 
8 371 
9-144 
9-880 
12-960 
13.720 
14.696 
15.315
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0.000 " 
o o o o  
0-000 
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0-000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000
F igure  45. M ixed injection o f  unsubstituted macrocycle, dodecaester, dodeca salt.
To try and solve this problem  we decided to lower the pH  o f the mobile phase to 5 
and to lower the organic content to 10% (table 17 M ethod B).
A naly tical M ethod  D evelopm ent- M ethod  B
Colum n Wave­
length
M obile Phase Flow
R ate
Sam ple
Concentration
R un
Time
C18 210nm 90:10 0.05M 
K2P 0 4:M e0H  (pH5)
0.3ml/
min
20mins
T ab le  17 : Analytical M ethod Development- M ethod B
Before running this method we noticed a carryover problem, the base line was drifting 
and becom ing noisy, we believe that some o f the absorbed acid was eluting o ff the 
column. A  cleaning m ethod had to be developed to eliminate this problem and is 
outlined as follows:
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1) flush 30 mL o f  90:10 H 20 :M e 0 H  followed w ith 30 mL 50:50 H20 :M e0 H  
(this had little effect)
2) 25 mL 95% H20/ACN followed by 25 mL THF followed by 95% ACN/H20  
(this procedure worked)
(Note that we found the column to be sufficiently saturated for sample injection after 
column washing.)
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A  fresh mobile phase was then prepared using 90% KLLPO4: 10% MeOH pH  5, four 
separate samples were prepared o f  the acid, ester, salt and macrocycle and injected 
individually, their retention tim es are listed in table 18.
C om pound R etention  tim e (m inutes)
Salt 4.216 and 4.741
Pyrogallol acetaldehyde tetramer 4.771
Ester 4.717 (single peak)
Acid 8.848
T ab le  18: Retention Time under M ethod B
An acid and ester mixture was also injected, two peaks were observed one at 4.685 
minutes and the other at 8.912 minutes (large peak tailing).
We also decided to increase the pH  o f the mobile phase to 9.3, however this had little 
effect on the retention times and resolution could not be achieved.
Conclusions- M ethod development.
A t the onset o f  the HPLC development work it was essential to develop a method that 
could detect at lower concetrations, this was achieved by column saturation. Also an
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effective column cleaning method was developed to prevent compound carry over 
after multiple injections. W e believe that this method is effective for analysis o f in 
vivo samples.
However attempts at developing a method that can properly resolve the peaks o f  the 
unsubstituted macrocycle from  the ester, acid/salt could not be achieved. Obviously 
separation o f  the partially substituted ester derivatives would be impossible at this 
point in time. However separation o f the ester from the acid could be accomplished, 
this is quite useful in determining if  conversion o f  esters to acids/salts (saponification 
step) is complete and could be used as a synthetic impurity method in the future. 
Outlined below we believe to be the optimum method that can be used for 
detection/quantitation o f  acids/salt:
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1) System set-up
A naly tical M ethod  D evelopm ent- M ethod  B
Colum n Wave­
length
M obile Phase F low
Rate
Sam ple
Concentration
R u n
Tim e
C18 210nm 85:15 0.05M 
K2P 0 4:M e0H  (pH7)
0.3ml/
min
0.5mg/ml 15mins
2) Overnight m ultiple injections for column saturation.
3) Sample standard preparation for calibration 0.0625mg/mL.
4) Inject samples, followed by column flushing using the cleaning procedure
described above.
5) Continue injection of samples.
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1.0 HPLC Method Development
The following HPLC methods were developed to separate the different derivatives o f 
pyrogallol[4]arenes. All compounds are derived from tetra-4-fluorophenyl 
pyrogallol[4]arene.
1.1 TopChem Laboratories® Analytical Development.
Instrument: Not Available
Column: C l 8
Wavelength: 210nm
Mobile Phase: 100% 0.05M KH2P 0 4) pH = 3
Flow Rate: 0.5ml/min
Sample Prep: 26mg/ml
Run Time: 60mins
1.2 Analytical Development; Method A
Instrument: Varian 9012, using the Varian Pro Star PDA Detector and a model 410
Varian Pro Star Aulosampler.
Column: Zorbax, RX - C l 8 4.6mm x 150mm, 5|.im
Wavelength: 210nm
Mobile Phase: 85% 0.05M KH 2P 0 4, 15% M ethanol, pH = 7 
Flow Rate: 0.5ml/min
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7.4 Experim ental:
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Sample Prep: 1.35mg/ml 
Run Time: 60mins
1,3 Analytical Development; Method B
Instrument: Varian 9012, using the Varian Pro Star PDA Detector and a model 410
Varian Pro Star Autosampler.
Column: Zorbax, RX - C l 8 4.6m m  x 150mm, 5p.m
W avelength: 210nm
M obile Phase: 85% 0.05M KH2PO4, 15% M ethanol, pH  = 7 
Flow  Rate: 0.3ml/min
Sample Prep: 0.5mg/ml 
R unT im e: 15mins
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Chapter 8 
Structural Diversity, 
Condensation with Dialdehydes
8.1 Introduction:
As a final section o f this research, we w anted to exploit the structural possibilities o f 
this new  class o f  macrocycle. W e began to explore the possibility o f  making more 
sophisticated macrocycles. On analysis o f  the rctt chair isom er o f  pyrogallol[4]arene 
we noticed that i f  we could bridge the two pendant aryl groups on the methylene 
bridges (derived from the aldehyde), we would have a macrocycle w ith three 
molecular rings. This new m arcocycle could open up possibilities in receptor 
chemistry, self assembly, drug delivery and even nano-technology. Figure 46 shows 
the crystal structure o f  tetra-4-fluorophenyl pyrogallol[4]arene, 65, highlighting the 
two pendant groups and how they could be linked.
F ig u re  46: Crystal Structure o f  tetra-4-fluoro phenylpyrogallol[4]arene,30, with 
pendant R-group linked to fo rm  a more sophisticated macrocycle.
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8.2 R esults and Discussion:
Our first synthetic strategy to prepare these macrocycles, involved the condensation o f 
an aryl dialdehyde with pyrogallol to form the target product (scheme 39).
O H  O H
Schem e 39: Condensation o f  p yro g a llo l with a dialdehyde
The first approach we attempted is outlined in scheme 40, and involved the 
conversion o f />bromomethyl benzyl bromide, 182, to the ethyl ester, 183, which was 
to be reduced to the aldehyde, 184 and subsequently protected. Then 185, (using 
ethane- 1,2-diol -  glycol, 71), would be converted into a Grignard, 186, and condensed 
with the other half o f  the protected aldehyde, 185. This would be then followed by a 
sim ple deprotection reaction to form the target product, 188.
cV /B r
C H 2Br
EtOH
60°C
C H 2Br
Schem e 40: First attempt at synthesising the dialdehyhe system.
This attempt failed in the first step, where the bromom ethyl group on the 4 position o f 
the benzene ring was also alkylated to give the ether ester, 183, (figure 47). This was 
verified by  'H-N M R and mass spectrometry. This is not a surprising result as the 
bromomethyl group is also susceptible to alkylation. W e had hoped that by using 
stiochiometric control we would be able to alkylate the acid bromide group in the 1 
position only, as it is m ore likely to be alkylated.
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Hd
(183)
F igu re  47: Product from  the fir s t  step o f  attempt 1, p-(ethyl ether) ethyl benzoate, 131.
J — a a . il
H b Hi
__1_. * —
He H d  H d '
I 'M'-O
_______ JU ll-i---
M S' V V
---- ——
V V V
NJ —*. —* coro
O CD CO 0 0O O —* CO octo. . . . . . . . . . . .
ppm(t1)G.O 7.0 6.0
1 1 ■ 
5.0
' 1 ' 
4.0
. . . . . .
3.0
. . , . 
2.0
. . 1 , . . 
1.0
F ig u re  48: 1H-NMR (DMSO-D$) o f  p-(ethyl ether) ethyl benzoate
The proton 1 H-NM R o f /;-(ethyl ether) ethyl benzoate, 183 (figures 47 & 48) gave a 
doublet o f  doublets at 7.2 and 7.5ppm which can be assigned to the 1,4-disubstituted 
phenyl ring (Ha) and the singlet at 4.25ppm represents the CH2 group (Hb) on the 4
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p o s i t io n  o f  th e  p h e n y l  r in g . T h e  e s te r  p ro to n s  a re  p re s e n t  as a  q u a r te t  a t 4 .1 5 p p m  (H e) 
a n d  a  t r ip le t  a t 1 .1 5 p p m  (H d ). T h e  e th e r  p ro to n s  a re  a  q u a r te t  a t 3 .2 5 p p m  ( H d ’), a n d  a  
t r ip le t  a t 1 .0 5 p p m  ( H d ’). T h e  e s te r  p ro to n s  a re  s lig h tly  sh if te d  d o w n  f ie ld  in  
c o m p a r is o n  to  th e  e th e r  p ro to n  o w in g  to  th e  c a rb o n y l g ro u p  o f  th e  e s te r.
T h is  s y n th e tic  p la n  w a s  a b a n d o n e d  in  f a v o u r  o f  a tte m p t 2  o u tl in e d  in  s c h e m e  4 1 . T h is  
p la n  in v o lv e d  th e  c o n d e n s a tio n  o f  /» -b ro m o m e th y l b e n z o ic  a c id , 189 w ith  g ly c o l, 71, 
to  fo rm  th e  d ia c id , 190 th is  w o u ld  th e n  b e  r e d u c e d  to  fo rm  th e  d ia ld e h y d e , 191. T h is  
r e a c tio n  c o u ld  le a d  to  a  m ix tu re  o f  s ix  c o m p o u n d s , w h ic h  w o u ld  h a v e  to  b e  s e p a ra te d  
b y  c o lu m n  c h ro m a to g ra p h y .
(189) (71) (190)
Schem e 41: Attem pt 2 at synthesising the dialdehyde system.
T h e  f ir s t  r e a c t io n  w a s  le f t  to  re a c t  fo r  3 d a y s  a n d  y ie ld e d  a  m ix tu re  o f  s ta r tin g  
m a te r ia l ,  m o n o a lk y la te d  a n d  d ia lk y la te d  a d d u c ts  (a n a ly s is  b y  'H -N M R  a n d  T L C ). T h e  
re a c t io n  w a s  th e n  re p e a te d  fo r  6 d a y s  w ith  e x tra  e q u iv a le n ts  o f  p o ta s s iu m  c a rb o n a te  
a d d e d  e a c h  d ay . T h is  re a c t io n  y ie ld e d  th e  s a m e  m ix tu re  a s  b e fo re , a n d  th is  p la n  w as  
a b a n d o n e d  in  f a v o u r  o f  a t te m p t 3 , ( s c h e m e  4 2 ).
o. H
+
OH
(192) (193) (194)
Schem e 42: Attem pt 3 at preparing the dialdehyde system.
In this attempt 4-hydroxybenzaldehyde, 192, was treated with 1,3-dibromopropane to 
give the dialdehyde, 194. This was verified by 'H-NMR. The product was 
recrystallised from hot methanol and was recovered in 35% yield. After the 
dialdehyde m oiety was synthesised the next step was to proceed in making our 
desired macrocycle, 196, as shown in scheme 43.
O H O H
° % / H
+
(195) (50) (196)
Schem e 43: Condensation o f  dialdehyde system, 142, with pyrogallol, 2.
The first attempt yielded a red precipitate after 24hours. This precipitate was found to 
be com pletely insoluble in  all solvents and therefore it was not possible to attain 'H- 
N M R data. The sample was sent for microanalysis and the results are outlined in table
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% C % H
Theoretical 69.59 4.83
Actual 64.44 4.53
Difference 5.15 0.30
Tab e 19: M icroanalysis Results fro m  dialdehyde condensation reaction.
It is clear from this table that the desired product was not obtained. Due to the poor 
solubility in m any different solvents, it was presumed that this product is a cross 
linked polymer.
In an attempt to inhibit polym er formation a series o f  reactions was set up, where the 
concentrations o f  the reactants were progressively decreased. Keeping the original 
concentration (100%) as a positive control and decreasing the concentration to 5%, 
unfortunately this had no effect on the reaction outcome, (concentrations are 
displayed in table 20), all six different concentrations gave the same insoluble red 
precipitate.
Reaction No. Cone. Pyrogallol Dialdehyde HC1 Ethanol
8.4.1-A 100% 0.50g (71 mg/ml) 0.56g (80mg/ml) 2ml 5ml
8.4.1-B 50% 0.50g (36mg/ml) 0.56g (40mg/ml) 4ml 10ml
8.4.1-C 25% 0.25g (18mg/ml) 0.28g (20mg/ml) 4ml 10ml
8.4.1-D 10% 0.1 Og (7.1mg/ml) 0 .112g (8mg/ml) 4ml 10ml
8.4.1-E 5% 0.05g (3.6mg/ml) 0.056g (4mg/ml) 4ml 10ml
Table 20: Concentration study.
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The next attempt at driving this reaction involved changing the condensation 
conditions, from hydrochloric acid to a weaker acid, acetic acid. Again this attempt 
was to no avail as the same insoluble red precipitate was produced.
The fourth and final attempt at this condensation involved a series o f  reactions 
w hereby the HC1 acid concentration was progressively lowered. Taking the lowest 
concentration (Reaction 8.4.1-E - 5%, table 20) from the previous concentration study 
the acid volume was initially halved and then progressively lowered from 2ml to
0.02ml and then even to 1 drop.
Once again these eight reactions gave the same product. This attempt was then 
abandoned in favour o f  the alkylation outlined in scheme 44.
N a 2C 0 3, Acetone
Schem e 44: Dialkylation o f  tetra-4-hydroxyphenyl pyrogallol[4]arene with 1,3-
dibromopropane.
This reaction gave a large mixture o f  compounds as mono-alkylation occurred along 
with alkylations o f  the pyrogallol hydroxyl groups. The only way this reaction would 
proceed is if  the pyrogallol hydroxyl groups were alkylated, however it is difficult to
do this without alkylating the lower rim hydroxyl groups as well. A synthetic plan for 
this reaction is currently being investigated in our research group as in scheme 45.
/  \
N C  C N
(201)
Scheme 45: Current investigation into synthesis o f sophisicated maerocyele.
8.3 E xperim ental:
8.3.1 Alkyaltion of p-bromomethyl benzylbromide, 182, with Ethanol
3.6mmol (l.Og) o f  p-brom om ethyl benzylbromide, 182, was added to 3.5ml o f 
Ethanol and the reaction was heated to 60°C and was stirred overnight under an inert 
atmosphere. The reaction m ixture had turned to a straw yellow colour upon which 
solvent was removed under reduced pressure. The resulting yellow oil was 
recrystallised from ethyl acetate and was washed w ith water via liquid-liquid 
extraction. The resulting dry oil was analysed by *H-NMR and Mass Spectrometry 
and was found to be the dialkylated adduct, 183.
'H -N M R- (400MHz) 5 (DM SO-D6) [ppm]
1.05ppm (3H, triplet, J=6.4Hz, Ar-CH2-0-CH2CH3), 1.15ppm (3H, triplet, J=6.4Hz, 
A r-C (= 0)-0-C H 2CH 3), 3.25ppm (2H, quartet, J=6.8Hz, Ar-CH2-0-CH2CH3), 4.1ppm 
(2H, quartet, J=6.8Hz, A r-C (= 0)-0 -C H 2CH3), 4.25ppm (2H, s, Ar-CH2-OR), 7.2ppm 
(2H, d, J=7.2Hz, Ar-H), 7.45ppm (2H, d, J=7.2Hz, Ar-H).
Mass Spec: M/Z: 231 (M+Na)
8.3.2 Condensation of/7-bromomethyl benzoic Acid, 189, with Glycol, 71.
4.65mmol (l.Og) of/»-bromomethyl benzoic acid, 189 and 1.86mmol (0.12g, 0.104ml) 
o f  glycol, 71 (ethan-l,2-diol) were treated with 7.44mmol (1.03g) o f  potassium 
carbonate in 5ml o f  acetone. The reaction was refluxed at 60°C for 3-6 days. On 
completion, the solvent was removed under reduced pressure, and dilute HC1 was
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added to neutralise excess potassium carbonate, 0.33g o f a white product precipitated. 
This was analysed by 'H -N M R  and found to be a mixture o f  products.
‘H-NM R- (400MHz) 8 (DM SO-D6) [ppm]
4.55ppm (1H, s, Ar-CH2-0 -C H 2R), 4.65ppm (1H, s, Ar-CH2-0 -C H 2R), 4.8ppm (1H, 
s, Ar-CH2-0 -C H 2R), 5.45ppm (2H, multiplet, Ar-CH 2-0-C H 2R), 7.5ppm (4H, 
m ultiplet, Ar-H), 8.0ppm (4H, multiplet, Ar-H).
8.3.3 Condensation of/>-hydroxybenzaldehyde with 1,3-dibromopopane.
8.2mmol (l.Og) of/>-hydroxybenz aldehyde, 192, and 4.1mmol (0.82g, 0.41ml) o f 1,3- 
dibromopropane, 193, were treated with 12.3mmol (1.70g) o f  potassium carbonate in 
10ml o f  acetone. The reaction was allowed to reflux for 6 days. The reaction mixture 
was filtered and exhaustively washed with acetone. The filtrates were collected and 
the solvent removed under reduced pressure, to leave an off-white solid. This solid 
was then recrystallised from hot methanol to yield 0.40g (1.44mmol , 35%) o f  a 
white powder, which was found to be the desired dialdhyde system, 194.
‘H-NM R- (400MHz) 5 (DM SO-D6) [ppm]
2.25ppm  (2H, quartet, J=6.4Hz, A r-0-C H 2-CH 2R), 4.30ppm (4H, Triplet, J=6.8Hz 
A r-0 -C H 2-CH2R), 7.15ppm (4H, d, J=7.2Hz Ar-H), 7.90ppm (4H, d, J=7.2Hz Ar-H), 
9.90ppm  (2H, s, Ar-COOH).
M ass Spec: M/Z: 303 (M +Na)
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8.3.4 Condensation of Dialdehyde system, 195, with Pyrogallol, 50.
2.0mmol (0.25g) o f  pyrogallol, 50, and l.Ommol (0.28g) o f  dialdehyde, 195, were 
treated with 1ml o f hydrochloric acid in 2.5ml o f  ethanol at 80°C overnight. The 
reaction m ixture was filtered to yield an insoluble red solid. The insoluble solid was 
sent for microanalysis.
M icroanalysis: C58H48O 16: Theoretical: %C -  69.59; %H -  4.83; Actual: %C - 64.44; 
%H -  4.53
8.3.4.1 Concentration Study of 8.4
A series o f  reactions were carried out as in Experiment 8.4, with the concentration o f  
reactants being progressively decreased as outlined in table 21.
Reaction No. Cone Pyrogallol Dialdehyde HC1 Ethanol
8.4.1 -A 100% 0.50g (71 mg/ml) 0.56g (80mg/ml) 2ml 5 ml
8.4.1--B 50% 0.50g (36mg/ml) 0.56g (40mg/ml) 4ml 10ml
8.4.1-C 25% 0.25g (18mg/ml) 0.28g (20mg/ml) 4ml 10ml
8 .4 .1-D 10% 0.1 Og (7.1 mg/ml) 0.112g (8mg/ml) 4ml 10ml
8.4.1-E 5% 0.05g (3.6mg/ml) 0.056g (4mg/ml) 4ml 10ml
Table 21: Concentration study.
8.3.4.2: Condensation of Dialdehyde system with Pyrogallol, using a weaker acid.
The reaction was carried out as in Experiment 8.4 using 0.8mmol (O.lg) o f  pyrogallol,
50, 0.04mmol (0.112g) and 4ml o f  acetic acid in 10ml in ethanol. As in Experiment
3.2 the reaction yielded an insoluble red solid.
8.3.4.3: A cid C oncen tra tion  S tudy
A series o f  reactions was set up as in Experiment 8.4.1-E, w ith the concentration o f 
acid halved initially and then being progressively decreased as described in table 22.
Reaction No. Pyrogallol Di aldehyde HC1 (Cone.) Ethanol
8.4.3 -A 0.05g 0.056g 2ml (0.167ml/ml) 10ml
8.4.3-B 0.05g 0.056g 1ml (0.091ml/ml) 10ml
8.4.3-C 0.05g 0.056g 0.5ml (0.048ml/ml) 10ml
8.4.3-D 0.05g 0.056g 0.25ml (0.024ml/ml) 10ml
8.4.3-E 0.05g 0.056g 0.1ml (O.OlOml/ml) 10ml
8.4.3-F 0.05g 0.056g 0.05ml (0.005ml/ml) 10ml
8.4.3-G 0.05g 0.056g 0.02ml (0.002ml/ml) 10ml
8.4.3-H 0.05g 0.056g 1 drop (<0.001ml/ml) 10ml
T ab le  22: A cid  concentration study.
Once again the insoluble red solid was formed, in all cases.
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8.3.5 Alkylation of tetra-4-hydroxyphenyl pyrogallol[4] arene, 88, with 1,3- 
dibromopropane, 193.
I.09mmol (l.Og) o f  tetra-4-hydroxyphenyl pyrogallol[4]arene, 88, and 2.18mraol 
(0.44g, 0.22ml) o f  1,3-dibromopropane, 193, were treated with 6.54mmoi (0.69g) o f  
sodium carbonate in 60ml o f  acetone. The reaction was refluxed at 60°C for 3 days. A 
brown precipitate was filtered and washed with acetone, and the resulting product was 
analysed by 'H-NMR. The 'H-NM R was found to be poorly resolved and this is due 
to a large mixture o f  compounds. The filtrate was also retained and the solvents were 
removed under rcduced pressure and the resulting yellow product was also analysed 
by 1 [ I-NMR, however there was no NMR signal. This product is presumed to be 
excess bromine salts.
8.4 Thesis Conclusion:
After com pleting all the above work, and revisiting our initial seven research 
proposals, w e can conclude the following:
The yield o f  the pyrogallol[4]arene condensation can be improved. A series o f 
optimisation experiments was carried out and we have now reported the optimum 
condensation conditions, with reproducible yields o f up to 93% depending on the 
aldehyde used.
The stereochemistry o f  the pyrogallol[4]arenes was thoroughly investigated and 
discussed. The prédominent stereoisomer derived from aryl aldehydes is the rctt chair 
isomer, and from  alkyl aldehydes is the rccc cone conformation. There are, however, 
some exceptions to this rule.
Biological investigations have shown us that the lead compounds are in fact mixtures 
o f  partially alkylated derivatives, The problem, however, lies in the development o f  a 
reproducible synthetic method to form partially alkylated derivatives. To date all we 
have been able to do is produce “enriched” samples o f partially alkylated derivatives.
W ith regard to specific structural limitations, for biological performance, the 
derivative needs to be partially alkylated (there may be some oxidation/reduction 
chemistry occurring with the residual hydroxy groups). There is a size effect issue 
also. The particle size in an aqueous solution o f  some o f these compounds was 
measured using PCS and a correlation was observed between the biologically active
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compounds and (hose o f smaller particle size. Finally our inability to alkylate a rccc 
cone stereoisomer leaves this investigation incomplete.
We have also developed an analytical HPLC method to detect these molecules. The 
method uses a low sample concentration and therefore is suitable for potential in vivo 
studies in the future.
The final element o f the research was an attempt to develop a more sophisticated class 
of pyrogallolarene and perhaps a new lead structure. We still believe that this is 
possible, however more work is required in the area.
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A p p e n d i c e s
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A ppendix 1:
X-ray crystal structure data for tetra-4-fluoro pyrogallol[4]arene82.
T ab le  1. Crystal data and structure refinement for kno06.
Identification code 
Empirical formula 
M olecular formula 
Form ula weight 
Temperature 
W avelength 
Crystal system 
Space group 
U nit cell dimensions
Volume
Z
Density (calculated) 
A bsorption coefficient 
F(000)
Crystal size 
Theta range for data 
collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 
26.00°
Absorption correction 
Max. and min. transmission 
Refinement method 
Data /  restraints /  parameters 
G oodness-of-fit on F2 
Final R indices [I>2sigma(I)] 
R indices (all data)
Largest diff. peak and hole
a =  62.7760(10)°. 
p= 72.812(2)°. 
y = 70.779(2)°.
kno06
Css H 88 O 22 F 4 Ss
C52 H36 O i2 F4 x 8 C2 Hg O S x 2  H2 O 
1589.86 
100(2) K  
0.71073 A 
Triclinic 
P - l  (#2)
a =  10.6871(10) A 
b =  14.0609(13) A 
c =  15.2198(15) A
1891.6(3) A3 
1
1.396 M g/m 3 
0.318 m m - 1 
836
1 .6 0 x 0 .8 0 x 0 .8 0  m m 3
2.05 to 26.00°.
- 1 3<=h<=13, —17<=k<= 17, -18<=1<=18 
29403
7410 [R(int) = 0.0222]
99.8 %
Sem i-em pirical from equivalents 
0.7850 and 0.6430 
Full-m atrix  least-squares on F2 
7 4 1 0 / 1 4 /5 3 0  
1.030
R1 =  0.0366, wR2 =  0.0966 
R1 = 0 .0401, wR2 = 0.0988 
0.434 a n d -0 .318  e.A - 3
T ab le  2. Atomic coordinates ( x 104) and equivalent isotropic displacement 
param eters (A2x 103)
for kno06. U(eq) is defined as one third o f the trace o f the orthogonalized U ‘J tensor.
A tom X y z U(eq;
C (l) 3488(1) -246(1) 3945(1) 15(1
C(2) 3514(2) 973(1) 3458(1) 17(1
C(3) 4232(2) 1366(1) 3799(1) 24(1
C(4) 4268(2) 2465(1) 3380(1) 26(1
C(5) 3599(2) 3167(1) 2594(1) 26(1
F (l) 3642(1) 4253(1) 2169(1) 36(1
C(6) 2915(2) 2821(2) 2207(2) 36(1
C(7) 2854(2) 1719(2) 2662(1) 29(1
C(8) 2902(2) -543(1) 3329(1) 15(1
C(9) 3725(2) -782(1) 2523(1) 16(1
0 (1 ) 5052(1) -769(1) 2325(1) 21(1
C(10) 3194(2) -1020(1) 1929(1) 17(1
0 (2 ) 4043(1) -1271(1) 1144(1) 22(1
C ( l l ) 1829(2) -1007(1) 2135(1) 16(1
0 (3 ) 1283(1) -1243(1) 1573(1) 21(1
C(12) 970(2) -692(1) 2895(1) 15(1
C(13) 1534(2) ^188(1) 3490(1) 16(1
C(14) -540(2) -548(1) 3022(1) 15(1
C(15) -999(2) -1622(1) 3552(1) 18(1
C(16) -265(2) -2574(1) 4192(1) 25(1
C(17) -775(2) -3519(2) 4715(1) 35(1
C(18) -2006(2) -3478(2) 4581(2) 40(1
F(2) -2494(2) —4411(1) 5097(1) 65(1
C(19) -2764(2) -2558(2) 3955(2) 36(1
C(20) -2246(2) -1630(2) 3437(1) 26(1
C(21) -1353(1) 243(1) 3522(1) 14(1
C(22) -1469(2) 1365(1) 2970(1) 16(1
0 (4 ) -807(1) 1720(1) 1998(1) 21(1
C(23) -2279(2) 2117(1) 3382(1) 17(1
0 (5 ) -2417(1) 3206(1) 2739(1) 24(1
-186-
C(24) -2927(2) 1744(1) 4380(1)' 16(1)
0 (6 ) -3763(1) 2447(1) 4818(1) 21(1)
C(25) -2779(1) 618(1) 4963(1) 15(1)
C(26) -1999(1) -110(1) 4521(1) 15(1)
0 (7 ) 6711(1) 9555(1) 10545(1) 25(1)
S (l) 7620(1) 8432(1) 10648(1) 23(1)
C(27) 7440(2) 8202(2) 9638(1) 32(1)
C(28) 9287(2) 8646(2) 10203(2) 32(1)
0 (8 ) 7457(1) 2589(1) -638(1) 37(1)
S(2) 6265(1) 2714(1) 152(1) 28(1)
C(29) 6494(2) 3718(2) 468(2) 34(1)
C(30) 6586(2) 1539(2) 1280(2) 33(1)
0 (9 A ) a) -663(2) 5740(1) 1207(1) 26(1)
S (3 A )a) 453(1) 5250(1) 1826(1) 24(1)
C (3 1 A )a) 272(8) 6175(6) 2380(5) 35(1)
C (3 2 A )a) -85(3) 4146(2) 2926(2) 36(1)
0 ( 9 B ) b) 75(14) 5300(11) 1267(9) 82(4)
e)
S (3 B )b) -656(5) 5647(3) 2138(3) 69(2)
C (31B )b) 540(30) 6040(30) 2420(30) 41(8)
e)
C (32B )b) -722(17) 4438(11) 3212(11) 59(4)
e)
0 (10  A) 6493(2) 4607(1) 3661(1) 32(1)
c)
S (4 A )o) 5965(1) 5828(1) 3103(1) 30(1)
C (3 3 A )c) 5754(5) 6035(4) 1909(3) 36(1)
C (34A )C) 4260(5) 6117(4) 3631(4) 73(2)
0(1  OB) 5848(8) 4532(6) 3632(6) 44(2)
d)e)
S (4 B )d) 4693(3) 5372(2) 3153(2) 40(1)
C (3 3 B )d) 5650(40) 6070(30) 2016(17) 113(13)
e)
C (3 4 B )d) 4107(14) 6301(12) 3709(12) 29(3)
e)
0(11) 9710(2) 3750(1) 822(1) 40(1)
a)s .o .f=  0.804(2) b)s.o.f. = 0.196(2) c) s .o .f=  0.776(2) d) s.o.f. = 0.224(2) [s.o 
site occupation factor; the sums o f the s.o.f. ’s a) and b) as well as c) and d) are 
constrained to be 1] e) only isotropic temperature factors could be refined.
Table 3. Bond lengths [Á] and angles [°] for kno06.
C (l)-C (8 )
C (l)-C (2 5 )# l
C (l)-C (2 )
C(1)-H (1A )
C(2)-C(7)
C(2)-C(3)
C(3)-C(4)
C(3)-H (3A )
C(4)-C(5)
C(4)-H (4A )
C(5)-C(6)
C (5 )-F (l)
C(6)-C(7)
C(6)-H (6A )
C(7)-H(7)
C(8)-C(13)
C(8)-C(9)
C (9 ) -0 ( l)
C(9)-C(10)
0(1)~H (1)
C (10)-0 (2 )
C (1 0 )-C (ll)
0 (2 )-H (2)
C ( l l ) -0 (3 )
C (ll)-C (1 2 )
0 (3 )-H (3 )
C(12)-C(13)
C(12)-C(14)
C(13)-H (13)
C(14)-C(15)
C(14)-C(21)
C(14)-H(14)
C(15)-C(16)
C(15)-C(20)
C(16)-C(17)
C(16)-H (16)
1.525(2)
1.527(2)
1.530(2)
1.0000
1.386(2)
1.393(2)
1.385(2)
0.9500
1.370(2)
0.9500
1.367(3)
1.3700(19)
1.393(3)
0.9500
0.9500
1.391(2)
1.391(2)
1.3640(18)
1.399(2)
0.8400
1.3827(18)
1.395(2)
0.8400
1.3656(18)
1.396(2)
0.8400
1.393(2)
1.524(2)
0.9500
1.520(2)
1.524(2)
1.0000
1.387(2)
1.398(2)
1.396(3)
0.9500
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C(30)-H (30C)
0(9A )-S (3A )
S(3A)-C(31A)
S(3A)—C(32A)
C(31 A )-H (31A )
C(31A )-H(31B)
C(31A)-H(31C)
C(32A )-H(32A)
C(32A )-H(32B)
C(32A )-H(32C)
0(9B )-S (3B )
S(3B)-C(32B)
S(3B)-C(31B)
C(31B)-H (31D)
C(31B)-H (31E)
C(31B)-H (31F)
C(32B)-H (32D)
C(32B)-H (32E)
C(32B)-H(32F)
0(10A )-S (4A )
S(4A)-C(34A )
S(4A)-C(33A )
C(33A )-H(33A )
C(33A)-H(33B)
C(33A )-H(33C)
C(34A )-H(34A )
C(34A )-H(34B)
C(34A )-H(34C)
0(10B )-S (4B )
S(4B)-C(34B)
S(4B)-C(33B)
C(33B)-H (33D)
C(33B)-H (33E)
C(33B)-H (33F)
C(34B)-H (34D)
C(34B)-H (34E)
C(34B)-H (34F)
0 ( 1 1)-H (10)
0.9800
1.5212(16)
1.784(5)
1.784(2)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
1.528(12)
1.743(12)
1.773(15)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
1.5156(16)
1.755(5)
1.776(4)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
1.495(8)
1.725(12)
1.750(15)
0.9800
0.9800
0.9800
0.9800
0.9800
0.9800
0.79(3)
-191-
0 (1 1)-H(20) 0.82(3)
C (8)-C (l)-C (2 5 )# l 111.28(12)
C (8 )-C (l)-C (2 ) 111.59(12)
C(2 5 )# 1 -C (  1 )-C (2) 113.26(12)
C (8)-C (1)-H (1A ) 106.8
C (2 5 )# l-C ( l)- 106.8
H(1A)
C (2)-C ( 1 )-H ( 1 A) 106.8
C (7)-C (2)-C (3) 117.50(15)
C (7 )-C (2 )-C (l) 122.16(14)
C (3)-C (2)-C (l) 120.33(14)
C (4)-C (3)-C (2) 121.82(15)
C (4)-C (3)-H (3A ) 119.1
C (2)-C (3)-H (3A ) 119.1
C (5)-C (4)-C (3) 118.18(16)
C (5)-C (4)-H (4A ) 120.9
C(3 )-C (4)-H (4  A) 120.9
C (6 )-C (5 )-F (l) 118.99(16)
C (6)-C (5)-C (4) 122.53(16)
F (l)-C (5 )-C (4 ) 118.46(16)
C (5)-C (6)-C (7) 118.23(16)
C (5)-C (6)-H (6A ) 120.9
C(7)-C (6)-H (6A ) 120.9
C (2)-C (7)-C (6) 121.65(16)
C (2)-C (7)-H (7) 119.2
C (6)-C (7)-H (7) 119.2
C (13)-C (8)-C (9) 118.25(13)
C (13)-C (8)-C (l) 121.82(13)
C (9 )-C (8 )-C (l) 119.67(13)
0 (1 )-C (9 )-C (8 ) 118.42(13)
0 (1)-C (9)-C (10) 121.18(13)
C (8)-C (9)-C (10) 120.39(14)
C (9 )-0 (1 )-H (l) 109.5
0 (2 )-C (1 0 )-C (1 1) 120.90(13)
0 (2 )-C (10)-C (9) 118.99(13)
C (ll)-C (1 0 )-C (9 ) 120.11(14)
C (10)-0 (2 )-H (2) 109.5
-192-
0(3 )—C (11)—C(10) 121.41(13)
0 (3 )-C (l 1)—C(12) 118.28(13)
C (1 0 )-C (ll)-C (1 2 ) 120.23(14)
C ( ll) -0 (3 ) -H (3 ) 109.5
C (13)-C (12)-C (l 1) 118.20(13)
C(13)—C(12)—C(14) 122.51(13)
C (ll)-C (1 2 )-C (1 4 ) 119.26(13)
C (8)-C (13)-C (12) 122.57(14)
C(8)-C (13)-H (13) 118.7
C (12)-C (13)-H (13) 118.7
C (15)-C (14)-C (12) 113.94(12)
C (15)-C (14)-C (21) 110.76(12)
C (12)-C (14)-C (21) 112.29(12)
C (15)-C (14)-H (14) 106.4
C( 12 )-C ( 14 )-H ( 14) 106.4
C(21 )-C ( 14 )-H ( 14) 106.4
C (16)-C (15)-C (20) 118.98(15)
C (16)-C (15)-C (14) 122.31(14)
C (20)-C (l 5)-C(14) 118.59(14)
C (15)-C (l 6)-C(17) 120.11(17)
C (15)-C (16)-H (16) 119.9
C (17)-C (l 6 )-H (l 6) 119.9
C( 18)-C ( 17)-C ( 16) 118.48(19)
C (18)-C (l 7)-H ( 17) 120.8
C (16)-C (l 7)-H ( 17) 120.8
C (17)-C (l 8)-F(2) 117.9(2)
C (17)-C (18)-C (19) 123.45(17)
F (2)-C ( 18 )-C (l 9) 118.6(2)
C (18)-C (19)-C (20) 117.56(18)
C( 18)-C ( 19)-H ( 19) 121.2
C(20)-C (19)-H (19) 121.2
C (19)-C (20)-C (15) 121.42(18)
C( 19)-C (20)-H (20) 119.3
C(15)-C (20)-H (20) 119.3
C (22)-C (21 )-C (26) 118.01(13)
C (22)-C (21)-C (14) 119.29(13)
C (26)-C (21 )-C ( 14) 122.71(13)
0 (4 )-C (2 2 )-C (2 1 ) 118.56(13)
-193-
0(4 )-C (22)-C (23) 120.59(14)
C (21 )-C (22)-C (23) 120.81(14)
C (22)-0 (4 )-H (4) 109.5
0(5 )-C (23)-C (22) 115.78(13)
0 (5 )-C (23)-C (24) 124.13(14)
C (22)-C (23)-C (24) 120.05(14)
C (23)-0 (5 )-H (5) 109.5
0 (6 )-C (24)-C (23) 122.54(14)
0 (6 )-C (24)-C (25) 117.37(13)
C(23)-C (24)-C (25) 120.04(14)
C (24)-0 (6 )-H (6) 109.5
C (26)-C (25)-C (24) 118.53(13)
C (26)-C (25)-C ( 1 )# 1 123.14(13)
C (24)-C (25)-C ( 1 )# 1 118.33(13)
C (25)-C (26)-C (21) 122.44(14)
C(25)-C (26)-H (26) 118.8
C (21 )-C (26)-H (26) 118.8
0 (7 )-S (l)-C (2 8 ) 105.40(8)
0 (7 )-S (l)-C (2 7 ) 105.34(8)
C (28)-S( 1 )-C (27) 98.85(10)
S(1)-C (27)-H (27A ) 109.5
S(1)-C (27)-H (27B ) 109.5
H (27A )-C (27)- 109.5
H(27B)
S(1)-C (27)-H (27C ) 109.5
H (27A )-C (27)- 109.5
H(27C)
H (27B )-C (27)- 109.5
H(27C)
S(1)-C (28)-H (28A ) 109.5
S(1)-C (28)-H (28B ) 109.5
H (28A )-C (28)- 109.5
H(28B)
S(1)-C (28)-H (28C ) 109.5
H (28A )-C (28)- 109.5
H(28C)
H (28B )-C (28)- 109.5
H(28C)
-194-
0 (8 )—S(2)—C(30) 106.44(9)
0 (8 )-S (2 )-C (29) 104.30(9)
C(30)-S(2)-C (29) 98.65(9)
S(2)-C(29)-H (29A ) 109.5
S(2}-C(29)-H (29B) 109.5
H (29A )-C (29)- 109.5
H(29B)
S(2)-C(29)-H (29C) 109.5
H (29A )-C(2 9)~ 109.5
H(29C)
H (29B)-C(29>- 109.5
H(29C)
S(2)-C(3 0)-H (3 0 A) 109.5
S (2)-C(3 0)-H (3 OB) 109.5
H (30A )-C (30)- 109.5
H(30B)
S (2)-C(3 0>-H(3 OC) 109.5
H (30A)-C(30)~ 109.5
H(30C)
H (30B )-C (30)- 109.5
H(30C)
0 (9 A )-S (3 A )- 106.3(3)
C(31A)
0 (9 A )-S (3 A )- 105.31(11)
C(32A)
C (31A )-S(3A )- 98.8(2)
C(32A)
0 (9 B )-S (3 B )- 106.3(8)
C(32B)
0 (9 B )-S (3 B )- 105.8(13)
C(31B)
C (32B )-S (3B )- 96.9(13)
C(31B)
S(3B )-C (31B )- 109.5
H(31D)
S(3B )-C (31B )- 109.5
H(31E)
H (31D )-C (31B )- 109.5
-195-
1-1(3 IE)
S(3B)-C(31 B )- 
H (31F)
H(31D)-C(31B>
H(31F)
H(31E)-C(31B)- 
H (31F)
S(3B )-C (32B )-
H(32D)
S(3B )-C (32B )-
H(32E)
H(32D)-C(32B>
H(32E)
S(3B )-C (32B )-
H(32F)
H (32D)-C(32B)
H(32F)
H (32E)-C(32B>
H(32F)
0 (  10A )-S (4A )- 
C(34A)
0(10A )-S (4A )~
C(33A)
C (34A )-S(4A )-
C(33A)
0 (1 0 B )-S (4 B )-
C(34B)
0 (1 0 B )-S (4 B )-
C(33B)
C (34B )-S(4B )-
C(33B)
S(4B )-C (33B )-
H(33D)
S(4B )-C (33B )-
H(33E)
H(33D)-C(33B)
H(33E)
S(4B )-C (33B )-
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5
106.03(19)
107.47(17)
98.1(3)
107.4(6)
96.9(14)
102.6(14)
109.5
109.5
109.5
109.5
H(33F)
H (33D )-C (33B )-
H(33F)
H (33E )-C (33B )-
H(33F)
S(4B)-C(34B>-
H(34D)
S(4B)-C(34B)—
H(34E)
H(3 4D )-C(3 4 B )- 
H(34E)
S(4B)-C(34B>-
H(34F)
H (34D )-C (34B )-
H(34F)
H (34E )-C (34B )-
H(34F)
H ( 1 0 ) - 0 ( l l ) -
H (20 )
109.5
109.5
109.5
109.5
109.5
109.5
109.5
109.5 
109(3)
Symmetry transformations used to generate equivalent atoms:
#1 —x,—y ,-z + l
T ab le  4. Anisotropic displacement param eters (A2x 103) for kno06. The 
anisotropic displacement factor exponent takes the form: -2 n 2[ h2 a*2U n + ... + 2 h k 
a* b* U 12 ]
Atom  U 11 U22 U33 U23 U 13 U 12
C (l)
C(2)
C(3)
C(4)
C(5)
F (l)
C(6)
C(7)
C(8)
C(9)
0 (1 )
C(10)
0 (2 )
C ( l l )
0 (3 )
C(12)
C(13)
C(14)
C(15)
C(16)
C(17)
C(18)
F(2)
C(19)
C(20)
C(21)
C(22)
0 (4 )
C(23)
0 (5 )
12(1
14(1
21(1
22(1
29(1
44(1
53(1
41(1
16(1
13(1
14(1
16(1
18(1
18(1
17(1
14(1
16(1
15(1
20(1
33(1
60(1
58(1
95(1
32(1
23(1
11(1
14(1
26(1
18(1
34(1
19(1
21(1
24(1
26(1
17(1
18(1
23(1
24(1
16(1
17(1
35(1
18(1
32(1
15(1
31(1
15(1
18(1
18(1
20(1
22(1
22(1
34(1
45(1
41(1
29(1
18(1
21(1
18(1
16(1
16(1
15(1
14(1
26(1
34(1
28(1
43(1
33(1
30(1
14(1
16(1
19(1
16(1
20(1
17(1
24(1
16(1
14(1
14(1
18(1
22(1
25(1
37(1
63(1
49(1
36(1
17(1
14(1
16(1
20(1
20(1
-8(1
-8(1
-5(1
-12(1
-8(1
-7(1
-6(1
-10(1
-6(1
-6(1
-16(1
-9(1
-17(1
-7(1
-20(1
-6(1
-8(1
-7(1
-12(1
-11(1
-8(1
-20(1
-19(1
-29(1
-20(1
-8(1
-7(1
-7(1
-6(1
-7(1
-2(1
0(1
-10(1
-8(1
-3(1
-14(1
-26(1
-19(1
-1(1
-3(1
1(1
-2(1
-2(1
-6(1
-3(1
-3(1
-2(1
-3(1
1(1
-4(1
-5(1
14(1
13(1
6(1
-2(1
-5(1
-3(1
2(1
-7(1
0(1
-3(1
-4 (1
-7(1
-8(1
-5(1
-7 (1
-2(1
-5(1
-3 (1
-2(1
-6(1
-1(1
-1(1
-3(1
-3(1
-4 (1
-3(1
-4 (1
-6(1
-8(1
-13(1
-32(1
-52(1
-21(1
-9(1
-2(1
-7(1
-8(1
-4 (1
-5(1
C(24) 13(1) 19(1) 19(1) -11(1) -4 (1 ) -2(1
0 (6 ) 24(1) 18(1) 21(1) -11(1) -2 (1 ) -2(1
0(25) 12(1) 20(1) 14(1) -8 (1 ) -5 (1 ) -4(1
C(26) 13(1) 16(1) 16(1) -6 (1 ) -5 (1 ) -3(1
0 (7 ) 23(1) 30(1) 22(1) -14(1) 0(1) -1(1
S (l) 21(1) 27(1) 20(1) -10(1) -1 (1 ) -5(1
C(27) 40(1) 29(1) 30(1) -16(1) -10(1) -4(1
C(28) 20(1) 37(1) 34(1) -13(1) -2(1) -6(1
0 (8 ) 42(1) 44(1) 34(1) -28(1) 5(1) -12(1
S(2) 22(1) 36(1) 32(1) -20(1) -5 (1 ) -4(1
C(29) 43(1) 30(1) 31(1) -19(1) -1(1 ) -6(1
C(30) 38(1) 30(1) 35(1) -15(1) -3 (1 ) -11(1
0(9A ) 24(1) 36(1) 22(1) -15(1) -7(1) -2(1
S(3A) 23(1) 31(1) 20(1) -11(1 ) -3(1) -7(1
C(31A) 44(3) 40(2) 30(2) -18(2) -9 (2 ) -12(3
C(32A) 39(2) 41(1) 27(1) -7 (1 ) -6 (1 ) -18(1
S(3B) 93(4) 49(2) 76(3) -15(2 ) -50(2) -15(2
0(1  OA) 49(1) 16(1) 27(1) -8 (1 ) -7 (1 ) -4(1
S(4A) 46(1) 16(1) 28(1) -9 (1 ) -7(1) -8(1
C(33A) 53(2) 33(2) 18(1) -3 (1 ) -8 (1 ) -15(1
C(34A) 77(3) 32(2) 52(2) -3 (2 ) 24(2) 9(2
S(4B) 53(2) 29(1) 42(1) -20(1) -2 (1 ) -10(1
0(11) 65(1) 26(1) 24(1) -10(1) 7(1) -19(1
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T ab le  5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 
10 3)
for kno06.
Atom X y z U(e
H(1A) 4445 -669 3946 18
H(3A) 4710 867 4333 28
H(4A) 4744 2725 3630 31
H(6A) 2493 3318 1642 43
H(7) 2348 1474 2421 35
H (l) 5383 -7 2 4 1737 32
H(2) 3864 -755 597 33
H(3) 1897 -1584 1259 32
H(13) 961 -303 4026 19
H(14) -758 -202 2330 18
H(16) 586 -2583 4275 29
H(17) -278 —4176 5154 43
H(19) -3616 -2559 3880 43
H(20) -2747 -983 2992 32
H(4) -855 2397 1775 31
H(5) -2814 3600 3065 36
H(6) -3724 3097 4424 32
H(26) -1903 -876 4913 18
H(27A) 6505 8180 9715 47
H(27B) 8035 7500 9643 47
H(27C) 7680 8798 9001 47
H(28A) 9331 9249 9537 48
H(28B) 9914 7973 10159 48
H(28C) 9533 8832 10667 48
H(29A) 7385 3485 652 50
H(29B) 5800 3793 1036 50
H(29C) 6422 4427 -110 50
H(30A) 6567 883 1214 50
H(30B) 5894 1633 1842 50
H(30C) 7473 1454 1406 50
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H (31 A) 547 6845 1862 53
H (31B) 841 5826 2896 53
1-1(31C) -6 7 0 6363 2686 53
H(32A) -971 4423 3260 53
H(32B) 564 3825 3383 53
H(32C) -1 4 4 3583 2739 53
H (31D) 1313 5418 2603 61
H (31E) 130 6267 2982 61
H(3 IF) 847 6656 1831 61
H(32D) -1267 4034 3156 88
H(32E) -1127 4616 3801 88
H(32F) 191 3983 3282 88
H(33A) 6637 5886 1503 54
H(33B) 5281 6797 1571 54
H(33C) 5226 5536 1994 54
H(34A) 3791 5664 3569 110
H(34B) 3857 6895 3279 110
H(34C) 4179 5953 4342 110
H(33D) 5046 6699 1587 169
H(33E) 6138 5575 1677 169
H(33F) 6285 6338 2146 169
H(34D) 4806 6688 3560 43
H(34E) 3876 5911 4437 43
II(34F) 3305 6834 3446 43
H (10) 9890(30) 3900(20) 240(20) 66(9)
M(20) 9330(30) 4310(20) 920(20) 56(8)
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Table 6. Torsion angles [°] for kno06.
C (8 )-C (l)-C (2 )-C (7 ) 10.9(2)
C (2 5 )# l-C (l)-C (2 )-C (7 ) -115.58(17)
C (8 )-C (l)-C (2 )-C (3 ) -168.13(14)
C (2 5 )# l-C (l)-C (2 )-C (3 ) 65.36(18)
C (7)-C (2)-C (3)-C (4) 1.4(3)
C (l)-C (2 )-C (3 )-C (4 ) -179.46(15)
C (2)-C (3)-C (4)-C (5) -1 .5(3)
C (3)-C (4)-C (5)-C (6) -0 .7(3)
C (3)-C (4 )-C (5 )-F (l) -179.33(16)
F (l)-C (5 )-C (6 )-C (7 ) -178.51(17)
C (4)-C (5)-C (6)-C (7) 2.9(3)
C (3)-C (2)-C (7)-C (6) 0.8(3)
C( 1 )-C (2)-C (7)-C (6) -178.25(17)
C (5)-C (6)-C (7)-C (2) -2 .9(3)
C (2 5 )# l-C (l)-C (8 )-C (1 3 ) 37.17(19)
C (2)-C (l)-C (8 )-C (13) -90.41(17)
C (2 5 )# l-C (l)-C (8 )-C (9 ) -148.78(14)
C (2 )-C (l)-C (8 )-C (9 ) 83.64(17)
C( 13 )-C (8 )-C (9 )-0 ( l ) 175.90(13)
C (l)-C (8 )-C (9 )-0 (1 ) 1.6(2)
C (13)-C (8)-C (9)-C (l 0) -3 .6(2)
C( 1 )-C (8 )-C (9 )-C (l 0) -177.81(13)
0(1  )-C (9 )-C ( 10 )-0 (2 ) 1.6(2)
C (8)-C (9)-C (10)-0 (2 ) -178.99(14)
0 (1 )-C (9 )-C (1 0 )-C (1 1) -178.73(14)
C (8)-C (9)-C (10)-C (l 1) 0.7(2)
0 (2 )-C (1 0 )-C (1 1 )-0 (3 ) 0.2(2)
C (9)-C (10)-C (l l ) -0 (3 ) -179.53(14)
0 (2 )-C (l 0)-C ( 11 )-C ( 12) -176.40(14)
C (9)-C  ( 10 )-C  (11 )-C  (12) 3.9(2)
0 (3 ) -C ( l 1)-C (12)-C (13) 177.87(13)
C (1 0 )-C (ll)-C (1 2 )-C (1 3 ) -5 .4(2)
0 (3 ) -C ( l 1)-C (12)-C (14) -1 .2(2)
C (1 0 )-C (ll)-C (1 2 )-C (1 4 ) 172.49(13)
C (9)-C (8)-C (13)-C (12) 1.9(2)
C (l)-C (8 )-C (13)-C (12) 176.04(14)
C (11)-C (12)-C (13)-C (8) 2.6(2)
C( 14 )-C ( 12 )-C ( 13)-C(8) -175.31(14)
C(13)—C(12)—C(14)—C(15) -103.86(16)
C( 11 )-C ( 12 )-C ( 14 )-C ( 15) 78.29(17)
C( 13)-C ( 12 )-C ( 14 )-C (2 1 ) 23.1(2)
C (11 )—C( 12)—C( 14)—C (21 ) -154.75(13)
C( 12 )-C ( 14 )-C ( 15)-C ( 16) 23.9(2)
C (21)-C (14)-C (15)-C (16) -103.89(16)
C (12)-C (14)-C (15)-C (20) -160.22(14)
C (21 )-C ( 14 )-C ( 15)-C(20) 72.03(17)
C (20)-C ( 15 )-C (l 6 )-C (l 7) -0 .4(2)
C (14)-C (l 5 )-C (l 6 )-C (l 7) 175.54(15)
C (15)-C (16)-C (17)-C (18) -0 .2(3)
C ( 16)-C ( 17)-C ( 18 )-F  (2) 179.87(16)
C (16)-C (17)-C (18)-C (19) 0.4(3)
C(17)—C (18)-C ( 19)-C(20) 0.0(3)
F (2 )-C (l 8)-C (19)-C (20) -179.45(17)
C (18)-C (19)-C (20)-C (15) -0 .6(3)
C( 16)-C ( 15 )-C (20)-C ( 19) 0.8(2)
C (14)-C (l 5 )-C (20 )-C (l 9) -175.26(15)
C( 15)-C ( 14 )-C (2 1 )-C (22) -155.79(13)
C( 12 )-C (l 4 )-C (2 1 )-C (22) 75.56(17)
C (15)-C (14)-C (21)-C (26) 23.86(19)
C( 12 )-C ( 14 )-C (2 1 )-C (26) -104.79(16)
C (26)-C (21 )-C (2 2 )-0 (4 ) 178.10(13)
C( 14 )-C (2 1 )-C (2 2 )-0 (4 ) -2 .2(2)
C (26)-C (21)-C (22)-C (23) -4 .1(2)
C (14)-C (21)-C (22)-C (23) 175.55(13)
0 (4 )-C (2 2 )-C (2 3 )-0 (5 ) 3.5(2)
C (21)-C (22)-C (23)-0 (5 ) -174.24(13)
0(4)-C (22)-C (23)-C (24) -178.68(13)
C (21)-C (22)-C (23)-C (24) 3.6(2)
0 (5 )-C (2 3 )-C (2 4 )-0 (6 ) -0 .8(2)
C (22)-C (23)-C (24)-0 (6 ) -178.41(13)
0(5)-C (23)-C (24)-C (25) 176.77(14)
C (22)-C (23)-C (24)-C (25) -0 .9 (2)
0(6)-C (24)-C (25)-C (26) 176.50(13)
C (23)-C (24)-C (25)-C (26) -1 .2(2)
-203-
0 (6 )-C (2 4 )-C (2 5 )-C (l )#1 -3 .2(2)
C (23)-C (24)-C (25)- 179.10(13)
C (l)# l
C (24)-C (25)-C (26)-C (21) 0.6(2)
C (l)# l-C (2 5 )-C (2 6 )-  -179.71(13)
C(21)
C (22)-C (21)-C (26)-C (25) 2.1(2)
C( 14 )-C (2 1 )-C (26)-C (25) -177.60(13)
Symmetry transformations used to generate equivalent atoms: 
#1 - x  ,-y  ,—z+ l
T able 7. Hydrogen bonds for kno06 [A a n d 0].
D -H ...A d(D -H ) d(H...A) d(D...A) <(DHA)
0 (1 1 )- 0.82(3) 2.11(3) 2.724(13) 131(3)
H (20)...0 (9B )#2
0 (1 1 )- 0.82(3) 2.24(3) 2.992(2) 152(3)
H (20)...0 (9A )#2
0 (1 1 )- 0.79(3) 2.03(3) 2.798(13) 163(3)
H (10)...0 (9B )#3
0 ( 1 1  y 0.79(3) 1.99(3) 2.772(2) 170(3)
H (10)...0 (9A )#3
0 (6 ) - 0.84 1.80 2.613(8) 163.5
H (6)...0(10B )#4
0 (6  y 0.84 1.95 2.787(2) 171.2
H (6)...0(10A )#4
0 (5 ) - 0.84 1.89 2.705(8) 162.6
H (5)...0(10B )#4
0 (5 ) - 0.84 1.86 2.694(2) 171.2
H (5)...0(10A )#4
0 (4 )-H (4 ) ...0 ( l 1)#4 0.84 1.95 2.7267(18) 153.3
0(3 )-H (3)...0 (8 )#5 0.84 1.89 2.6584(16) 152.2
0 (2 )-H (2 )...0 (7 )#6 0.84 1.87 2.7107(17) 173.8
0(1)-H (1)...0(7)#7 0.84 1.91 2.6933(16)
Symmetry transformations used to generate equivalent atoms:
#1 - x - y , - z + l  #2 x+ l,y ,z  #3 - x + l ,- y + l ,- z
#4 x-1 ,y,z #5 —x + 1 - y  ,-z  #6 - x + 1 ,-y + 1 - z + 1 
#7 x ,y - l ,z - l
154.4
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A p p e n d ix  2:
Cmpd
Number
Concentration
(ug/ml)
Syncytia
(♦/-)
Estimated 
% Control 
I
Estimated Cell 
Growth % of 
Control 
infected
Estimated Cell 
Growth % of 
Control 
uninfected
EC50 TC50 Selectivity
Index
1151C 400 - 73 69 0.25 500 2000
Harris 80 - 105 100
Comp. 16 - 92
3.2 - 92
0.64 ST-/+ 17 72
0.128 ST-/+ 63 30
0.0256 + 28
04-002 400 TC50 41 42 0.015 350 23333
80 - 93 94
16 - 99
3.2 - 104
0.64 - 101
0.128 - 14 100
0.0256 ST-/+ 30 46.5
04-003 400 TC50 44 45 0.012 350 29166
80 - 100 100
16 - 96
3.2 - 100
0.64 - 100
0.128 - 0 100
0.0256 ST-/+ 25 55
04-004 400 T40 41 41 0.32 350 1100
80 - o o 100
16 - 100
3.2 - 94
0.64 ST-/+ 27 70
0.128 ST+/- 99 34
0.0256 + 29
AC- 200 T 16 16 8 30 3,75
40 T25 29 31
8 ST-/+ 54 58 98
1.6 + 99 27 100
0.32 + 27
0.64 + 24
AZT 2 - 100 100 0.016 >1000 >62500
0.016 ST+/- 51 49
Cmpd
Number
Concent
ration
(ug/ml)
Syncytia
(+/-)
Estimated 
% Control 
I
cell
growth
U
gp120 
% Control
Estimated
%
Inhibition
EC50 TC50
Selectivity
Index
Comments
SC 103A 10000
2000
400
80
16
T
T30-
NT-/+
+
+
10.69
55.32
63.55
50.95
32.36
9.63
69.20
91.04
96.75
104.70
22.40
30.48
61,15
72.67
77.60
69.52
38.85
27.33
190
ug/ml
4600
ug/ml
24.21 IC 17.3%
SC 103B 400
80
16
3.2
0.64
T50-
T20-
ST-/+
+
+
52.18
78.39
91.66
48.99
32.64
41 10
77.16
89.84
92.72
88.58
15.01
19.26
95.89
98.28
84.99
80.74
4.11
1.72
10.8
ug/ml
320
ug/ml
29.63 IC 17.3%
SC 103C 2000
400
80
16
3.2
T50-
T30-
ST-/+
+
+
58.73
75.59
81.80
51.57
35.05
41.21
65.96
89.03
108.29
103.25
17.35
22.75
102.61
97.67
82.65
77.25
0.00
2.33
58
ug/ml
1420
ug/ml
24.48 IC 17.3%
SC 103D 2000
400
80
16
T50-
NT-/+
+
+
42.85
64.50
42.25
30.90
45.50
92.90
99.80
85.40
4.52
10.18
89.90
93.19
95.48
89.82
0.00
6.81
283
ug/ml
1850
ug/ml
6.54 IC 24%
SC 103E 10000
2000
400
80
16
3.2
T-
T50-
T40-
ST-
NT+
+
17.80
54.55
64.60
77.65
56.10
28.90
19.30
51.10
55.30 
76.50 
90.70
83.10
3.38
3.07
103.57
85.59
96.62
96.93
0.00
14.41
57.8
ug/ml
2250
ug/ml
38.93 IC 24%
SC 103F 2000
400
80
16
3.2
0.64
T50-
T30-
T10-
NT-/+
+
+
43.30
73.55
74.50
29.05
27.70
25.65
43.10
75.30
78.50
84.70
85.30 
93.60
6.04
33.64
53.31
75.79
93.96
66.36
0.00
24.21
5.4
ug/ml
1660
ug/ml
307.41 IC 24%
SC 103N 10000
2000
80
16
3.2
0.64
T-
T50-
ST-/+
NT-/+
-/+
+
14.25
72.20
55.00 
22.90
18.00 
17.30
11.70
69.10
78.60
85.40
87.00
95.50
42 46 
45.41 
54,43 
61.31
57.54
54.59
45.57
38.69
9.5
ug/ml
4700
ug/ml
494.74 IC 24%
Control 100 100 0 — — —
1C - Infected control 
U - Uninfected control 
T - Compound Toxic 
ST - Slightly Toxic 
NT - Non Toxic
Dilutions of compounds in 50 uls, are mixed with T-cells C8166, 40,000/well, 
Virus HIV-1 111B is added at M.O.I of 0 01 and incubated for 5 days.
Syncytia observed from days 3-5
Cell viability by XTT-Formazan method at day 5.
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